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Abstract 
Anticoagulant resistance was discovered in Norway rats in the United Kingdom nearly 70 
years ago, and since then the number of resistance mutations and resistance foci has 
increased. In no other country are mutations that are thought to confer serious practical 
resistance so widespread. Numerous studies have shown multiple resistance genotypes and 
phenotypes across south-east England. Despite this, the extent of these resistance foci and the 
resistance factors possessed by these rats are not known. The experiments described herein 
were designed to reveal the extent and impact of resistance mutations in south-east England. 
304 tissue and faecal samples were taken from rats across the study area, in order to 
identify and delimit foci of VKORC1 resistance conferred by mutations in the VKORC1 
gene. The L120Q resistance mutation was found to be prevalent across the study area, with 
the majority of rats possessing the homozygous form of the mutation, suggesting that for 
years, resistance has been selected for through use of ineffective second generation 
anticoagulant rodenticides (SGARs). Two strains of L120Q-resistant laboratory rats were 
dosed with SGARs and their prothrombin times (PT) measured, and resistance factors 
generated by comparison with data from susceptible strains. L120Q in its strongest form was 
found to confer practical resistance to bromadiolone and difenacoum, but not to resistance 
breakers such as brodifacoum. Finally, field trials were carried out in the L120Q resistance 
focus of central-southern England, which showed conclusively that brodifacoum is 
efficacious against L120Q-resistant rats in both Berkshire and Hampshire. 
The UK rodenticide stewardship scheme, proposed by the Campaign for Responsible 
Rodenticide Use (CRRU) will see “resistance breaking” SGARs available for use against 
Norway rats only by competent users as of April 2017. Results indicate this development is 
both timely and necessary for proactive Norway rat control in the UK. 
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Chapter 1: Introduction 
1.1 The Norway rat 
1.1.1 Early history 
The Norway rat (Rattus norvegicus), also known in the scientific literature as the sewer rat 
and brown rat, is thought to have originated in the grassy steppes north of the Caspian Sea 
before undergoing a population explosion and migrating outwards, eventually boarding ships 
and spreading throughout Europe (Lund, 2015). It was first recorded in the United Kingdom 
in 1728 (Brooks and Jackson, 1973). Along with another major commensal (lit. “sharing 
one’s table” – Meehan, 1984) rodent, the house mouse (Mus musculus), it is a major pest in 
the UK. The black rat (Rattus rattus), also a commensal pest species, was introduced in 1100 
but has disappeared from much of the UK since the introduction of the Norway rat and is 
consequently less of a concern in the UK at the present time (Corbet and Southern, 1977); 
this appears to be the case in many areas where the Norway rat has arrived subsequently to 
the black rat (Lund, 2015). 
 
1.1.2 Norway rats as pests 
1.1.2.1 Food spoilage and consumption 
Norway rats are ubiquitous in the agricultural environment and may take advantage of poor 
hygiene, storage and husbandry practices. In the UK, losses of crops in the field due to 
Norway rats are limited compared to  the levels of damage, for example, in Asia  as the result 
of the activity of other, similar, species such as the buff-breasted rat Rattus flavipectus 
(Huang et al., 2011), Polynesian rat Rattus exulans (Tobin, 1994), lesser ricefield rat Rattus 
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losea, ricefield rat Rattus argentiventer and black rat (Buckle, Yong and Abdul Rahman, 
1985; Stenseth et al., 2003; Brown et al., 2005; Meerburg, Singleton and Leirs, 2009). The 
greatest economic losses to Norway rats in the UK are conversely not due to direct 
consumption, but the associated damage to packaging and contamination of food products 
with hair, urine and faeces. An adult Norway rat may produce 14,600 droppings and 5.4 litres 
of urine a year (Smith and Meyer, 2015), contaminating far more food than they can 
consume. Norway rats in California were found to very rarely leave droppings in their 
burrows, which increases the likelihood that these contaminants will find their way onto and 
into human produce (Pisano and Storer, 1948). Furthermore, the potential financial losses to a 
farm or manufacturer are far greater should the contamination go unnoticed until the product 
reaches consumer level; at this point estimation of financial losses would be purely 
speculative, but could easily result in loss of custom, complaints and compensation, and 
additional health inspections. 
1.1.2.2 Disease transmission 
In the UK, the most direct impact the Norway rat has as a pest is as a reservoir for zoonotic 
pathogens such as hantavirus, with the recent discovery in the UK of  Seoul hantavirus, 
known to cause haemorrhagic fever with renal syndrome (HFRS), linked to Norway rats on 
farms in the north of England (Jameson et al., 2013, 2014). Diseases such as salmonellosis 
(Richards, 1989), leptospirosis (Michna and Campbell, 1970; Webster, Ellis and Macdonald, 
1995), campylobacter (MacIntyre, unpublished) and foot-and-mouth virus (Capel-Edwards, 
1970) are all found in rats in the UK, and all may act as zoonotic pathogens, as well as having 
significant economic and welfare impacts due to their effects on farm animals. Due to the 
proclivity of Norway rats to leave droppings in areas where feed is stored and / or distributed 
to livestock, these may act as a source of transmission to farm stock feeding at the same 
location. In addition to the risks posed to livestock and humans in rural environments, 
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Norway rats also pose a disease risk to humans in the built environment including in their 
own homes as well as in food outlets A recent study in New York suggests that urban 
Norway rats may carry multiple strains of multiple diseases known to cause gastroenteritis in 
humans (Firth et al., 2014). 
The actual impacts of food spoiling and consumption are limited in Europe 
(Meerburg, Singleton and Leirs, 2009) compared to the potential direct suffering caused by 
zoonotic diseases for which Norway rats act as reservoirs (for recent details of these 
Zoonoses in England, see Public Health England, 2015). In the UK at least, Norway rats do 
not present a physical threat to people unless cornered and unable to escape (Meehan, 1984). 
Rodents as vectors and / or reservoirs of zoonotic infections, and the direct and indirect routes 
by which these pathogens may be spread, are explored in detail by Meerburg, Singleton and 
Kijlstra (2009). 
1.1.2.3 Ecological impacts 
Norway rats, along with other members of the Rattus genus and house mice, are also viewed 
as pests due to their impact on native species when they become established as introduced 
species in areas to which they are not native, normally as a stowaway on human shipping. 
They may compete with native fauna for food or nest sites, indirectly harm native fauna by 
harming plants used as shelter, or directly prey upon native fauna and flora (Howald, Ross 
and Buckle, 2015). The best known of these is the depredations of invasive rodents upon the 
nesting sites of ground-nesting birds. An exhaustive review of Norway rat impacts on island 
seabirds is not possible here, but see Jones et al. (2008). Examples of these direct impacts by 
Norway rats in the UK are rare beyond their displacement of the similarly invasive black rat 
(Corbet and Southern, 1977), but both species were successfully eradicated from Lundy in 
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the Bristol Channel after their presence was linked to the loss of breeding Manx shearwater 
Puffinus puffinus and Atlantic puffins Fratercula arctica from the island (Lock, 2006). 
 
1.1.3 Adaptations for commensalism 
Norway rats are generalist omnivores, capable of surviving alongside humans anywhere in 
the world (Lund, 2015). They are highly athletic, being able to swim for 72 hours before 
tiring, and smaller individuals have been seen scaling sheer brick walls (personal 
observation). Norway rats are highly neophobic, displaying fear and avoidance of new 
objects in their environment, making them difficult to trap and / or poison (Barnett, 1958). 
This neophobia apparently differs between populations; in some areas of Hampshire, control 
of Norway rats using chemical rodenticides has failed entirely due to heightened neophobia 
(Brunton, MacDonald and Buckle, 1993). Due in part to their neophobia, Norway rats may 
travel several kilometres a night in order to access a trusted food source (Fenn, Tew and 
MacDonald, 1987). Norway rat burrows are typically shallow, but contain multiple concealed 
exits or “bolt holes” which allow egress when the burrow is disturbed (Pisano and Storer, 
1948), thus making it difficult to cover all exits during the use of gas or ferrets to eliminate a 
burrow. 
Norway rats have a physical predisposition towards being successful pests of man, but 
their reproductive systems also contribute to their enormous impact. Rodents such as voles 
and the murine rats and mice tend to be r-strategists (MacDonald, Fenn and Gelling, 2015), 
with high reproductive rates but usually poor survival of offspring. Norway rats produce a 
large number of offspring due to the combination of several factors within their reproductive 
behaviour: firstly the female gives birth after a gestation period of just 20 – 23 days (Meehan, 
1984), resulting in the creation of a new generation within three weeks. Litter sizes are 
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typically from seven to nine but as many as sixteen is possible. In ideal conditions (i.e. not 
food or harbourage limited), females undergo a post-partum oestrus: they are ready to mate 
within hours of giving birth. This causes a slight delay in egg implantation (two to five days – 
Meehan, 1984), meaning that individuals have the potential to give birth to a new litter every 
24 days. This is aided by the short weaning time: a minimum of 20 days. Furthermore, 
Norway rats reach sexual maturity at 8 – 12 weeks. This means that not only can one female 
produce a large number of offspring in a short amount of time, but generation time is 
minimal; at peak reproduction, this allows for seven new generations in two years. These two 
facets of their physiology enhance their potential to become pests, and to make them difficult 
to control, along with the neophobic behaviour they display (Barnett, 1958). 
 
1.2 Pest control and pesticides 
Pest control comes in three forms: physical, biological and chemical. Physical control 
includes directly hunting the pest species (or chopping down and burning in the case of 
plants), using traps to kill or capture individuals, or excluding pests from areas wherein they 
can cause harm to humans or damage crops. In the case of most rodents (and even smaller 
organisms), traps and hunting are often of only limited use due to the number of target 
individuals involved. Biological control involves introducing predators, parasites or 
pathogens of the pest species into the affected area. As a reduction of a pest’s impact is the 
end desire of pest control rather than its  extermination (Smith and Meyer, 2015), by this 
definition, the use of dogs and other aggressive domesticated animals as predator deterrents 
by livestock herders would be considered a form of biological pest control. 
Lethal control tends to provide the fastest results in terms of measurable reduction of 
pest damage to goods, property and foodstuffs, resulting in a heavy emphasis on chemical 
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control: direct applicationof synthetic or biological chemicals designed to kill the target 
species. The first recorded forms of chemical pesticides were insecticides. By 2500 BC, the 
Sumerian people were using sulphur as an insect repellent, and records from 1200 BC 
apparently reveal the use of various insecticides to protect seeds from granivorous arthropods 
in China (Banaszkiewicz, 2010). Despite their potential advantages, however, chemical 
pesticides are also associated with a range of problems and limitations. 
 
1.2.1 Problems arising with chemical control (including biopesticides) 
Chemical insecticides, in their wide variety and lengthy history, provide many examples of 
the problems inherent with the use of chemicals (of both synthetic and biological origin) to 
control pests, in particular impacts on non-target species and resistance to the chemical agents 
themselves. See, for example, the various non-target impacts of the organochloride DDT 
(Carson, 1962; U.S. Department of Health and Human Services, 2002), and the numerous 
orders of insects now displaying resistance to the modern Pyrethroids (Dong, 1997; Schuler 
et al., 1998; Chen et al., 2010). Genetically modified (GM) maize, modified with the addition 
of the Cry1Ac gene from the bacterium Bacillus thuringiensis (utilisation of a micro-
organism as a form of biopesticide), has been shown to cause toxicological effects in non-
target monarch butterflies Danaus plexippus (Losey, Rayor and Carter, 1999; Mendelsohn et 
al., 2003), while target species such as pink bollworm Pectinophora gossypiella (Bagla, 
2010) and corn earworm Helicoverpa zea (Tabashnik et al., 2008) have shown resistance to 
the toxic effects of the gene. Target species resistance is not limited to just insects, or to 
direct chemical applications. Glyphosate is the active ingredient of many proprietary 
herbicides worldwide, resistance to which has been discovered in the pigweed Amaranthus 
palmeri, a pest of soybean, cotton and peanuts in the USA, sufficient to prevent 12 times the 
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recommended application rate achieving full control (Culpepper et al., 2006). Controversy 
has surrounded recent evidence suggesting the chemical is linked to carcinogenic effects in 
mammals (Guyton et al., 2015), despite previous evidence claiming it was safe (Giesy, 
Dobson and Solomon, 2000). Methicillin-resistant Staphylococcus aureus, a bacterium 
resistant to the penicillin antibiotics, was typically associated with hospital settings, until the 
mid 1990s when it was found in people across Europe, North America and Australasia who 
had not contracted it in hospitals, or been exposed to those who had (Raygada and Levine, 
2009). Resistance to Myxomatosis, a disease caused by the Myxoma virus (another example 
of biopesticide), has been present in UK rabbits Oryctolagus cuniculus since at least the 
1950s (Ross and Sanders, 1984). Because the virus could be passed from rabbit to rabbit 
(unlike chemical pesticides), there could be no regulation of its application, and therefore no 
conservation of susceptible individuals as in the refuge strategy sometimes employed 
concurrently with insecticide application (e.g. Tabashnik et al., 2008; susceptibility is a 
required resource if chemical applications are to continue for any given pest species). The 
issues mentioned here indicate that further independent research is required to ensure both the 
safety and efficacy of many chemical pesticides. 
 
1.3 Control of Norway rats 
1.3.1 Traps and other physical control measures 
Because of the very serious effects that Norway rats have as commensal pests, a wide variety 
of methods have been used to control them. The most effective, in terms of reducing their 
impact, is to proof any premises they might attempt to enter. This requires that: all materials 
they might come into contact with (including by digging, swimming, climbing and jumping) 
are harder than 5.5 on the Mohs scale (MacDonald, Fenn and Gelling, 2015);  any apertures 
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be at most 25 mm wide (to prevent adult rats squeezing through, although doing so would not 
exclude house mice);  all debris,  cover and overhanging vegetation be removed; and that 
climbing guards be placed anywhere that is scalable (Smith and Meyer, 2015).  
Another option is to remove the food incentive for commensal rodents, thereby 
reducing the scale of the infestation, and the survival rate of individual rats. For example, 
stored grain on farms is significantly negatively correlated with bait consumption rates during 
rodenticide trials (Quy et al., 1992). However, making such changes is expensive, and for 
most farm buildings would require a complete rebuild; new residential and commercial 
buildings are typically easier to adapt or build to resist rodent invasion, but the removal of 
food from human housing and food outlets in urban areas is not an option. Therefore, this 
form of control is largely impractical on farms, and can be limited in more urban buildings. 
Conversely, the simple removal of vegetation and other farming equipment (e.g. pallets and 
other debris) that afford rats shelter through good housekeeping practices has the potential to 
significantly and cost-effectively reduce rat populations by increasing competition between 
individuals for food and refugia (Lambert et al., 2008). 
Shooting and trapping are still carried out in the UK and are certainly effective against 
individual rats, but provide no guarantee of gaining complete control of a Norway rat 
population. The combination of these two methods proved efficacious during the eradication 
of escaped coypus (Myocastor coypus) in East Anglia (Gosling and Baker, 1987, 1989), but 
in this case the target species was up to three times larger than the Norway rat, and inhabited 
a specific habitat type in a limited area of the country. In comparison, Norway rats are found 
throughout the country and are much smaller, more numerous and breed at a faster rate, 
making the likelihood of killing an entire population via trapping and shooting low. In 
addition, the operatives hired to extirpate the coypu in East Anglia were assured of a 
significant financial bonus upon completion; it could be argued that continuous control of 
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Norway rats represents a great deal of work for typical pest control officers (PCOs), and their 
complete extirpation might not actually be desired by the very people usually tasked with 
their control (Greaves, 1995). For individual farmers capable of effectively utilizing guns, 
traps and / or dogs (see below), combining these methods with good housekeeping practices 
(Lambert et al. (2008) may have some positive impacts. Recent evidence regarding the extent 
of Norway rat migratory behaviour is mixed (Haniza et al., 2015; Berny et al., in prep), but 
the threat of reinvasion suggests that where possible, physical control measures should be 
undertaken.  
 
1.3.2 Biological control 
Vertebrate predators of rats are widespread in the UK, and may target Norway rats outside of 
urban areas and farmsteads, but there are few species large enough to hunt rats regularly that 
live closely alongside humans. Domestic cats are often numerous in urban areas and on farms 
but it is unlikely that they can access refugia such as burrows and sewers. Although cats will 
kill and sometimes eat rats, it has been shown that the size of Norway rats prevents large 
adults being taken (Childs, 1986). In northern England, dogs are still used to hunt rats on 
farms but, as with shooting, there is no guarantee of killing every single rat in the population. 
Repeated visits might reduce numbers sufficiently for the rat impact to be negligible, but 
because of the relative effort required (both in time and manpower), it is unlikely that dogs 
are the future of rat control in the UK. Use of parasites or bacterial or viral diseases is not 
desirable, due to the risk this would present to domestic animals and humans. Given the 
breeding rates of rats and the inability to control the application of infectious diseases, it is 
possible that a situation would arise similar to that of the Myxoma virus in rabbits (see 
above). 
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1.3.3 Chemical control 
Due to the greater number of individual rats that can be killed by a feeding at a single bait 
station (as opposed to a single kill trap), chemical rodenticides have proven to be the most 
popular, effective and cost-efficient method of lethal control (Hadler and Buckle, 1992). 
There are three main categories of rodenticides: acute, subacute and anticoagulant (Buckle 
and Eason, 2015). The modes of action of the acute and subacute rodenticides are highly 
varied, as are their active ingredients. Extensive summaries of the most commonly used 
chemical agents, including their modes of action and their histories, can be found in Meehan 
(1984) and Buckle and Eason (2015). Acute rodenticides are typically highly toxic and can, 
therefore, be extremely dangerous. For instance, thallium sulphate can be absorbed through 
the skin, and zinc phosphide is so toxic that it was originally with emetics (rats being 
incapable of emesis) in order to prevent death of non-target animals and humans during the 
targeting of rats (Krieger, 1952). It is still in use under the name “Ratron,” registered for use 
in the control of field voles (Microtus agrestis). The quick acting effects of  acute 
rodenticides means, however, that an individual ingesting a non-lethal dose would cause it to 
become sick rapidly but allow recovery; as a consequence, surviving animals learn to 
associate the symptoms they have suffered with the new food ingested (i.e. the bait) and 
avoid it in the future (“bait shyness”). Because of their toxicity and speed of effect, acute 
rodenticides represent a severe danger to non-target organisms including humans and 
domestic animals. Even the foul taste of rodenticides such as red squill is not a guarantee of 
non-target safety (Fitzpatrick, McGirr and Papworth, 1955). Most acute and subacute 
rodenticides also have no available antidote (e.g. “1080”; Krieger, 1952), or antidotes that 
can only be administered with a short time period after exposure  (e.g. Sodium Fluoracetate 
can be treated by barbiturates within  three hours; McGirr and Papworth, 1955). Due to these 
issues, the acute and subacute rodenticides are, for the most part, not authorised for use in the 
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UK (Buckle and Eason, 2015) or indeed the rest of the EU (European Community, 1998). 
Those that are, are usually ineffective against rats (see Buckle, 2013a) or, like calciferol, not 
widely used despite some success against resistant rats in Wales (Rennison, 1974) and more 
recent studies suggesting that in combination with coumatetralyl, it is effective against 
bromadiolone-resistant rats in Germany (Endepols et al., 2017). As such, rodenticides used 
against rats in the UK are almost exclusively anticoagulants. 
 
1.3.4 Anticoagulants: discovery and use  
The discovery of anticoagulant rodenticides is rooted in a series of cattle deaths in Canada 
almost a hundred years ago. These cows were initially suspected to have a communicable 
haemorrhagic septicaemia (Schofield, 1984) but, in the absence of any causative bacteria, the 
deaths were linked to the consumption of spoiled sweet clover silage. The “sweet clover 
disease”, as it was initially known (Link, 1959), was replicable by feeding cattle or sheep 
improperly cured sweet clover hay, after which their blood clotting power was reduced, and 
fatal haemorrhage occurred with 30-50 days. After years of studying spoiled sweet clover, a 
small spoonful of crystalline dicoumarol was extracted in 1939 (Link, 1959). It was 
established that coumarin, a naturally occurring bitter-tasting compound in many plants, 
formed a 4-hydroxycoumarin when oxidised; when naturally fermented (during the process in 
which sweet clover became spoiled), or when formaldehyde is added in the laboratory, 
dicoumarol is formed. During the ensuing years, dozens of compounds were synthesised from 
dicoumarol, including sodium warfarin in 1948, then known as Compound 42 (Mills, 1955). 
Warfarin was found to be much more potent as an anticoagulant than dicoumarol, and was 
promoted for use as a rodenticide. Because of its potency and the antidotal effects of vitamin 
K (Link, 1959), it was also promoted for use in humans, and in 1955 the President of the 
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United States, Dwight D. Eisenhower, was treated with warfarin after suffering a heart attack. 
Warfarin was found to be efficacious against Norway rats in formulations of only 0.005% 
(Bentley, Hammond and Taylor, 1955), and other anticoagulant rodenticides, of varying 
effectiveness, soon followed (Bentley and Rowe, 1956; Bentley and Larthe, 1959).  
Furthermore, anticoagulant rodenticides do not possess many of the weaknesses 
associated with acute poisons. Their delayed and chronic mode of action (animals usually 
take at least two days to suffer symptoms) means that animals fail to associate symptoms of 
poisoning with the bait they have consumed, (Drummond and Rennison, 1973). The slow 
onset of symptoms also allows rodents to keep feeding on the bait until a large enough dose 
has been consumed to cause mortality (ideally by the onset of symptoms the rodent will have 
consumed a lethal dose). Therefore it is to be expected that if a pest animal overcomes its 
neophobia and finds an anticoagulant bait palatable, it will eat this bait until it dies. 
Anticoagulant rodenticides are also much safer because their slower mode of action increases 
the amount of time available to seek medical or veterinary attention and the antidote (Vitamin 
K) is readily available. 
 
1.3.5 Anticoagulants: mode of action 
1.3.5.1 Vitamin K cycle 
Anticoagulants interfere with the vitamin K cycle, the process by which the body recycles 
vitamin K in its various forms (Figure 1.1), which takes place largely in the endoplasmic 
reticulum of liver cells (Olsen, 1984). The reduced form of vitamin K, Vitamin K 
hydroquinone, is a cofactor in a reaction in which a carboxylase enzyme catalyses the 
conversion of glutamate residues (Glu) in substrate proteins to gamma-carboxy-glutamate 
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(Gla) (Thijssen, 1995), thus beginning the coagulation cascade (see Figure 1.2), which results 
in the production of insoluble fibrin, forming a blood clot (Stenflo and Suttie, 1977). As part 
of its catalytic action, the carboxylase oxidises the hydroquinone, forming Vitamin K 
epoxide. The epoxide is recycled to vitamin K and then to hydroquinone by the enzyme 
Vitamin K-2, 3-epoxide reductase (VKOR); each molecule of vitamin K may be recycled in 
this manner up to 10,000 times. Anticoagulants act as antagonists for complex subunit 1 
(VKORC1) of Vitamin K-2, 3-epoxide reductase (Rost et al., 2004). The 4-
hydroxycoumarins form a tightly bonded complex with the reductase which is effectively 
irreversible, because the enzyme is normally reactivated by a reduction reaction (Fasco et al., 
1983). Once the target animal’s liver has become saturated and there are no more free 
enzymes in either anticoagulant-susceptible stage of the vitamin K cycle, the absence of 
hydroquinone will reduce the effectiveness of the carboxylation of the Glu residues, thereby 
preventing the initiation and completion of the coagulation cascade. The vitamin K antidote is 
efficacious because alongside the Vitamin K-2, 3-epoxide pathway there is a low-affinity 
quinone reductase enzyme which directly reduces vitamin K to the required hydroquinone 
(Whitlon, Sadowski and Suttie, 1978). The low affinity of this pathway, and the fact that 
when its use is required there is no recycling of hydroquinone, means that it is only of use 
when vitamin K can be obtained in high doses in order to stave off anticoagulant-induced 
haemorrhage. Both the enzyme (VKOR) and substrate (Vitamin K epoxide) can be limiting 
factors e.g.; the symptoms of anticoagulant poisoning can be stimulated in rats prevented 
from consuming their own faeces, an important source of dietary vitamin K (Mameesh and 
Johnson, 1959). 
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Figure 1.1: A simplified diagram of the anticoagulants’ interference in the Vitamin K Cycle (from Kaesler et al., 
2012) 
 
1.3.5.2 Coagulation cascade 
The normal function of the vitamin K cycle starts the coagulation cascade, a series of 
reactions in which the inactive zymogens Factors II, V, IX and X are activated in turn to 
protein sereases Factors IIa, Va, IXa and Xa (Figure 1.2). Glu residues that are activated as 
part of the coagulation cascade are also found on the surface of proteins S, C and Z. The 
gamma-carboxylated residues on each clotting factor chelate Ca2+, thus enabling them to bind 
to phospholipid bilayers on platelets, ensuring that clotting takes place at the damaged site. 
Each activated clotting factor then cleaves the inactive zymogen next in the cycle, thereby 
activating it and allowing it to bind to Ca2+, thus continuing the series of reactions. The final 
stages of the reaction cascade, in which the extrinsic and intrinsic pathways converge, see 
Factors Va and Xa form a complex (prothrombinase) which activates prothrombin, forming 
thrombin. The activation of thrombin forms part of a positive feedback loop, activating 
Factors VIII and V. Thrombin also cleaves fibrinogen by proteolysis, forming small chains of 
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fibrin monomers. The fibrin monomers bind to adjacent chains, leading to polymerisation 
(Davie, Fujikawa and Kisiel, 1991). Finally, Thrombin also activates Factor XIII, which 
forms the covalent bonds that link fibrin polymers together, resulting in a blood clot. By 
preventing the carboxylation of Gla residues, anticoagulants cause an increase in the number 
of precursor zymogens (Harauchi et al., 1986) because the activation process does not occur. 
When the Vitamin K-2, 3-epoxide reductase binding sites in the liver are saturated with 
anticoagulants, the multi-step coagulation cascade is not fully initiated. Therefore, any 
clotting factors circulating in the body decay, with varying half-lives (Kerins and MacNicoll, 
1999). The delayed action of the anticoagulant rodenticides (which prevents bait shyness 
being engendered in target organisms) is a function of this decay; clotting time is not 
extended until any of the clotting factors falls below 10% of normal levels. The saturation in 
the liver also functions to extend the action of anticoagulant action of these poisons by 
forcing the liver to clear the anticoagulants in a biphasic elimination; excess anticoagulant 
must be cleared from the body before hepatic binding sites can release 4-hydroxycoumarin 
molecules without binding more of the same molecules (Huckle, Hutson and Warburton, 
1988), thereby extending the anticoagulant effect.  
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Figure 1.2: The coagulation cascade (from Berg, Tymoczko and Stryer, 2002) 
 
 
1.4 Anticoagulant resistance in Norway rats 
1.4.1 History of resistance to anticoagulant poisons 
Boyle (1960) described how a population of Norway rats in Scotland were treated with 
diphacinone and warfarin, but despite good acceptance of bait, control was not achieved. 
Crucially the paper states that the treatments were conducted properly, leading to the 
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conclusion that the rats were not behaviourally resistant (i.e. bait shy), nor did the treatments 
fail due to poor housekeeping on the farm in question. Therefore, it is accepted that control of 
the population was not achieved because the animals in question were able to tolerate the 
anticoagulant to a previously unseen degree. The population in question was eventually 
eradicated but, within 18 months, a new infestation was found that also displayed warfarin 
resistance (Cuthbert, 1963). Rats from this infestation were captured and subjected to 
laboratory choice tests; although many were in fact susceptible, and died within a few days of 
feeding on 0.005% warfarin bait, the five (of 91) surviving rats went on to survive a 24-day 
period of no-choice feeding on 0.005% warfarin bait. Warfarin-resistant house mice were 
also found in Harrogate (Dodsworth, 1961) in the same year. A decade later, 20 farms were 
sampled randomly from within a 20 km2 area centred on the original site of resistance in 
Scotland; every site which had rat infestations had rats which were, after warfarin feeding 
tests, classified as resistant (Brodie, 1976). Subsequently, many foci of resistance to the 
anticoagulants were found throughout the UK, with 14 foci of varying sizes identified 
(Greaves and Rennison, 1973). 
Shortly after the discovery of resistance in Scotland, a large resistance focus was 
discovered on the Anglo-Welsh border. Resistant rats from this focus were identified through 
survival of a six-day no-choice feeding test with 0.005% warfarin (Bentley, 1968), and the 
level of resistance displayed was such that tests against warfarin and Vitamin K against the 
two strains, as well as their inter-bred offspring, confirmed through observation of grouped 
clotting times that Welsh and Scottish resistances were phenotypically and genetically 
different, although the full mechanisms of resistance were not yet understood (Greaves and 
Ayres, 1982). This form of resistance conferred such strong tolerance to the anticoagulants 
available that a containment zone was implemented around areas of confirmed resistance 
(Drummond, 1966). This belt of land had a total circumference of 160 miles and, within this 
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area, zinc phosphide was used as a countermeasure to the warfarin-resistant rats (Pamphilon, 
1969). These measures appeared to be successful in preventing the spread of Welsh 
resistance, which otherwise appeared to spread outwards at the same rate that resistant rats 
could migrate (Drummond and Bentley, 1965; Drummond, 1970). Unfortunately, the 1967-
68 outbreak of foot-and-mouth disease forced the cessation of the containment action and 
resistant populations of Norway rats were found outside the former perimeter shortly 
afterwards. 
During the attempts to control the Welsh resistance outbreak, a six-day feeding test 
with warfarin bait at 0.005% strength was proposed as definitive test procedure for 
confirming resistance in individual rats (Drummond and Wilson, 1968); this was quickly 
adopted as the standard resistance test (Bentley, 1968; Telle, 1971; Brooks and Bowerman, 
1973). Overall, 98% of anticoagulant-susceptible rats were shown to die after feeding periods 
of 3-4.82 days (LFP98; Brooks and Bowerman, 1974). During the ten years following the first 
discovery of resistance in Scotland, resistance was also found in many sites in Denmark. In 
1962, rats from two farms in Jutland were found to be resistant to warfarin when taken into 
the laboratory and subjected to feeding tests, with only a 33% mortality rate over multiple 
five-day feeding tests with 0.005% warfarin, and those that died survived longer than 
susceptible rats would typically (Lund, 1964). Resistance was found in more farms that year, 
with six individuals from these areas surviving warfarin feeding tests for 51 days (Lund, 
1988). Further tests confirmed that Danish resistant rats were not simply warfarin-resistant; 
they possessed cross-resistance to all anticoagulants to some degree (Lund, 1966). By 1972, 
warfarin was no longer being used in areas of known resistance in Denmark (Lund, 1988). 
For ten years, anticoagulant resistance in Norway rats was not recorded outside of Denmark 
and the UK. Soon after this, however, multiple records of anticoagulant resistance in Norway 
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rats had been reported in the US (Brothers, 1972; Brooks and Bowerman, 1973), Germany 
(Telle, 1971) and the Netherlands (Ophof and Landeveld, 1969). 
The first generation anticoagulant rodenticides (FGARs, including warfarin, 
coumatetralyl, chlorophacinone and diphacinone: reviewed by Brooks and Jackson, 1973) 
were used widely across Eurasia and North America, with different countries favouring 
different active ingredients (Bentley, 1972); where they failed, the acute rodenticides were 
still available as a last resort. During this early period, coumatetralyl was increasingly seen as 
superior to warfarin where resistance was occurring, but 100% control was not guaranteed 
(Bentley, 1968; Lund, 1969). Differences were noted between Norway rats and house mice, 
the two most problematic commensal rodents in areas where resistance was likely to be 
found, in their response to anticoagulants. Chlorophacinone was seen as very efficacious 
against house mice compared to warfarin (Lund, 1971), whereas against Welsh-resistant 
Norway rats it performed no better than warfarin (Bentley, 1968). However, as with Norway 
rats, coumatetralyl was shown to be more toxic to mice than warfarin, but could not be fully 
recommended against resistant animals (Rowe and Redfern, 1968). The situation was not 
helped by the slow and variable progression of the symptoms of FGARs, which caused a 
great deal of intra-strain variability in the response of rats to consumption of anticoagulant 
poisons, even among susceptible animals (Brodie, 1976; Chmela, Rupes and Privora, 1978). 
By 1992, it was thought that the use of warfarin in most of Western Europe was 
unlikely to result in control (Myllymäki, 1995). As more resistance foci were discovered, and 
the severity of the problem was realised, the number of products available for use increased, 
and in the 1970s a more potent second generation of anticoagulant rodenticides (SGARs) 
were marketed (Hadler and Shadbolt, 1975); the first of these were difenacoum (Hadler, 
Redfern and Rowe, 1975) and bromadiolone (Marsh, 1977), both of which were claimed to 
be effective against animals resistant  to FGARs. By the 1990s, however, many of the 
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differing foci had been shown to also be resistant against one or both of these SGARs 
(Redfern and Gill, 1978; Greaves, Shepherd and Gill, 1982; Greaves, Shepherd and Quy, 
1982; Greaves and Cullen-Ayres, 1988; Cowan et al., 1995; Quy et al., 1995). 
In addition to difenacoum and bromadiolone there are three other second generation 
anticoagulants: brodifacoum (Rennison and Dubock, 1978), difethialone (Lechevin and 
Poche, 1988) and flocoumafen (Bowler, Entwhistle and Porter, 1984). These are sometimes 
known as “resistance breakers” (Daniells, Prescott and Buckle, 2011; Buckle, 2013a) due to 
their higher toxicity and the fact that, to date, no Norway rats have been found with practical 
resistance to these compounds (Myllymäki, 1995). Due to their very high toxicity and 
persistence in the bodies of target animals (HSE, 1986), and consequently the perceived risk 
of primary and secondary poisoning of non-target species, in the UK they were limited only 
to use against rodents living primarily indoors until recently. Given the mobility of Norway 
rats and their wide-ranging feeding behaviour, this has made these more potent SGARs 
effectively illegal for the control of Norway rats. This is reflected in survey data from both 
urban and rural areas (Mcdonald and Harris, 2000; Dawson and Garthwaite, 2004; Dawson, 
Bankes and Garthwaite, 2003). The excessive use of frequently non-efficacious rodenticides 
has had severe consequences promoting resistance.  
 
1.4.2 Mechanism of anticoagulant resistance 
Resistance is a very technically precise phenomenon, and has been best summarised by 
Greaves, (1994): “Anticoagulant resistance is a major loss of efficacy in practical conditions 
where the anticoagulant has been applied correctly, the loss in efficacy being due to the 
presence of a strain of rodent with a heritable and commensurately reduced sensitivity to the 
anticoagulant.” This definition naturally precludes dietary based resistance wherein 
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anticoagulant-susceptible rats fed high protein diets have significantly reduced clotting 
impairment 53 hours after a lethal dose of anticoagulant, compared with rats fed normal diets 
(Colvin and Wang, 1974). There is also no room for naturally low susceptibility in this 
definition: For instance, wild-type susceptible house mice are naturally less susceptible to 
FGARs than are Norway rats and can survive higher doses of these rodenticides (Fisher, 
2005). See Song et al. (2011) for in depth discussion of the Algerian mouse (Mus spretus), 
genetic introgression of which has been shown to confer a further form of genetic resistance 
to house mice. Tests using anti-bacterial drugs to remove gut bacteria which produce Vitamin 
K2 showed that they do not influence the resistance status of individual rats (Lund, 1964), and 
that, therefore, the resistance mechanism interfered with the effect of the anticoagulants 
themselves, rather than bypassing them. 
For over 40 years after the first discovery of anticoagulant resistance, the location of 
the resistance genes and their structures were unknown, and it was not possible to allocate a 
rat of unknown origin to a known resistance focus with certainty. However, a critical 
discovery was made when the location of the gene which causes resistance in rodents was 
identified. Pharmacodynamic resistance, in which animals display genetic mutations in the 
vitamin K-2, 3-epoxide reductase gene (VKORC1), is now thought to be the major 
mechanism of anticoagulant rodenticide resistance in Norway rats (Li et al., 2004; Rost et al., 
2004, 2009). With the exons of the gene sequenced, a range of single nucleotide 
polymorphisms (SNPs) – mutations in the code caused by a single base pair changing and 
therefore coding for a different amino acid – were identified (Pelz et al., 2005). Subsequently, 
the scientific literature has been largely concerned with sampling rat tissue and identifying 
the mutation(s) underlying some of the resistance foci across Europe and the UK and, where 
possible, determining the susceptibility of these individuals to the various anticoagulants 
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available (Lasseur et al., 2007; Grandemange et al., 2009, 2010; Prescott et al., 2010; Baert et 
al., 2012; Buckle, Klemann and Prescott, 2012; Meerburg et al., 2014).  
Nine SNPs have been found in wild Norway rats in the UK, and five of these are 
known to have a significant impact on the efficacy of some anticoagulants; no other country 
has populations of rats of each resistance strain established in the wild. This is likely 
explained by the fact that in other EU countries in which resistance is present, no heavy 
restrictions on SGAR use such as those in the UK have been in place (Buckle, 2013a). The 
five mutations are described here in the context of their known presence in the UK, and 
summarised in Table 1.1: 
(1) Also known either as “Berkshire” or “Hampshire” resistance, the L120Q mutation 
confers a very strong form of resistance, known to be responsible for cases of practical 
resistance to bromadiolone and difenacoum (Redfern and Gill, 1978; Greaves, Shepherd and 
Gill, 1982; Gill et al., 1993, 1994; Quy et al., 1995), and technical resistance (resistance 
detectable in the laboratory, but with no practical effect in the field) to brodifacoum (Gill, 
Kerins and MacNicoll, 1992; Gill et al., 1994). However, despite having an identical SNP, 
historically Norway rats from Hampshire and Berkshire were reported to have different levels 
of resistance to a variety of anticoagulant compounds (see Section 2.2.2.1). Recently, in a 
Hampshire site where treatments with large amounts of difenacoum and bromadiolone had 
failed over the course of two years, brodifacoum was used to quickly eradicate the population 
of rats in question (Meyer, 2009). Tests to determine the effect of this mutation on vitamin K 
requirement in rats have shown the Hampshire and Berkshire forms of this resistance to be 
very different in their effect (see Section 1.4.3). This mutation has recently been found in 
continental Europe (e.g. see Baert et al., 2012). 
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(2) Also known as “Scottish” resistance, the L128Q mutation caused the initial 
resistance focus reported in 1959 when anticoagulant resistance in Norway rats was first 
identified. It is apparently unique in that the altered active site of Vitamin K epoxide 
reductase allows for a reversible bond (Thijssen, 1995) with some FGARs: the enzyme is 
reactivated in the same manner as it is after interacting with Vitamin K epoxide. In contrast, 
the other mutations described in this section reduce the likelihood of a bond forming at all, 
thereby increasing the dietary requirement for vitamin K. The SGARs are all thought to retain 
their efficacy against rats with this mutation (Hadler, Redfern and Rowe, 1975; Greaves and 
Ayres, 1982; Greaves and Cullen-Ayres, 1988); the altered Vitamin K epoxide reductase, 
when exposed to SGARs, has been shown not to reactivate (Thijssen, 1995). This mutation 
has also been found in parts of France (Grandemange et al., 2010). Rats that possess this 
mutation are known to have a very high vitamin K requirement (see Section 1.4.3). 
(3) Also known as “Gloucester” resistance, most of what is known of the impact of 
the Y139C mutation comes from work conducted in continental Western Europe. It has been 
found in Germany (Pelz, Hänisch and Lauenstein, 1995), the Netherlands (Meerburg et al., 
2014), France (Grandemange et al., 2010) and Denmark (Lodal, 2001). As with L120Q, rats 
with this mutation appear to be largely resistant against bromadiolone and the FGARs 
(Endepols et al., 2012) and, to a lesser extent, difenacoum (Buckle et al., 2013) but can be 
controlled using brodifacoum baits (Buckle, Klemann and Prescott, 2012). It is believed that 
difethialone and flocoumafen baits would also be fully effective against this strain of rats. 
There have been numerous studies on the pleiotropic effects of this mutation, showing wildly 
different results (see Section 1.4.3). 
(4) Only recently discovered in the UK (Prescott et al., 2010), the Y139F (or “Kent”) 
mutation is widespread in North-Western Europe (Buckle, 2013a). Most of what is known 
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about this mutation’s impact on efficacy comes from work conducted in continental Western 
Europe. Rats with this mutation are known to be resistant to FGARs, bromadiolone and 
difenacoum (Grandemange et al., 2009). An older study showed that infestations of resistant 
rats in Kent could be controlled with difenacoum (Rennison and Hadler, 1975), but because 
this experiment took place 30 years before the discovery of the Y139F mutation, it cannot be 
confirmed that the rats in question possessed it or not. 
(5) Until recently, the Y139S mutation had only ever been found in one focus on the 
Welsh-Shropshire border, and consequently has become known as “Welsh” resistance. One 
individual with this mutation was found in Yorkshire (Haniza et al., 2015), but the authors 
admit this might have been misidentified. Due to repeated failures to control it upon its first 
discovery (Bentley, 1968; Greaves, 1994), it is not known how large this focus is. Rats with 
this mutation are known to be resistant to FGARs but are effectively controlled with all 
SGARs in the field (Rennison and Hadler, 1975; Rennison and Dubock, 1978; Richards, 
1981; Greaves and Cullen-Ayres, 1988; Buckle, Endepols and Prescott, 2007). As with the 
L128Q mutation, this mutation is associated with serious pleiotropic costs to rats that possess 
it (see Section 1.4.3). 
Table 1.1: Five mutations of exon 3 of VKORC1 that confer practical resistance to Norway rats 
Original location in UK Mutation Wild-type amino acid (nucleotides) 
Mutation amino acid 
(nucleotides) 
Berkshire/Hampshire L120Q 
Leucine 
(Cytosine-Thymine-
Guanine) 
Glutamine 
(Cytosine-Adenine-
Guanine) 
Scotland L128Q 
Leucine 
(Cytosine-Thymine-
Guanine) 
Glutamine 
(Cytosine-Adenine-
Guanine) 
Gloucester Y139C 
Tyrosine 
(Thymine-Adenine-
Thymine) 
Cysteine 
(Thymine-Guanine-
Thymine) 
Kent Y139F 
Tyrosine 
(Thymine-Adenine-
Thymine) 
Phenylalanine 
(Thymine-Thymine-
Thymine) 
Wales Y139S 
Tyrosine 
(Thymine-Adenine-
Thymine) 
Serine 
(Thymine-Cytosine-
Thymine) 
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1.4.3 Pleiotropic costs of resistance 
The altered state of vitamin K-2, 3-epoxide reductase in resistant rats means that coumarin 
derivatives such as warfarin no longer act as antagonists, but it also affects the animal’s 
vitamin K cycle in the absence of anticoagulants. In many cases, resistant animals suffer 
deficient vitamin K metabolism due to the VKOR enzyme’s reduced activity (Pelz et al., 
2005) or binding affinity for both anticoagulants and vitamin K epoxide (Bell and Caldwell, 
1973). They therefore have a greater dietary requirement for vitamin K than susceptible 
animals (Greaves and Cullen-Ayres, 1988; Markussen et al., 2003), with animals 
homozygous for resistance mutations affected to a much greater extent than heterozygous 
individuals (Greaves and Cullen-Ayres, 1988; Jacob et al., 2012). 
The pleiotropic costs of resistance mutations are highly variable between strains. 
Welsh-resistant rats (Y139S) have been extensively studied in this regard. When left to breed 
freely, the number of males in Welsh-resistant litters very quickly starts to drop significantly 
compared to the number of females (Bishop, Hartley and Partridge, 1977). When this strain 
of rats is maintained on a low vitamin K diet and blood-prothrombin levels measured, 
concentrations in resistant animals diminished at a significantly faster rate than did those of 
susceptible animals (Bishop, Hartley and Partridge, 1977). In similar experiments, Welsh 
heterozygotic, homozygotic and susceptible rats were maintained on varying dietary levels of 
vitamin K in order to determine the effect on their resting one-stage prothrombin time (PT); it 
was found that heterozygotes required 2-3 times more vitamin K in their diets than 
susceptible rats in order to maintain a similar PT, while homozygotes required more than 10 
times as much (Hermodson, Suttie and Link, 1969). These experiments were replicated and 
shown to be even more profound in the case of male homozygotes, some of which required 
up to double the dietary vitamin K of female homozygotes. These experiments also showed 
that coprophagy is an important source of vitamin K for anticoagulant-susceptible and 
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heterozygous Norway rats, but this behaviour could not supply the requisite vitamin K for 
homozygous-resistant animals. A heavily resistant population of Welsh-resistant rats in the 
field showed a significant decline in the proportion of resistant animals present during an 18-
month hiatus in the application of FGARs (Partridge, 1979). 
Further experiments showed that litters of Norway rats from two heterozygotic-
resistant parents suffered significantly more mortality than those from one susceptible and 
one heterozygotic-resistant parent (Partridge, 1980). Scottish-resistant (L128Q) subadult 
males rats were found, even when supplied with vitamin K3 (menadione) in their water, to 
suffer from reduced growth rates compared with Welsh-resistant male rats of the same age, 
which in turn had reduced growth rates compared with susceptible male rats (Smith, 
Townsend and Smith, 1991). An earlier study showed, however, that Scottish resistant rats 
(known then as HS rats) require lower levels of dietary vitamin K than do Welsh resistant rats 
(known then as HW rats) in order to prevent prothrombinaemia (Greaves and Ayres, 1973). 
There have also been several studies on Danish resistant rats (Y139C aka “Gloucester 
resistant”). Here, evidence for pleiotropic costs is mixed. One study has suggested that the 
mutation results in reduced litter sizes (Jacob et al., 2012); resulting in a gradual reduction in 
the proportion of resistant animals in a population (Lund, 1966). However, a further study on 
resistant rats from Denmark found no costs associated with the breeding of resistant rats in 
the absence of treatment (Heiberg, Leirs and Siegismund, 2006), while a population study 
that took place over two years found that the prevalence of resistance did not fall for the 
duration (Siegismund, Heiberg and Leirs, 2002); however, it was acknowledged that the 
menadione in the lab-pellets used may have influenced this. 
Despite the increased survivability and population fitness conferred by vitamin K-rich 
food sources, it has been shown that rats from Germany which have very high pleiotropic 
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costs conferred by their specific resistance mutation (despite having the same resistance 
mutation as rats from Denmark - see Section 3.1.4.3; Jacob et al., 2012) do not select food 
sources based upon their  vitamin K content, and therefore do not preferentially seek out 
dietary vitamin K despite their high requirement for it (Jacob and Freise, 2011). Hampshire-
resistant rats (homozygous for the L120Q mutation) have a dietary vitamin K requirement up 
to four times greater than that of Welsh-resistant rats (Greaves and Cullen-Ayres, 1988). 
Studies previously carried out at the University of Reading contradict these findings: 
suggesting that Hampshire-resistant rats, when fed a vitamin K deficient diet, suffer less 
prolonged prothrombin times than do Welsh-resistant rats on the same diet; and that 
Berkshire-resistant rats suffer prolonged prothrombin times when fed vitamin K deficient 
diets (Pelz and Prescott, 2015). A subsequent study showed resistant rats from southern 
England (their exact provenance is not stated) suffered no size-related costs compared with 
susceptible animals (Smith et al., 1993), indicating that they are capable of social dominance 
in populations of mixed resistance status (Brooks and Jackson, 1973). To compound the 
confusion around this, it has been clearly shown that any pleiotropic costs of resistance are 
readily offset by the typically high levels of menadione in animal feed on farms, and that 
farm animal feed even increases the selection of resistant rats in the presence of anticoagulant 
treatment, because it has no antidotal effect on susceptible rats (MacNicoll and Gill, 1993b).  
 
1.4.4 Practical impacts of resistance 
The greatest, most immediate, impact of anticoagulant resistance is the reduction in 
effectiveness of anticoagulant treatments (Cowan et al., 1995; Quy et al., 1995; Meyer, 
2009). Failure to control rodent populations can result in spoilage and loss of foods and 
goods, zoonotic disease transmission and direct harm to vulnerable species as described 
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above. Invariably, subsequent attempts to control rodent outbreaks are implemented such 
that, regardless of the success or failure of these further attempts, more money will be spent 
on eradicating or controlling resistant populations than susceptible populations. In this 
manner, anticoagulant resistant Norway rats cost farmers and landowners money both 
directly and indirectly. The prevalence of resistance resulted in the development of the 
SGARs, and the requirement for new baiting techniques utilising more rodenticide bait than 
ever before, such that concerns have been raised that resistance is actually a financially 
lucrative problem for the pesticide industry, at the cost of those people living with rodent 
infestations in their homes and / or workplaces (Greaves, 1995). 
As with many chemical pesticides, the use of anticoagulant rodenticides has led to 
both lethal and non-lethal exposure of non-target organisms due to accidental misuse and / or 
deliberate abuse of these baits. Because most vertebrates have similar physiologies, pesticides 
targeting vertebrates often have non-target impacts (Smith and Shore, 2015). Mammals and 
birds have the same coagulation pathway (Gentry, 2004), albeit with varying levels of the 
blood clotting factors described above, and are therefore vulnerable to non-target poisoning. 
Due to their high toxicity and the perceived danger they present non-target species, the 
resistance breaking SGARs were, until recently, restricted solely for use against rodent 
infestations in the UK that lived primarily indoors, making them effectively illegal to use 
against Norway rats. Bromadiolone and difenacoum, on the other hand, were authorised for 
use “indoors and outdoors”. This lack of restriction on their use resulted in massive use of 
these compounds in rural areas, (Mcdonald and Harris, 2000; Dawson, Bankes and 
Garthwaite, 2003). This over-use may have been further exacerbated by their ineffectiveness 
in many areas of the UK, thereby resulting in severe exposure of non-target wildlife. 
Victims of primary non-target poisoning (whereby animals directly consume 
anticoagulant rodenticides; Smith and Shore, 2015) are usually rodents that, due to the 
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relatively large size of Norway rats, are able to access any bait point / box that a rat can. Bank 
voles Clethrionomus glariolus, field voles and wood mice Apodemus sylvaticus are all 
potential victims of primary poisoning, and their numbers fell by an average of 56% in a 
series of field trials using coumatetralyl to target Norway rats at farms and pheasant 
Phasianus colchicus feeding sites (overseen by gamekeepers) in the UK (Brakes and Smith, 
2005). However, it is important to note that the use of coumatetralyl in this experiment, 
selected to reduce the potential risk to birds, may have exacerbated the impact on non-target 
animals; three of the VKORC1 mutations present in Norway rats in the UK are thought to 
confer practical resistance to coumatetralyl (Y139C; Endepols et al., 2007; Y139S and 
L128Q; Buckle, 2013a), and the other two are known to confer strong resistance to SGARs 
(e.g. Y139F; Grandemange et al., 2009; L120Q; Gill, Kerins and MacNicoll, 1992) 
Therefore, it is unlikely that coumatetralyl would effectively control the rat population, 
leading to an increase in the volume of coumatetralyl used, thereby exacerbating the impact 
on non-target animals. 
Victims of secondary non-target poisoning are predators or scavengers that hunt, or 
consume, the bodies of animals that have themselves consumed anticoagulant rodenticides 
(Smith and Shore, 2015). Anticoagulants are highly persistent in mammalian tissue, 
particularly the liver. For example, brodifacoum has a half-life of 307.4 days in the liver of 
house mice, and other SGARs have liver half-lives of between 28.1 and 93.8 days 
(Vandenbroucke et al., 2008). Therefore, animals which survive the consumption of 
rodenticide baits (a figure which is directly influenced by the level of resistance in 
commensal species in the UK) present an amplified risk to predators and scavengers (Shore et 
al., 2015) as do other animals that consume baits and survive (or die). Resistant rats from 
south-east England, which are more likely to survive exposure to anticoagulants than are 
susceptible rats, have also been shown to absorb and retain (due to higher consumption) 
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significantly more difenacoum than susceptible conspecifics (Atterby, Kerins and MacNicoll, 
2005). 
Species living in close proximity to humans are especially at risk; red kites Milvus 
milvus have been shown to be highly active around farm buildings, typically scavenging dead 
rats in one farm site within 12 hours (Ntampakis and Carter, 2005). Of 23 red kites found 
dead and handed in to the Predatory Bird Monitoring Scheme (PBMS) between 1994 and 
2005, 17 (73.9%) contained residues of at least one anticoagulant rodenticide, with an 
average concentration in the liver of 0.166 mg/kg. Summary data from The Toxicology 
Laboratory of the College of Veterinary Medicine (Lyon, France) 1992 – 2002 in France are 
presented by Berny and Gaillet (2008), and further suggest a correlation between 
anticoagulant rodenticide use and residue presence in birds of prey carcasses submitted for 
analysis. Red foxes Vulpes vulpes are also predators of commensal rodents and, depending 
upon available prey, may frequently have SGAR liver residues (Tosh et al., 2011a). Non-
target animals that consume rodenticides may also provide a route of contamination for 
secondary poisonings; given the rate of exposure of non-commensal rodents (Brakes and 
Smith, 2005) and the distances they can carry an anticoagulant load (sufficient to leave the 
boundaries of the farm on which they were exposed – Tosh et al., 2012), it is not surprising 
that species such as polecats Mustela putorius (Shore et al., 1996), barn owls Tyto alba 
(Walker et al., 2008), weasels Mustela nivalis and stoats Mustela erminea (McDonald et al., 
1998) are all frequently found with liver residues of SGARs.  
In addition, although rarely active during the day, Norway rats have been shown to 
lose their normal nocturnal behaviour when suffering from anticoagulant poisoning, resulting 
in their being readily available as prey (Cox and Smith, 1992) for both diurnal and nocturnal 
predators. This may therefore be the causal factor in the high numbers of kestrels (diurnal 
hunters of mice and voles) that have been were found to contain SGAR residues (65% of 
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individuals analysed between 2001 and 2005; Shore et al., 2007); wood mice, known to be 
able to carry up to 0.64 mg/kg brodifacoum in their livers (Tosh et al., 2012), and bank voles 
respond in the same manner (Brakes and Smith, 2005), thereby representing a contamination 
pathway for diurnal predators. This does not, however, explain the number of sparrowhawks 
Accipiter nisus found with anticoagulant contamination in Scotland between 2000 and 2010; 
despite restricting their predation to birds, they had similar rates of anticoagulant 
contamination to species that prey on rodents (Hughes et al., 2013). The absorption of 
environmental anticoagulant rodenticide residues by earthworms may represent a pathway of 
exposure from passerines to sparrowhawks (Booth et al., 2003; Liu et al., 2015). 
Furthermore, the use of liquid chromatography mass spectrometry (LCMS) has 
enabled researchers to identify SGAR residues in invertebrates (Brooke et al., 2013), and 
suggests that they represent a contamination pathway for insectivorous mammals such as the 
European hedgehog Erinaceus europaeus (Dowding et al., 2010). The increased sensitivity of 
this methodology, relative to high performance liquid chromatography (HPLC), may also 
come to reveal the extent of non-target poisoning in the UK to be worse than previously 
thought (Dowding et al., 2010). A recent study utilising HPLC has shown slugs to represent a 
high-risk secondary exposure pathway hedgehogs, common shrews Sorex araneus and 
starlings Sturnus vulgaris (Alomar et al., 2018). 
The actual effect of the extensive non-target contamination on its victims in the UK 
is, however, ambiguous. The number of residues found is influenced by a variety of factors, 
including operational bias. The Wildlife Incident Investigation Scheme (WIIS) is a statutory 
organisation set up to investigate instances of suspected poisoning of UK wildlife (Brown et 
al., 1996), but due to the nature of its investigations, only animals that died of poisoning (or 
appeared to have died of poisoning) are recorded, potentially inflating the apparent rate of 
non-target poisoning in the UK. Meanwhile, PBMS data for 2007-2008 state that of 98 barn 
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owls examined in those years, 79 contained residues of at least one SGAR, and 53 contained 
residues of multiple SGARs. Of these 98, >80% had sum liver residues of <0.08 mg/kg of all 
SGARs (Walker et al., 2010). These data rely on opportunistic sampling, and therefore 
cannot be used as an estimate of total populations exposed to anticoagulant rodenticides. In 
laboratory tests, it was found that the lethal range for SGAR residues in barn owl livers began 
at > 0.2 mg/kg (Newton et al., 1999), however it is possible that sub-lethal liver 
concentrations do impact individual fitness and therefore indirectly contribute to mortality. 
Furthermore, barn owls are one of many species secondarily exposed to SGARs, and data 
from France show wild foxes, buzzards and red kites suffering mortality as result of SGAR 
exposure (Berny et al., 1997; Berny and Gaillet, 2008).  
In addition, according to Buckle, (2013b) none of the species often found to be 
victims of non-target poisoning in the UK are of conservation concern, or even thought to be 
decreasing (however, see Fournier-Chambrillon et al., 2004 for evidence of residues found in 
critically endangered European mink Mustela lutreola in France). The lack of central (i.e. 
governmental) co-ordination among the various governmental schemes, NGOs and industry 
means that it is likely that instances of poisoning go under-reported in the UK (Sainsbury et 
al., 2001). The negative effect of the misuse of anticoagulants in concert with Norway rat 
resistance is avoidable and, given the lack of humaneness associated with the symptoms and 
effects of anticoagulant poisoning (Mason and Littin, 2003), its prevention is desirable.  
 
1.4.5 Stewardship scheme 
With the impending (31st October 2014 – 31st January 2017) expiry of all anticoagulants from 
the Biocidal Products Directive (BPD; Buckle, 2013a), and the continued issues of resistance, 
a new system of rodent control was required. From the 1st April 2016, the UK rodenticide 
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stewardship scheme, co-ordinated by the Campaign for Responsible Rodenticide Use 
(CRRU), was put into effect (Buckle et al., 2017). The concept behind the scheme is simple: 
by shifting the responsibility of responsible rodenticide use to the users, and requiring proof 
of competence  from them, the capability of users to deal with resistant Norway rat 
populations would be enhanced, as would their knowledge on how to reduce incidences of 
non-target poisoning. It is thought that by enabling users to access any SGAR and changing 
their patterns of use, a greater impact can be had on rat infestations whilst simultaneously 
minimising negative environmental/non-target impacts (Eason et al., 2001). At the time of 
writing (April 2017), the “use by period” (a grace period in which products purchased before 
proof of competence was required could be utilised) has ended. From this point on, all 
rodenticide products that fall under this stewardship regime will carry the following 
statement: “For supply to and use only by professional users holding certification 
demonstrating compliance with the UK rodenticide stewardship scheme requirements”. A 
survey of farmers in Northern Ireland found that the majority of farmers who use rodenticides 
do not search for or remove rat carcasses following rodenticide treatments, and do not 
remove bait in response to rat population decline (Tosh et al., 2011b). Only 1% of farmers 
surveyed had attended a training course on the safe use of anticoagulant rodenticides (Tosh et 
al., 2011b), so the advent of the stewardship scheme was both necessary and timely. 
Foxes in Ireland, where use of brodifacoum and flocoumafen is much more prevalent 
than in the UK, have a higher rate of flocoumafen and brodifacoum residues than do the 
foxes of the UK (Tosh et al., 2011a). Given that data from the UK show that non-target 
residues are linked with anticoagulant usage (Walker et al., 2010; Hughes et al., 2013), it is 
reasonable to assume that incidences of non-target poisoning involving the resistance-
breaking SGARs will have increased in the year since the stewardship scheme was 
introduced, regardless of the increased level of “competence” among users. As the sales of 
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brodifacoum, flocoumafen and difethialone increase, especially now that old rodenticide 
stock can no longer be used, monitoring this issue as it continues to develop will be an 
important measure of the success of the scheme in its aims. CRRU has already nominated the 
barn owl as its sentinel species for this work (Buckle et al., 2017), but monitoring of other 
species will also be necessary in the coming years. 
 
1.4.6 Anticoagulant resistance in Norway rats in the south-east of England 
Loss of fitness due to pleiotropic costs as described above is thought to have little impact in 
areas where resistance is prevalent, because there are few susceptible animals present to 
compete with resistant individuals (CSL, 2002). The established presence of several of the 
resistance-conferring VKORC1 mutations in the south-east of England (Pelz et al., 2005; 
Prescott et al., 2010; Haniza et al., 2015), in combination with the frequency of recorded 
treatment failures and apparently resistant populations (Greaves, Shepherd and Quy, 1982; 
Cowan et al., 1995; Quy et al., 1995; Meyer, 2009) suggests that anticoagulant resistance in 
Norway rats in the south-east of England has reached a point where susceptible rats are so 
few and far between that, with limited gene flow between populations (Haniza et al., 2015), it 
can only be dealt with by successfully controlling the strongest forms of resistance in Norway 
rats. Prior to the commencement of the stewardship scheme described above, the Rodenticide 
Resistance Action Group (RRAG, 2012) suggested that in Hampshire, Berkshire and parts of 
several other southern counties, control of Norway rats by legal chemical means was 
impossible, and should not be attempted. 
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1.5 Aims of the current study 
1.5.1 Locate and delimit resistance foci 
It can with be stated with complete certainty that in the UK there are at least five resistance-
conferring mutations in Norway rats that have significant effects upon efficacy of 
anticoagulant rodenticides in the field, and that the three mutations that confer the greatest 
level of resistance can all be found in the south-east of England. However, that is the limit of 
what can be said with confidence. Whilst we know where there is at least one focus of each 
of the three strongest mutations present in south-east England, what we do not know is the 
precise extent of each focus, and indeed exactly how many foci of each mutation there are. It 
is important to try to delimit each focus, in order to understand how much of this area is 
affected by these mutations. For instance it is known that the Y139F mutation is present in 
Kent, and it is thought to be impossible to achieve complete control over rat populations with 
this mutation with bromadiolone and difenacoum (Grandemange et al., 2009). Therefore it is 
suggested that knowing that this mutation (and others like it) occurs in Kent is not enough; 
the extent of this focus needs to be explored, as does the possibility that other foci of the 
Y139F mutation exist. If this mutation appears in – or spreads to – geographical locations in 
which the SGARs difenacoum and bromadialone are still currently used this will serve to 
increase the proportion of rats with the mutation in the local population, thereby reducing any 
chance for control in the near future and exposing non-target wildlife to an increased risk of 
lethal secondary poisoning. As stated above, it is currently thought that there are five 
mutations in the VKORC1 gene conferring significant resistance to wild Norway rats in the 
UK. It is necessary therefore to keep up to date with the locations of all of these mutations in 
the UK, as the presence of a mutation previously unknown in a given area could lead to 
treatments with inappropriate (i.e. non-effective) rodenticides and therefore result in an 
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increase in number of resistant rats and exposure of non-target wildlife to secondary and / or 
primary poisoning. Most, if not all, of what we know of the practical effects of resistance 
mutations comes from wild examples of animals from the various foci undergoing laboratory 
tests. For this reason we already have an indication of what effect a known mutation will 
have when a population of resistant rats undergoes anticoagulant rodenticide treatments. 
What is not known is the effect of two foci extending outwards and crossing over, allowing 
rats with different resistance conferring mutations to interbreed. This situation has already 
arisen in the field (Haniza et al., 2015), and identifying further areas where this may occur, or 
has already, will be invaluable given the established presence of the strongest resistance 
mutations in the south-east of England (Pelz et al., 2005; Prescott et al., 2010; Haniza et al., 
2015). Using maps to display the locations and size of resistance foci may also allow 
subsequent studies to utilise data from the PBMS and WIIS to quantify the effect that 
rodenticide resistance has on non-target exposure to rodenticides. The extent to which 
resistance exacerbates non-target effects is not yet known, and would be useful for the 
prevention and reduction of further harm to non-target wildlife. 
 
1.5.2 Establish which anticoagulants are safe to be used 
In order to directly control the highly resistant Norway rat populations of south-east England, 
the level of resistance conferred by the dominant mutation(s) in the region must be 
established. Within a decade of the discovery of anticoagulant resistance in Norway rats and 
house mice, wild and laboratory rodents were subjected to laboratory tests to quantify and 
qualify the effect of resistance (Drummond and Wilson, 1968; Rowe and Redfern, 1968). 
With the advent of the UK rodenticide stewardship scheme, the usage of the resistance 
breaking SGARs is likely to have increased, and to continue increasing. It is imperative 
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therefore that information regarding the effect of each of the SGARs on the resistant rats of 
south-east England is made available, in a standardised form, for the first time. These 
laboratory experiments will build on the work of Prescott et al. (2007) to provide resistance 
factors for resistant strains of rats, as well as effective doses of the relevant anticoagulants. 
 
1.5.3 Confirm their impact in the field 
Because exact SGAR doses (or the equivalent bait consumption) cannot be guaranteed in the 
field, and the genetic profile of a population of wild rats is unlikely to be as uniform as that of 
a laboratory strain, the results obtained in a laboratory test are not always an accurate 
representation of what will occur in the field. Utilising the results obtained in laboratory 
experiments to determine the resistance factors for the SGARs against the resistant rats likely 
to be found in the south-east of England, suitable locations and anticoagulant rodenticides 
will be identified for brodifacoum field trials. These field trials will explore the practical, 
real-world impact of resistance on rodent control using a variety of SGARs, including those 
only recently cleared for use under the stewardship scheme (Buckle et al., 2017). By 
recording the volume of total active ingredient consumed during the trial and monitoring 
tracking patches in order to determine Norway rat activity, these trials will allow us to 
estimate the impact of the stewardship scheme on rodent control success throughout the UK. 
In addition to elucidating the feasibility of rodenticide use in the south-east of England, the 
results of these field trials may confirm the findings of the laboratory experiments – if they 
do, it will allow future users to safely rely on the results similar experiments using other 
SGARs and other strains of resistant rats to predict likely outcomes in the field. 
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Chapter 2: Methods 
2.1 Identifying and delimiting resistance foci 
2.1.1 Resistance identification 
The first discoveries of anticoagulant resistance in Norway rats centred on failed rodenticide 
treatments in the field during attempts at control. Nearly 60 years later, this would still appear 
to be the method most commonly used by PCO (or other stakeholder) to establish that a wild 
populations of rodents contain individuals that are resistant to certain anticoagulant 
rodenticides; primarily because of financial and temporal constraints, PCOs are reluctant to 
delay attempts at controlling rodent populations in order to ascertain whether or not any of 
the animals on site carry a resistance mutation. This is an unreliable method of determining 
whether or not resistance is present, for a variety of reasons. Firstly, rats may avoid 
consuming anticoagulant bait due to neophobia or the presence of alternative food sources 
(Quy, Shepherd and Inglis, 1992); before resistance is confirmed, it must be established that 
the bait in question has been properly and effectively used and sufficient bait uptake to cause 
mortality has occurred (Quy et al., 1992). Reinvasion by rats or the presence of other rodents 
may also provide false-positive evidence of survival of consumption of rodenticide bait. If 
during a rodenticide treatment it appears that resistance is present, the time taken to establish 
this via failure to achieve control despite following proper procedures, may be sufficient for 
negative impacts of the application to occur (such as selecting for resistant rats within the 
population and exposing predators of rats and non-target rodents to secondary poisoning). A 
further problem with this method is that it provides little information regarding the strength of 
the resistance conferred by the mutation, and the prevalence of the mutation within the 
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population. The only information provided is survivability at a single concentration of a 
single active ingredient, with an unknown feeding period.  
 
2.1.2 Molecular techniques 
For many years, the phrase “cross resistance” was used in reference to different strains of rats 
and mice for which resistance against multiple anticoagulants could be demonstrated. In 
2004, three exons of the VKORC1 gene were identified and sequenced, and were believed to 
code for functional components of the enzyme vitamin K epoxide reductase (Rost et al., 
2004; see Section 1.3.5.1) and a series of anticoagulant resistance-conferring mutations were 
discovered. These mutations were shown to be responsible for the known resistance foci 
across Europe. Crucially, all the known major resistance mutations were subsequently found 
to be located on the third exon of VKORC1, confirming that every mutation that confers 
resistance to a given anticoagulant will confer resistance to all other anticoagulants. Some of 
these resistances may only be technical resistance, where there is no discernible effect on 
treatment outcome. 
Molecular techniques are most often used to analyse a small amount of blood, tissue 
or faecal matter from a rodent. These methods are advantageous as they do not involve the 
use of live animals. Methods which rely on the response of animals to direct application of 
anticoagulants are both time consuming and relatively inhumane due to the stress caused by 
exposing wild animals to unfamiliar environments and handling by researchers. The 
molecular technique most often used is the Amplification Refractory Mutation System 
(ARMS) Polymerase Chain Reaction (PCR), which determines the presence or absence of a 
single mutation in wild rodents, as in studies from Germany (Pelz et al., 2005), Denmark 
(Heiberg, 2009), and Belgium (Baert et al., 2012). In the present case, all three exons of 
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VKORC1 were sequenced to determine for which (if any) VKORC1 mutations each rat was 
positive. Assuming that fresh tissue or faecal matter from wild rats is readily available, these 
tests are ideal in terms of humaneness, because no laboratory-housed animals are required 
whatsoever. From March 2009 to September 2015, tissue and faecal samples were collected 
by researchers with a focus on the south-east of England. VKORC1 exons 1, 2 and 3 were 
sequenced and subsequently generated chromatograms were analysed individually by eye for 
all SNPs. Primers were generated using Primer3web 4.0.0 (Koressaar and Remm, 2007; 
Untergasser et al., 2012). Primers used are detailed in Section 3.2.5. 
 
2.1.3 Obtaining samples 
2.1.3.1 Tail samples 
As of March 2009, the University of Reading and the University of Huddersfield had entered 
into an agreement with industry representatives to analyse Norway rat tissue samples 
supplied by pest controllers. Samples sent to the University of Reading were to be from the 
west Midlands, East Anglia and central-southern England. Following the decision in 2012 for 
the University of Reading project to focus on a contiguous area in the south-east of England, 
on behalf of an industrial partner (Killgerm), the focus shifted to obtaining fewer samples 
from a greater number of sites, spread evenly across the south-east of England. While this 
increased the chance of recording false negatives (obtaining tail samples from susceptible rats 
in a population where a resistance mutation was present in some, but not all rats), it also 
maximised the chances of accurately delimiting resistance foci. From April 2012 until 
September 2015, tail samples were obtained from rats that had been live trapped and killed, 
found in kill-traps or killed directly using dogs or firearms. The last ~five cm of tail was 
removed with a clean blade, and stored in 5 ml vials. These were filled with industrial 
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methylated spirits (IMS) diluted to 70 – 80%. Vials were then frozen as soon as possible. 
Following this methodology, no more than two tails were taken from any one site, and never 
from two juvenile animals caught or killed in the same area due to the likelihood of their 
being related, and therefore having the same VKORC1 SNP profile. Initially, tails were 
sampled directly by researchers. Areas that had not been sampled were identified on a map 
and farms and other sites of likely rat infestation visited. Once permission to do so had been 
granted by the landowner, attempts were made to capture rats in cage traps, which were then 
humanely killed on site in a CO2 chamber and their tails harvested. Due to the requirement to 
check traps daily, in areas increasingly further afield from Reading, it quickly became 
apparent that, in order to obtain samples from across the whole of south-east England, 
assistance would be required. Because the results of the study were to be made public by 
RRAC, in order to allow farmers, PCOs and other stakeholders to identify resistance foci 
covering their areas and respond to Norway rat infestations accordingly, it was hoped that 
they would in turn be invested in aiding attempts to obtain samples for testing. Therefore the 
editors of gamekeeper trade publications were contacted in order to publicise the study and 
request help in obtaining samples from areas outside Reading’s immediate surroundings. This 
resulted in articles in the Winter editions of Keeping the Balance 2012 and 2013, and 
Countryman’s Weekly in 2013 (see Appendix 1). In addition, pest control companies known 
to operate in the south-east were contacted, as were various industry contacts from among the 
members of RRAC. Those who expressed interest via phone calls and email were provided 
with a protocol for correct handling of tail samples and how many samples to take from a 
single site (see Appendix 1), as well as vials filled with 70 – 80% IMS free of charge. Interest 
was also generated due to several television appearances from those involved with the 
project, including ITV local news, The One Show and Ladykillers, and a Radio Berkshire 
broadcast. A large number of tail samples were obtained when a local borough council signed 
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a contract with the University of Reading to provide 100 tail samples from the central 
Reading conurbation, in return for all results obtained. Regardless of provenance, an exact 
postcode or x,y data were required with each sample in order to map results accurately. 
Despite the effort made to solicit the assistance of stakeholders who could contribute tail 
samples, very few individuals and companies made contact as a result, even fewer of which 
were located outside of the original “central-southern England” designation of Berkshire, 
Hampshire and Surrey, and it was decided that a different approach was required. 
2.1.3.2 Faecal samples 
Between September 2013 and December 2013, farms in Kent, East Sussex and East Anglia 
were visited, and Norway rat faecal samples collected for molecular analysis. Once 
permission to search the site for suitable samples had been obtained, rat droppings were 
examined visually, and those that appeared the most moist and glossy selected. Where 
droppings were very close together in a group or pile, only two were taken in an attempt to 
avoid taking too many samples from one individual. However, aside from grouping of 
droppings, there was no way to be entirely sure that droppings came from different 
individuals, so multiple droppings were taken from different areas of each site. Droppings 
were stored in vials and stored in a portable fridge within 30 minutes. Following a maximum 
of five days of collection, vials were transferred to a laboratory freezer and stored at -200C.  
 
2.1.4 Molecular analysis 
The DNEasy Blood and Tissue Kit (Qiagen Ltd, Crawley, West Sussex, UK) was used for 
DNA extraction from tail samples as follows: 
1. Heat Buffer ATL to 55 0C. 
2. Shave 2-3 mm of tissue off tail sample using a razorblade. 
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3. Add 180 µl of Buffer ATL and 20 µl of Proteinase K to tissue sample. 
4. Place in incubator. Set temperature to 50-55 0C, and shaker speed to 50 RPM. Leave 
overnight. 
5. Remove sample from incubator. Vortex for 15 seconds. 
6. Make a mixture of 50% Buffer AL and 50% ethanol; Add 400 µl of this to each 
sample. 
7. Vortex for 15 seconds. 
8. Pipette sample into a spin column contained within a 2 ml tube. 
9. Centrifuge at 8000 RPM for one minute. 
10. Add 500 µl of Buffer AW1. Centrifuge at 8000 RPM for one minute. 
11. Add 500 µl of Buffer AW2. Centrifuge at 13,000 RPM for three minutes. Put spin 
column in a new 1.5 ml Eppendorf. 
12. Add 70 µl Buffer AE. Wait for two minutes. 
13. Centrifuge at 8000 RPM for one minute. 
 
The QIAamp DNA Stool Minikit (Qiagen Ltd, Crawley, West Sussex, UK) was used 
for DNA extraction from faecal samples as follows: 
1. Weigh and separate 180-220 mg of stool sample. 
2. Add 1.6 ml Buffer ASL. Vortex for one minute. 
3. Centrifuge at 13,000 RPM for one minute and discard pelleted stool, retaining liquid 
supernatant. 
4. Add one InhibitEX Tablet. Vortex for one minute. 
5. Repeat Step 3 twice. 
6. Extract 600 µl of liquid supernatant. Add to 25 µl Proteinase K. 
7. Add 600 Buffer ASL. Vortex for 15 seconds. 
8. Incubate at 700C for 10 minutes. 
9. Add 600 µl of 96-100% ethanol to the lysate. Vortex for 15 seconds. 
10. Apply 600 µl of the lysate from Step 9 to a spin column contained within a 2 ml tube. 
Centrifuge at 13,000 RPM for one minute and discard the 2 ml tube containing the 
filtrate. 
11. Apply 600 µl of the lysate from Step 9 to the retained spin column, housed in a new 2 
ml tube. Centrifuge at 13,000 RPM for one minute and discard 2 ml tube containing 
the filtrate. 
12. Repeat Step 11. 
13. Repeat Step 11 with 500 µl of Buffer AW1 instead of lysate. 
14. Apply 500 µl of Buffer AW2 to the retained spin column, housed in a new 2 ml tube. 
Centrifuge at 13,000 RPM for three minutes and discard 2 ml tube containing the 
filtrate. Put spin column in a new 1.5 ml Eppendorf. 
15. Add 20 µl Buffer AE. Wait for one minute. 
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16. Centrifuge at 13,000 RPM for one minute. 
 
Extracted DNA was then amplified by PCR, and PCR products were evaluated by 
electrophoresis and examination under UV light. The PCR conditions were: two minutes at 
94◦C; followed by 35 cycles of denaturation at 94◦C for 30 seconds, annealing at 57◦C for 30 
seconds, elongation at 72◦C for 30 seconds; followed by a final extension at 72◦C for three 
minutes. Subsequently, the temperature was reduced to and held at 4◦C until the samples 
were removed. Primers are described in Section 3.2.5. DNA samples taken prior were 
amplified and analysed as described by Prescott et al. (2010). 
The QIAamp PCR Purification Kit (Qiagen Ltd, Crawley, West Sussex, UK) was 
used to purify PCR products as follows: 
1. Add Buffer PB at a ratio of 5:1 to PCR product. 
2. Transfer to a spin column housed in a 2 ml tube. Centrifuge at 13,000 RPM for 40 
seconds; discard flow-through. 
3. Add 750 µl Buffer PE. Centrifuge for 40 seconds at 13,000 RPM. Discard flow 
through, and centrifuge again for one minute. 
4. Transfer column to a 1.5 ml eppendorf. Add 25 µl Buffer EB. Wait for three minutes. 
5. Centrifuge at 13,000 RPM for one minute. The resulting elution is the final DNA 
product. 
 
Final DNA products were sent to Source Bioscience (Source BioScience plc, 
Nottingham, Nottinghamshire, UK) for Sanger sequencing. Sequences were received in the 
form of chromatograms which were individually analysed by eye in order to determine if 
there were any SNPs present, and their zygosity. Visual analysis was necessary firstly 
because the sequencing did not consistently recognise one nucleotide over another in a 
heterozygous base, and secondly because in chromatograms that show some evidence of 
contamination (which were frequent in the case of faecal samples) a human can still 
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sometimes determine the presence of a mutation in areas minor contamination that a 
chromatogram display application can’t recognise. 
 
2.1.5 Delimiting resistance foci 
After successful sequencing, the postcode of each sample was converted to OS x and y grid 
references using an online postcode converter (www.streetmap.co.uk/gridconvert.html). 
These were then added to an OS basemap (Ordnance Survey Ltd, Southampton, Hampshire, 
UK) using ArcGIS (Esri UK Ltd, Aylesbury, Buckinghamshire, UK), and assigned 
symbology based on the presence or absence of VKORC1 exon 3 mutations and their 
zygosity. These spatial data could then be analysed in terms of distance between resistance 
foci and their presence/absence in specified counties. 
 
2.2 Quantifying anticoagulant resistance in resistant strains of Norway rat 
2.2.1 Blood clotting response tests 
Very soon after the first discovery of anticoagulant resistance in rodents (Boyle, 1960) rats 
from populations that appeared to be exhibiting resistance (due to an apparent lack of efficacy 
of established anticoagulant poisons when applied to the populations in question) were often 
live trapped and subjected to laboratory feeding tests in order to determine whether 
physiological resistance was present, and if so to what degree. A lethal feeding period was 
established (Drummond and Bentley, 1965) with bait containing 0.005% warfarin for six 
days, during or after which 99% of susceptible rats are expected to die (LFP99). Those that 
survived were classified as resistant. A similar test was established for difenacoum, when it 
became clear that it was efficacious against rats from the Welsh resistance focus but 
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questionable against rats from central-southern England (Redfern and Gill, 1978). Because 
different rats respond differently to captivity and to specific baits, and feeding usually takes 
place over several days, the LFP99 does not give an exact dose at which 99% of rats are 
expected to die (LD99). In order to administer a known concentration of active ingredient, a 
system of limited bait intake must be applied, wherein the volume of bait supplied to an 
individual must be measured in terms of its concentration and the weight of the rat. This is 
typically much lower than the usual daily food intake of a rat in order to assure 100% 
consumption. Even so, 100% consumption, and therefore application of the full dose within 
the accepted time frame, can never be guaranteed. Another method of delivering a known 
concentration of active ingredient is through oral gavage or intraperitoneal injection. While 
this is a much more precise method than feeding tests, there is a requirement to wait for 
animals to suffer the symptoms of anticoagulant poisoning or die. This, along with the 
number of animals required for these tests, makes them both relatively impractical and 
inhumane. In due course, blood clotting response (BCR) tests were developed which allowed 
researchers to directly record the ability (via the time taken) of blood to clot. Using gavage or 
subcutaneous injection to administer the dose meant the entire dose could be delivered at 
once. This allowed blood to be taken at a fixed point, a known timeframe after the delivery of 
the entire dose.  Blood samples taken in this way can be used to determine an effective dose 
(ED) of a given concentration of an anticoagulant. In the first of these tests, warfarin was 
dissolved in dimethyl formide and injected subcutaneously; blood was extracted retro-
orbitally both before and after dosing, and prothrombin times measured using Diagen “Two-
Seven-Ten” (Greaves and Ayres, 1967). This method was subsequently refined over many 
years for the identification of resistant rats (Martin et al., 1979; MacNicoll and Gill, 1993; see 
Section 4.1.1 for details). Because of the small amounts of blood required, animals classified 
as resistant – and therefore likely to survive the anticoagulant dose administered – could later 
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be used in feeding tests to confirm the results of BCR tests (Greaves and Ayres, 1967) or in 
other tests entirely. With the establishment of laboratory-resistant strains of Norway rats, 
BCR tests increasingly focused on identifying ED99 values for susceptible rats, and then 
administering these doses to resistant rats in order to determine the likely impact of resistance 
in the field (Gill et al., 1994; Prescott and Buckle, 2000). However, it was not until the 
standard methodology was established (Prescott et al., 2007) that a system was created that 
would make all future data generated for the various strain-anticoagulant combinations 
comparable and therefore of use to everyone, providing the methodology was correctly 
followed. The new methodology, particularly its statistical analysis, also enabled the 
quantification of resistance (resistance factors, RF) conferred by the recently identified 
VKOR mutations (Pelz et al., 2005). The history, implications and liabilities of these 
methodologies are discussed in greater detail in Section 4.1.1.  
 
2.2.2 Strains of resistant Norway rat housed at Reading 
2.2.2.1 Strain origins 
Both feeding tests and oral gavage require live capturing wild rats and bringing them into a 
laboratory. Before tests can begin a mandatory treatment for ectoparasites and an 
acclimatisation period is necessary. Research on anticoagulant resistance in the UK has been 
aided by the establishment of various strains of laboratory rodents that are homozygous for an 
anticoagulant resistance mutation that was derived from a particular geographical location. 
Norway rat strains include the “Scottish strain”, the “Welsh strain”, the “Hampshire strain”, 
and more recently the “CSL Berkshire strain”, and house mouse strains include the 
“Cambridge creams” and the “Reading Berkshire strain”. The use of such strains overcame a 
number of problems associated with laboratory tests on wild caught animals, including: Extra 
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time required to acclimatise to laboratory conditions, inconsistency of feeding during test, 
difficulties of handling, stress-induced humaneness issues, unexpected mortality when 
maintained in the laboratory, and the uncertain nature of procuring a given number of wild 
rats in time for a predetermined experiment. The first resistant laboratory rats were descended 
from wild rats brought into the laboratory for feeding tests (see Section 2.2.1). Rats that 
survived the susceptible LFP99 and were classified as resistant were crossed onto susceptible 
laboratory rats and their offspring subjected to further feeding tests in order to obtain a strain 
of captive resistant rats. There are currently three strains of resistant rats housed at the 
University of Reading (see Section 4.1.3 for details), all of which underwent testing to 
quantify their level of resistance as part of this study. 
The first strain of anticoagulant-resistant laboratory Norway rats were captured in 
Scotland (Boyle, 1960; Greaves and Ayres, 1973) and taken back to the laboratory. There, via 
feeding tests against anticoagulants, a group of animals was established to be homozygous for 
Scottish (L128Q) resistance. These animals were subsequently back-crossed onto susceptible 
laboratory rats over several generations resulting in a domesticated line, fully homozygous 
for Scottish resistance. The second to be generated came from a group of resistant rats from 
Wales (Bentley, 1968) which were captured and selected for homozygosity (Y139S) and 
back-crossed onto susceptible laboratory rats as described above. The third strain to be 
generated came from a site in Hampshire where rats were demonstrated to possess practical 
resistance to both warfarin and difenacoum (Greaves and Cullen-Ayres, 1988). Rats captured 
there were selected for homozygosity (L120Q) and back-crossed onto susceptible laboratory 
rats as described above. The fourth strain to be generated came from a site in north Berkshire 
where rats were discovered in 1992 to have a mutation that conferred technical resistance to 
Brodifacoum (Gill, Kerins and MacNicoll, 1992). These rats were taken to two different 
laboratories to be back-crossed onto susceptible rats, resulting in two separate strains of 
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“Berkshire” resistant laboratory rats (also L120Q). At the times that the resistant lines of 
laboratory rats were generated, it was established that the fully homozygous strains possessed 
differing levels of tolerance to anticoagulants (Greaves and Cullen-Ayres, 1988), as well as 
differing levels of dietary vitamin K requirement (Greaves and Ayres, 1973). 
2.2.2.2 Maintenance of rats 
All rats were housed in plastic cages with removable metal lids. Cage floors were covered in 
sawdust to absorb urine, faeces and water. Rats were presented with cardboard tubes and/or 
empty glove boxes for enrichment and hiding opportunities, along with shredded card 
bedding and wooden blocks for chewing. RM3 Laboratory Diet (Special Diet Services, 
Braintree, United Kingdom) and water were supplied ad libitum. Cages and all contents were 
changed weekly, with a small amount of bedding and sawdust retained in order to allow rats 
to become accustomed to their new cages. Tubes were also retained if they remained 
relatively clean and intact. Each cage was labelled with the number and sex of rats housed 
therein, along with their unique identity code and date of birth. Rats were always housed in 
same-sex groups of no more than four, and no less than two, siblings. The room housing 
cages was maintained at 18-23ºC, on a 12-hour light/dark cycle. 
2.2.2.3 Breeding  
Rats in sibling groups were assigned a code which identified their parents and which 
generation they came from. This information was used to avoid inbreeding. Up to two males 
and two females were assigned to new breeding pairs when necessary. A single male and a 
single female were removed from their respective cages and placed in a new cage together, 
with a small amount of bedding and sawdust from their original cages. The cages and 
maintenance for breeding pairs were identical to all other rats, except that their water was 
supplemented with menadione (Vitamin K3). This was supplied as a precaution at a time 
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when breeding females are likely to haemorrhage, in order to overcome the higher dietary 
requirement of vitamin K that is known to occur in some resistant animals. Vitamin K-
infused water was made by introducing 0.4 g of Vitamin K3 (Menadione; Sigma-Aldrich 
Company Ltd, Dorset, England) to 20 litres of water. Fresh batches of this water were made 
up every two weeks. The RM3 Laboratory Diet provided is known to contain 4.14 mg/kg of 
menadione, which is more than required to prevent a vitamin K deficiency in the strains of rat 
present at this laboratory (Hussain, 1998). The female would typically become pregnant 
within a month, however this was highly variable. Once the female gave birth, the cleaning 
schedule was relaxed, and old sawdust replaced when necessary, rather than moving the 
parents and offspring into a new cage. However, despite attempts to minimise disturbance of 
females with very young offspring, some infanticide occurred (assumed, but not confirmed, 
to be committed by the males), and some females rejected and ate their young. In pairs where 
this occurred, during the next round of pregnancy males were removed and housed 
separately. If this failed to remedy the problem, the parents were not reunited, and a 
replacement breeding pair was made up. Six weeks after birth, surviving offspring were 
weaned and split into groups as described in Section 2.2.2.2. Two males and two females 
from each litter were retained for future breeding until another litter from the same parents 
was successfully weaned. Breeding pairs were separated after six pregnancies. 
 
2.2.3 Dosing methodology 
In order to determine the impact of rat size on Prothrombin time, 78 rats underwent BCR 
tests, as described above, without anticoagulant dosing. These rats all resulted from 
abandoned attempts to cross the CSL Berkshire and Reading Berkshire strains, and were 
therefore all homozygous for the L120Q mutation (although with unknown heritable traits 
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from the two parent strains). The males (N: 25) weighed between 106 and 465 grams. The 
females (N: 53) weighed between 91 and 324 grams. Linear Regression Models were used to 
determine whether any of the male, female and grouped datasets showed a significant PT 
response to individual weight. Animal weight did not have any significant effect on PT 
response time (see Section 4.3.1); rats of any size could be selected for BCR testing when 
required by the study, with no requirement to select for a particular body weight. 
Triethanolamine and PEG200 (polyethylene glycol, molecular weight 200) were obtained 
from Sigma Aldrich (Sigma-Aldrich Company Ltd, Dorset, England). The second generation 
anticoagulants brodifacoum, flocoumafen, difenacoum and bromadiolone were obtained in 
pure powder form to be processed into stock solutions of either 10 mg/ml (brodifacoum. 
bromadiolone and difenacoum) or 1 mg/ml (flocoumafen). Difenacoum and bromadiolone 
were supplied by Pelgar (Pelgar International Ltd, Hampshire, England), flocoumafen was 
supplied by Fluka (now Honeywell, Bucharest, Romania) and brodifacoum was supplied by 
Sigma Aldrich. These ingredients were supplied to Reading Scientific Services Ltd, who used 
the following methodology to produce the required stock solutions: 
 
To produce a 1 mg/ml stock solution: 
1. 0.25 g technical anticoagulant measured into a 250 ml volumetric flask. 
2. 0.05 ml triethanolamine and 0.3 ml PEG 200 added. 
3. Flask swirled in a 60ºC water bath, and ultrasonicated at 60ºC to aid dissolution. 
4. After complete dissolution, the solution was made to its 250 ml volume with PEG 
200. 
 
To produce a 10 mg/ml stock solution: 
1. 2.5 g technical anticoagulant measured into a 250 ml volumetric flask. 
2. 2.5 ml triethanolamine and 7.5 ml PEG 200 added. 
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3. Flask swirled in a 60ºC water bath, and ultrasonicated at 60ºC to aid dissolution. 
4. After complete dissolution, the solution was made to its 250 ml volume with PEG 
200. 
 
A brodifacoum 10 mg/ml stock solution was made and diluted by a factor of 10 to 
produce a 250 ml 1 mg/ml stock solution. All work was carried out in subdued lighting, and 
all containers were covered with aluminium foil in order to exclude light throughout the 
procedure. 
These stock solutions were known to provide, when administered to rats at a rate of 
0.5 ml per 100 g of bodyweight, a dose of 1% or 0.1% active ingredient, respectively. Stock 
solutions were then diluted by weight with PEG200 to the required concentrations for dosing 
via oral gavage. In order to preserve accuracy, no stock solution was ever diluted by more 
than a factor of 1 in 10. For instance, if a stock solution of 0.1 mg/ml bromadiolone was 
required, an initial stock solution of 1 mg/ml had to be created from the original 10 mg/ml 
solution. For ease of handling, rats were typically dosed when they weighed between 150 g 
and 400 g. Males were selected after eight weeks of age and before 3 months; females were 
selected after eight weeks of age but rarely grew to exceed 400 g. After 24 hours, rats were 
sedated under terminal anaesthesia with isoflurane (Merial, Harlow, United Kingdom), and 
0.9 ml of blood withdrawn via cardiac puncture into 0.1 ml of 3.2% tri-sodium citrate (to 
prevent clotting). The latter was made by dissolving 3.2 g of pure tri-sodium citrate crystals 
(Sanofi UK, Guildford, United Kingdom) in 100 ml purified water. The blood samples were 
centrifuged at 5300 rpm for six minutes, resulting in plasma being separated from all other 
blood contents. Plasma was removed using a pipette and either processed immediately, or 
frozen at -21oC for future processing.  
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2.2.4 BCR methodology 
BCR tests were conducted using Amelung KC4 micro semi-automatic haemostasis 
equipment (Diagnostica Stago UK Ltd, Theale, United Kingdom). Four cuvettes were used 
for each plasma sample. Diagen freeze dried rabbit brain thromboplastin (Diagnostic 
Reagents Ltd, Thame, United Kingdom) was reconstituted with 5 ml purified water and left 
for 10 minutes, as per manufacturer’s instructions.  
With each cuvette: 
1. a ball bearing was placed in each cuvette 
2. 50 µl rabbit brain thromboplastin added 
3. 50 µl plasma was added, and the cuvettes were allowed to heat in the Amelung for 
two minutes 
4. 25 ml calcium chloride (Diagnostic Reagents Ltd) solution was added using an 
automated pipette which starts the Amelung timer 
5. On clot formation the ball bearing was prevented from moving and the timer was 
stopped 
6. The clotting time (or prothrombin time) was recorded 
 
The calcium chloride initiated the clotting cascade by forming complexes with the 
activated clotting factors, which in turn activate further clotting factors in the coagulation 
cascade, resulting in the activation of prothrombin to thrombin. For each plasma sample, the 
four replicate values were recorded, and if three values were within a 10-second window, the 
average of these was taken as the final PT. If three values were not within a 10-second 
window, the process was repeated. If recorded PTs lasted beyond 100 seconds, this rule was 
relaxed. 
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2.2.5 Analysis of BCR results and application to real world pest control 
Where numbers allowed, rats were dosed at single concentrations in groups of ~10. PT values 
over 47.5 s (equivalent to INR of >5) were classified as “responders”; PT values below 47.5 s 
(equivalent to INR of <5) were classified as “non-responders”. Based on the size of the dose-
groups and bias towards responders and non-responders, subsequent suitable doses for each 
of the anticoagulants were identified. The data were analysed by Probit Analysis (Statistical 
Analysis System, Marlow, United Kingdom), providing 95% fiducial limits for effective dose 
percentiles (ED01-ED99) when enough doses had been administered. Once ED percentiles 
were generated for an anticoagulant against both males and females of a strain, the two 
datasets were combined, and compared with one another via Genmod Analysis in SAS 
(Appendix 2). This established whether the response lines for males and females of the same 
strain were statistically separate, parallel or coincident, and based on this result, new effective 
dose percentiles for males and females were generated. These effective doses could then be 
compared with established effective doses previously recorded for susceptible laboratory 
animals (Prescott et al., 2007). Using this methodology, the resistance statuses of the three 
strains of rat described above have been evaluated, and at the ED50 level, resistance factors 
generated. 
 
2.3 Field trials of anticoagulant rodenticides in areas of known L120Q 
resistance 
2.3.1 Site identification 
The final stage in the evaluation of an anticoagulant rodenticide, prior to its approval by 
regulators in the EU, is a series of field trials in which the rodenticide is presented in a 
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systematic fashion and the volume of bait taken is carefully measured. This method was used 
in order to investigate the impact that the L120Q mutation has on real life attempts to control 
populations of Norway rats. Before this process can be started, suitable trial sites must be 
identified, and permission to use them obtained. Farms located within the Berkshire-
Hampshire, and subsequently known as L120Q, focus in central-southern England were 
visited in order to ascertain their suitability for an anticoagulant rodenticide field trial. Sites 
were selected based on the obvious presence of Norway rat infestations. Sites were rejected if 
free-ranging poultry and livestock, domestic animals or wildlife would obviously be put at 
risk by the presence of rodenticides. Most farmers were receptive to the idea of hosting field 
trials due to their having trouble in controlling infestations, in the hope that the experimental 
trials might be “successful” – i.e. eradicate the Norway rat population. Due to the extremely 
thorough nature of scientific field trials (as opposed to standard treatments conducted by 
landowners or PCOs) some farms were rejected because access could not always be 
guaranteed, or farmers would not tolerate bait points in close proximity to their livestock. 
Four farm sites were identified as suitable locations to trial proprietary bromadiolone or 
difenacoum baits, and two farm sites were selected to host trials of experimental brodifacoum 
baits, resulting in six separate trial locations. The field trials of difenacoum and bromadiolone 
(2009 – 2010) were undertaken by the University of Reading several years before the 
brodifacoum trials (2016), and the total control achieved during the bromadiolone and 
difenacoum trials (according to census bait consumption – see Section 2.3.8) has been 
reported elsewhere (Daniells, 2011). Data from these trials have been explored in further 
detail herein in order to compare performance with that of brodifacoum baits. 
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2.3.2 L120Q confirmation 
Rats at all trial sites were trapped and killed, and their tails removed, and in the case of the 
brodifacoum trials, fresh droppings were collected from sites. DNA from tissue samples 
taken from previous trial sites (henceforth referred to as Sites/Trials A, B C and D) was 
analysed following the methodology of Rost et al. (2004). DNA from tail and faecal samples 
from sites of brodifacoum trials (henceforth referred to as Sites/Trials E and F) was extracted, 
amplified and analysed using the same methodology as described in Section 2.1.4, in order to 
confirm presence and prevalence of the L120Q resistance mutation. 
 
2.3.3 Bait types 
Over the course of six field trials, four second generation anticoagulant rodenticide bait 
products were tested against resistant rats. Trials A and C were conducted with Ratak Pellets, 
containing 50 ppm difenacoum; Trials B and D were conducted with Contrac Pellets, 
containing 50 ppm bromadiolone; Trials E and F were conducted with experimental 
brodifacoum formulations, containing less than 30 ppm brodifacoum. All trials used whole 
wheat bait during pre and post-trial censuses. 
 
2.3.4 Bait points 
Three types of bait points were used in field trials: bait boxes, tyre baiters, and bait trays 
under natural cover.  Bait boxes were wooden or plastic boxes with two entrance holes 
through which an adult Norway rat could pass. Within the box, a plastic tray (if required) was 
placed, containing the bait. The lids of the boxes could be removed in order to access the bait 
and measure bait take. Bait boxes had approximate dimensions of 31cm x 22cm x 14.5cm, 
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with a wall thickness of approximately 2cm and a floor thickness of 1 cm. The two 
rectangular entrances into the bait boxes were approximately 7.5cm x 5cm. Tyre baiters were 
metal stands with three-pronged bases, on which a car tyre was placed, holding the tyre a 
number of centimetres off the ground. In the centre of the base was a tall screw, onto which a 
lid was placed. Rats gained access by crawling underneath the tyre: thus preventing access 
and providing a degree of safety for domesticated animals.  Researchers could remove the lid 
to access and weigh bait. Bait was placed in wooden or plastic trays. Wooden and plastic bait 
trays all had approximate dimensions of 16 cm x 11 cm x 5 cm, with rims of approximately 2 
cm. Bait trays under natural cover were either wooden or plastic, and allowed bait to be 
positioned under cover, using materials and natural cover found on site or using wooden 
boards measuring approximately 60 cm x 30 cm x 1 cm. The cover was used to protect the 
baits against non-target species. Natural cover included wooden planks found on site, large 
feed and water troughs or disused farm equipment. Where necessary, bait was split between 
two bait trays in order to more safely accommodate large volumes without spillage.  
At bait points where the bait had clearly not been touched, the data was labelled ‘NT’ 
(No Take) and recorded as 0. At bait points where there had been clear bait consumption, 
evidence of nibbling, or movement of bait, the remaining bait was weighed, and the figure 
subtracted from the original weight of laid bait, to obtain a measure of the amount of bait 
taken from each individual bait point. The recorded data was labelled ‘P’ (Partial). At bait 
points where no bait remained, the figure recorded was equal to the weight previously 
applied, and labelled CT (Complete Take). Using the saturation baiting methodology during 
Trials A, B, C and D, if a bait point was labelled CT, the subsequent volume of bait laid there 
was doubled or otherwise increased. During Trials E and F the pulse baiting technique was 
used, resulting in more frequent visits because the volume of bait could not be increased. 
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Based on weight of bait consumed and strength of formulation, weekly consumption of active 
ingredient was calculated. 
 
2.3.5 Tracking patches 
Tracking patches consisted of fine sand and were at least 100 mm x 150 mm, with sufficient 
depth to ensure a flat surface. Each day the site was visited, tracking patches were checked 
and assigned a score based on the following scale. 
 0 = no sign of rodent tracks 
 1 = 1-5 individual rodent footprints 
 2 = >5 footprints and up to 25% of patch covered with footprints 
 3 = 26% - 95% of patch covered with footprints 
 4 = > 95% of patch covered with footprints 
Tracking patches were then smoothed over and fresh sand added if necessary. 
 
2.3.6 Carcass searching 
In order to comply with study protocols in line with those of the European and Mediterranean 
Plant Protection Organisation (EPPO, 1999a) carcass searches were carried out at Sites E and 
F. A preliminary carcass search was carried out in the first week of the trial in order to find 
carcasses of any animals in the trial site or its environs. Carcass searches were then carried 
out weekly throughout the trial, using the same route. The route encompassed the entirety of 
the active trial area, and where possible extended up to 400 m from the nearest bait point.  
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2.3.7 Stages 
Pre-treatment censuses were initiated at a trial site once it had been established that the site 
was suitable. Between 50 and 94 bait points and between 35 and 54 tracking patches were 
established in suitable locations. The sites were visited on a daily basis over a four to six day 
period to record pre-treatment census bait take and tracking patch activity. Following the end 
of the pre-trial census, a pre-trial lag period of between five and 11 days ensued. During the 
pre-trial lag phase, bait points and associated bait were removed and trial sites were not 
visited. Tracking patches remained in place, in the same number, throughout the entirety of 
the trials. After the lag phase, the trial phase began with application of trial bait in bait points 
that were positioned in different locations to those used for the pre-treatment census. Trial 
sites were visited two or three times per week for a minimum of five weeks. Trial phases 
ended if, after five weeks, Norway rat activity had plateaued, begun to increase or ceased 
entirely. If rat activity was still falling, trials were allowed to continue until one of the above 
circumstances occurred. After trial phases ended, a second, post-trial lag phase ensued, 
lasting between two and four days. Post-trial lag phases were carried out in identical fashion 
to pre-trial lag phases. Finally, a post-trial census lasting either four or six days was carried 
out, in identical fashion to that of the pre-trial census. 
 
2.3.8 Interpretation 
Trial efficacy was quantified by comparing census bait take and tracking patch scores 
between the pre and post-trial censuses. Maximum nightly score for each activity census from 
the pre-trial census was compared with that of the post-trial census, utilising the following 
calculation (EPPO, 1999a): 
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% efficacy = pre-treatment activity – post-treatment activity * 100 
    Pre-treatment activity   
The resulting values indicated as a percentage how much rat Norway rat activity 
decreased or increased over the course of the field trial. 
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Chapter 3: Locating and delimiting Norway rat resistance 
foci in south-east England 
3.1 Introduction 
3.1.1 History of resistance identification 
In many UK sites where rodent pest control is attempted, the practical efficacy of 
anticoagulant rodenticides against Norway rats has steadily diminished over the last 50 years 
due to the occurrence and discovery of anticoagulant resistance. This resistance was first 
discovered in Norway rats in the UK in 1959, and reported shortly thereafter (Boyle, 1960). 
The intervening years have led to an increase in the number of resistance foci in the UK 
(Greaves and Rennison, 1973; Pelz et al., 2005; Prescott et al., 2010; Haniza et al., 2015). 
Over time it became clear that different resistance foci exhibited greater or lesser 
resistance to the various anticoagulants (or none at all), leading to individual rat populations 
being variously described as being resistant to individual anticoagulants, with no realisation 
that all resistance-conferring mutations in fact confer a level of cross-resistance (though often 
merely “technical” resistance, with little to no effect in real applications of rodenticides) to 
most, if not all anticoagulants. Thijssen (1995) describes differing sensitivity of VKOR 
enzymes, and differing modes of pharmacodynamics resistance, in two different resistance 
foci (“Scottish” resistance and “Welsh” resistance, see Section 1.4.2), and how different 
resistance types may confer resistance to some anticoagulants but not others, but no 
description of the underlying genetic mutations was available at the time.  
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3.1.2 Resistance identification methodology 
Tests to determine anticoagulant resistance in an individual animal were costly both in terms 
of time and money, as they required capturing the animal alive and performing resistance 
tests in the laboratory (Drummond and Rennison, 1973). These Lethal Feeding Period (LFP) 
tests were based on the feeding period required to achieve 99% mortality in susceptible 
animals, as determined by Probit analysis. Suspected resistant animals were given the 
rodenticide for this feeding period as a checking test, and survival of these feeding tests were 
taken as initial evidence that the animals were resistant, although not all animals fed 
consistently during the feeding test, and it was often difficult to distinguish between 
resistance and poor feeding (RRAG, 2012) or resistance-induced vitamin K deficiency 
(Martin et al., 1979). A quicker alternative is the blood clotting response (BCR) test. In these 
tests, animals are dosed by oral gavage with a known quantity and concentration of 
anticoagulant, and 24 or 96 hours later the ability of their blood to clot is tested. Test animals 
are considered resistant when their blood continues to clot despite being given a dose of 
anticoagulant that would prevent or delay clotting in susceptible animals. When used to 
determine whether or not an animal is to be considered resistant, these tests were merely a 
quicker and more humane alternative to the LFP tests described above. Initially they were 
validated by performing the BCR test to assign animals to either “resistant” or “susceptible” 
groups, and then the results were confirmed using traditional LFP tests (Greaves and Ayres, 
1967). Subsequent refinement of the methodology has improved the consistency and 
precision of these tests, allowing the generation of Probit dose response data for many 
anticoagulant active ingredients against male and female Norway rats and house mice, thus 
determining the level of tolerance to various anticoagulants through the statistical generation 
of effective doses (Prescott et al., 2007). This methodology is explored more thoroughly in 
Section 2.2.1, and used extensively in Chapter 4. 
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Despite the reduced time, reduced cost and reduced humaneness concerns (when 
compared with LFP tests), the BCR method cannot on its own determine which resistance 
mutation is involved when resistance is detected in an individual animal. Because the 
resistance gene is dominant (Greaves and Ayres, 1967), it is not always possible to determine 
whether the individual in question is homozygous or heterozygous for resistance. 
Furthermore, when wild rodents are tested in the laboratory for resistance using LFP tests or 
BCR tests, the researcher is exposed to an aggressive wild animal, with risks of bites, 
scratches, and the potential for disease transmission. The stress of extensive handling and 
being restrained for the rat is also a source of concern. 
 
3.1.3 DNA analysis 
A faster method for determining the resistance status of an animal is through DNA analysis, 
wherein fresh tissue or faecal matter is broken down so that the DNA material therein can be 
extracted, amplified, purified and examined (Pelz, Rost and Müller, 2007). Work done by 
Rost et al. (2004) identified the gene vitamin K epoxide reductase complex subunit 1 
(VKORC1) in humans and Norway rats for the first time, finding it to be responsible for 
coding for functional elements of the vitamin K epoxide reductase multiprotein complex 
(VKOR, which recycles vitamin K epoxide through various stages into vitamin K 
hydroquinone, the cofactor which allows the carboxylation and activation of certain blood 
clotting factors in the body) and the mutations therein causing known, identifiable resistance 
to the anticoagulants in wild Norway rats. Subsequently, through sequence analysis of wild 
and laboratory Norway rats classified through BCR tests as either susceptible or resistant, a 
range of resistance mutations and their locations in the VKORC1 gene were identified (see 
Section 1.4.2). By expressing rat VKORC1 and five of the associated resistance-conferring 
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SNPs as membrane-bound proteins in yeast Pichia pastoris, Hodroge et al. (2011) and 
measuring associated kinetic and inhibition properties, the recombinant proteins were shown 
to carry out the same functions as the proteins involved in the Vitamin K cycle in rat liver 
microsomes, confirming the effect of the VKORC1 mutations. These five mutations are 
known to occur on the UK mainland and confer practical resistance to at least some first 
generation anticoagulants rodenticides (FGARs) if not some second generation anticoagulant 
rodenticides (SGARs) are the main focus of this study. All of these mutations are single 
nucleotide polymorphisms (SNPs): wherein a single codon (nucleotide triplet that codes for a 
single amino acid) changes due to a single nucleotide change. This mutant codon causes an 
amino acid change that results in a protein complex with an altered active site, affecting its 
natural function and conferring resistance to anticoagulants. 
 
3.1.4 Stewardship scheme 
Until recent changes in legislative procedures, the anticoagulants available for use against 
outdoor populations of Norway rats in the UK had reduced efficacy against some of these 
resistance foci, with a complete absence of efficacy being demonstrated at many sites. These 
include bait containing widely used and common active ingredients such as warfarin 
(Greaves and Cullen-Ayres, 1988) and the second generation anticoagulant rodenticides 
(SGARs) difenacoum (Greaves, Shepherd and Gill, 1982) and bromadiolone (Quy et al., 
1995). Before the advent of the rodenticide stewardship scheme implemented by CRRU 
(Buckle et al., 2017), the use of the most potent anticoagulant rodenticides (difethialone, 
flocoumafen and brodifacoum) was restricted to use against populations of rodents that 
existed predominantly indoors, due to their perceived increased risk to non-target species. 
This effectively prevented their usage against Norway rats, which rarely restrict their 
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movements to indoor environments. These developments are relatively recent, and it is too 
early to determine if they have had any impact on the control of commensal rodents in the 
UK, or the prevention of non-target poisoning. With more options for rodent control available 
to all users, it is more important than ever that information on the status of anticoagulant 
resistance in the UK is made available in order to prevent misuse of rodenticides. 
 
3.1.5 Identifying and delimiting resistance foci in south-east England 
Since 2009 the University of Reading has, through funding from various bodies, been 
working to identify and delimit the various foci of anticoagulant rodenticide resistance 
mutations in the Norway rats of the UK. In order to continue this work and properly explore 
and delimit the extent of resistance-conferring VKORC1 mutations in Norway rats it was 
decided that the area initially covered should be contiguous, and therefore in 2012 a new 
project based at Reading University was started. The locations specified for this work were 
changed and expanded to include the whole of Surrey, Oxfordshire, Berkshire, West Sussex, 
East Sussex, Essex, Cambridgeshire, East Anglia, and London. The aim was to produce a 
map showing individual locations spread evenly over this contiguous area: each location on 
the map would be represented by a symbol which indicated the type (if any) of anticoagulant 
resistance mutation present, and its zygosity. These data will be made freely available to pest 
controllers through the web site of the Rodenticide Resistance Action Committee (RRAC) of 
CropLife International. The long term objective is to enable the identification of areas of 
known resistance, thereby preventing the application of ineffective rodenticides; which would 
exacerbate the resistance problem and increase the risk to non-target species. Displaying 
these results on a map would also facilitate future research into the repercussions of two 
different resistance foci encroaching into one another - with the possibility of interbreeding 
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between Norway rats from different resistance foci producing offspring with more than one 
resistance conferring mutation. 
 
3.2 Materials and methods 
3.2.1 DNA samples 
In order to identify the spread of the various resistance mutations and delimit the foci wherein 
they were discovered, sites across the south-east of England were visited in order to obtain 
DNA samples. Due to ease of access and generally high Norway rat abundance, farms were 
most often visited. Farms were identified using Ordnance Survey maps (Ordnance Survey 
Ltd, Southampton, Hampshire, UK), and owners or tenants approached on site by the 
researchers. Initially sites with no recent history of anticoagulant rodenticide treatment were 
preferentially selected. This was to prevent inflation of the number of resistant animals 
discovered, as recent or ongoing treatments would kill off susceptible animals, assuming 
correct application of rodenticides. This practice was subsequently abandoned when it 
became clear that stakeholders applied rodenticides with a frequency that made finding rat 
populations that had undergone no recent chemical control untenable. Alternatively, 
stakeholders were contacted or made aware of the study, with the intention that they would 
supply DNA samples of their own volition. Stakeholders included landowners, gamekeepers, 
farmers, public health officials and PCOs. PCOs were contacted via industry contacts, and the 
study was publicised by various print and television media outlets. 
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3.2.2 Tissue samples 
DNA samples were obtained from tail tips taken from recently killed Norway rats. Rats were 
caught by researchers in live traps and dispatched using a Home Office schedule 1 method. 
Tails tip were removed immediately and stored in 70 – 80% IMS and then frozen at -200C 
until analysis. Stakeholders were requested to follow the same methodology in order to 
prevent degradation of tissue. Stakeholders were requested not to take tail tips from rats 
found dead at sites where anticoagulant rodenticides were being used, and not to take tail tips 
from rats that had been dead for more than 24 hours. However, whether all stakeholders 
abided by these rules could not be ascertained. 
 
3.2.3 Faecal samples 
By 2013 it had become clear that most of the larger pest control companies – the main source 
of tails sent to the University – were hesitant to get involved with supplying samples, despite 
adverts in trade publications and repeated appeals from senior figures in the industry. In 
addition, despite clear instructions being repeatedly provided to suppliers of tissue samples, 
the number of samples where it was not possible to extract viable DNA due to degradation or 
contamination indicated that some tail samples were being handled or selected incorrectly. 
Due to the neophobic nature of Norway rats (Barnett, 1958; Inglis et al., 1996) and the large 
study area, it was decided that having researchers attempt to make up the bulk of samples via 
direct captures of live rats would be inefficient. Therefore, from September until December 
2013, researchers visited farms in Kent and East Anglia and collected faecal samples for 
analysis. Suitably fresh samples were identified by sight. Because it was impossible to 
ascertain which samples came from different individuals, selected droppings were collected 
together in vials. Once at the laboratory, faecal samples were frozen at -200C until analysis. 
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3.2.4 DNA extraction 
DNA was extracted from tail tips using the DNeasy Blood and Tissue Kit following a 
modified version of the manufacturer’s instructions (Qiagen Ltd, Crawley, West Sussex, 
UK). See Section 2.1.4. See Prescott et al. (2010) for details of samples taken prior to 2012. 
DNA was extracted from faecal samples using the QIAamp DNA Stool Mini Kit 
(Qiagen Ltd, Crawley, West Sussex, UK) following a modified version of the manufacturer’s 
instructions for human faecal samples. See Section 2.1.4. 
 
3.2.5 DNA amplification 
Elutions resulting from DNA extraction of faecal and tail samples were amplified by PCR 
(see Section 2.1.4). Because the study was exploratory, with the presumed potential for any 
mutation to be exhibited by rats in any location, it was necessary to detect all the possible 
single nucleotide polymorphisms of the VKORC1 gene. In order to cover this range of sites 
of potential SNPs, primers were obtained from Invitrogen (Life Technologies Ltd, Paisley, 
Renfrewshire, UK) that flanked codons from before and after as many of the known SNP 
sites as possible in each of the three exons. Primers used from 2012 onward for detecting 
SNPs in exon 1 were F: GAG GAG CCC TGG ACG TTT and R: AGG AGA AGA CGC 
GGG AAC; primers used for exon 2 were F: GGT GGA GCA CGT GTT AGG AG and R: 
GGT CAC CAA GAC ATG AGG TG; primers used for exon 3 were F: TGA GTT CCC 
TGG TGT CTG TC and R: TTT TAG GGA CCC ACA CAC GA. PCR products were 
resolved by electrophoresis and the resulting gel examined under UV light. Providing the 
PCR was shown to be successful, PCR products were purified using the QIAquick PCR 
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Purification Kit (Qiagen Ltd, Crawley, West Sussex, UK). Primers used prior to 2012 were 
based on those used by Rost et al. (2004). 
 
3.2.6 Sequencing and interpretation 
PCR products were sent to Source Bioscience for Sanger sequencing (Source BioScience plc, 
Nottingham, Nottinghamshire, UK). Chromas Lite and Finch TV were used to open the 
resulting chromatogram files; with the majority of the three exons of the VKORC1 gene 
displayed onscreen, mutations could be identified simply by visual analysis of all relevant 
codons and comparison with those found in the genomic DNA of a wild-type Norway rat. In 
order to measure the size of confirmed mutation foci and identify areas where further samples 
were required, location data for every individual site where results could be obtained were 
displayed as point shapefiles on ArcGIS (Esri UK Ltd, Aylesbury, Buckinghamshire, UK). 
 
3.3 Results 
3.3.1 Exon 3 
Between April 2012 and September 2015, exon 3 of the Norway rat VKORC1 gene was 
successfully analysed from genomic DNA that was extracted from 164 tail samples and 14 
faecal samples. In addition, results for 126 tail samples taken prior to the revised agreement 
between the University of Reading and Killgerm (April 2012) are presented here. A further 
41 tail samples and 20 faecal samples were tested but no results could be obtained. For the 
tail samples, this was most likely because of contamination or degradation of the DNA, as a 
result of poor storage prior to arrival at the laboratory. In the case of the faecal samples, it is 
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likely that the DNA is less stable than in tail samples, when stored for a prolonged time 
period at -200C. 
Table 3.1: Total number of VKORC1 exon 3 mutations found in successfully tested samples. 
Mutation Total number of samples 
Homozygous (% of 
total) 
Heterozygous (% of 
total) 
L120Q 224 173 (77.23%) 51 (22.77%) 
L128Q 9 2 (22.22%) 7 (77.78%) 
Y139C 9 1 (11.11%) 8 (88.89%) 
Y139F 19 10 (52.63%) 9 (47.37%) 
Y139S 2 0 (0%) 2 (100%) 
L120Q and L128Q 6 0 (0%) 6 (100%) 
Susceptible/wild-type (% 
of all samples) 35 (11.15%)   
 
Table 3.2: Presence-absence of L120Q, Y139C and Y139F in English counties (findings unknown prior to 2017 
are highlighted in bold; asterisks indicate uncertainty due to the grouping of West and East Sussex by Haniza et 
al., 2015). 
County L120Q presence Y139C presence Y139F presence 
Berkshire Yes   
Dorset Yes   
East Sussex Yes*  Yes 
East Yorkshire  Yes  
Essex Yes   
Gloucestershire  Yes  
Greater London Yes   
Hampshire Yes   
Kent Yes  Yes 
Norfolk Yes Yes Yes 
Oxfordshire Yes   
South Yorkshire  Yes  
Suffolk   Yes 
Surrey Yes Yes  
West Sussex Yes*   
Wiltshire Yes   
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Figure 3.1: VKORC1 exon 3 mutations in south-east England. Squares represent homozygous animals; 
diamonds represent heterozygous. Blue = Y139F; Red = L120Q; Green = Y139C; Black Diamonds = 
susceptible (wild-type). Location of Y139F-positive samples taken by Prescott et al. (2010) is included for 
context. 
 
 
 72 
 
Figure 3.2: VKORC1 exon 3 mutations in Wales, north England and Scotland. Squares represent homozygous 
animals; diamonds represent heterozygous. Green = Y139C; Yellow = L128Q; Pink = Y139S; Black Diamonds 
= susceptible (wild-type); Yellow and Red = L128Q and L120Q co-mutation. 
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Of the 304 samples, 269 (88.49%) were found to be positive for at least one VKORC1 
exon 3 mutation. Of the 269 samples that were found to be positive for VKORC1 exon 3 
mutations, 186 (69.15%) were homozygous for that mutation (see Table 3.1). In the south-
east of England foci of the L120Q, Y139C and Y139F mutations were found to be 
widespread (see Table 3.2). 
 
3.3.2 Exons 1 and 2 
Of the 178 samples taken post-April 2012 that were successfully tested for VKORC1 exon 3 
mutations, 92 were successfully tested for four SNPs in exon 1 and 86 were successfully 
tested for four SNPs in exon 2 (see Table 3.3). Among the mutations investigated in exon 1, 
no SNPs were found in any of the 92 samples, despite three of them having previously been 
found in the UK (Rost et al., 2009). Only two SNPs were found in exon 2 across all samples. 
Nineteen samples were positive for the silent mutation I82I. A previous study in the south-
east of England showed that in a sample group of 10 wild rats, the exon 3 mutation Y139F 
was positively linked with the exon 2 mutation I82I (Prescott et al., 2010). However, of the 
19 samples herein that were positive for I82I, only four were associated with Y139F. Six 
were associated with L120Q, two were associated with Y139C, and seven weren’t associated 
with any of the main five exon 3 mutations. Three rats were homozygous for the I82I 
mutation; one with the Y139F mutation, and two which were wild-type at exon 3. Five 
samples (including two with I82I), were found to have a new mutation at position 99, 
wherein cysteine was substituted for phenylalanine (C99I). All 5 of these samples were 
heterozygous for this mutation, and were associated in four cases with the L120Q resistance 
and in one case with Y139F resistance. Thus of 86 samples, 22 were positive for SNPs of 
exon 2. 
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Table 3.3: SNPs of exons 1 and 2. SNPs marked with an asterisk (*) are original to this study. 
SNP Total Number found Mutation type Exon 
A26T 0 Amino Acid Substitution 1 
R33P 0 Amino Acid Substitution 1 
R35P 0 Amino Acid Substitution 1 
Y39N 0 Amino Acid Substitution 1 
E67K 0 Amino Acid Substitution 2 
I82I 17 Silent Mutation 2 
I82L 0 Amino Acid Substitution 2 
L94L 0 Silent Mutation 2 
C99I* 3 Amino Acid Substitution 2 
I82I and C99I* 2 Silent Mutation and Amino Acid Substitution 2 
 
3.4 Discussion and conclusions 
3.4.1 Spread of resistance foci and homozygosity 
The results shown in Figure 3.1 are not encouraging for stakeholders in the south-east of 
England, where the bulk of the study has been focused. Of the 304 samples analysed for exon 
3, 269 (88.49%) possessed a VKORC1 mutation; of the 86 samples analysed for exon 2, 22 
(25.58%) possessed a VKORC1 mutation; and of the 92 samples analysed for exon 1, there 
were no VKORC1 mutations. The lack of association between the exon 2 I82I and exon 3 
Y139F mutations (both were primarily found in the other’s absence) indicates that there is 
unlikely to be any association between resistance-conferring mutations of exon 3 and other 
mutations in the VKORC1 coding exons. Only 11 of the 269 samples (4.09%) positive for a 
VKORC1 exon 3 resistance conferring mutation had only L128Q or Y139S, and none of 
these came from the main study area (see Table 3.1). The three stronger resistance conferring 
mutations (L120Q, Y139C and Y139F) were discovered to be located in areas they had never 
been found before 2017 (see Table 3.2).  
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3.4.2 History and causes of resistance 
The presence of the stronger resistance-conferring mutations throughout the study area most 
likely indicates the use of ineffective rodenticides sufficient to allow the selection of 
resistance to occur across the south-east of England. This is in spite of the known pleiotropic 
costs of resistance in Norway rats from Hampshire (Greaves and Cullen-Ayres, 1988). 
Evidence for and against pleiotropic costs of the L120Q mutation is mixed (see Gill, Kerins 
and MacNicoll, 1992), but the presence of these mutations wherever they are looked for in 
south-east England is an indication that ineffective anticoagulant rodenticides have been used 
there, sufficiently to allow the mutations to become established in Norway rat populations. 
There is also a high degree of homozygosity across these resistant populations, providing 
clear evidence that resistance is being, and for years has repeatedly been selected for, via 
application of ineffective anticoagulant rodenticides such as FGARs, bromadiolone and 
potentially difenacoum. The selection for resistant animals is compounded by the use of 
menadione as a supplement in animal feed on farms. Normally, in the absence of the 
application of anticoagulant rodenticides, some strains of resistant rats will have a reduced 
fitness compared to susceptible animals, because of their higher dietary requirement for 
vitamin K (Hermodson, Suttie and Link, 1969; Greaves and Ayres, 1973; Bishop, Hartley 
and Partridge, 1977; Markussen et al., 2003; Jacob et al., 2012). However, due to the 
widespread use of menadione-supplemented feed on farms, this pleiotropic effect of the 
VKORC1 resistance mutations is nullified, thereby maintaining the prevalence – or at least 
presence – of resistance in Norway rat populations. Therefore, when ineffective rodenticides 
are applied, their failure to gain complete control of the population is already assured. Due to 
restrictions on use of certain anticoagulant active ingredients in the UK (European 
Community, 1998) prior to the introduction of the CRRU rodenticide stewardship scheme, 
RRAG advocated avoiding the use of difenacoum or bromadiolone to control rat populations 
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known to possess any of the three mutations found in south-east England (RRAG, 2012). The 
Campaign for Responsible Rodenticide Use (CRRU) has developed a stewardship scheme for 
the Health and Safety Executive (HSE) which is currently being put into place, under which 
stronger SGARs (brodifacoum; difethialone; flocoumafen) thought to be efficacious against 
resistant rats will be used by persons trained in their safe and effective use (Buckle et al., 
2017). Similar schemes are being put in place in France, Germany and Spain and are 
recommended by the EU. The success of UK stewardship scheme is vital to the future of 
rodent control in the UK; the results of this study are evidence that the previous model of 
legislation for rodenticides was unsustainable and at some point could have led to serious 
public health, economic and environmental fallout. 
 
Figure 3.3: Anticoagulant resistance in Norway rats in the UK in 1970. Filled symbols = confirmed resistance. 
From Greaves and Rennison (1973). 
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The size and locations of resistance foci, along with the surprising presence of 
numerous mutations in close proximity, may elucidate the origins of some of the UK’s 
Norway rat resistance. No other country has a comparable variety and number of resistance 
foci, but aside from the Welsh mutation, all other VKORC1 exon 3 resistance conferring 
mutations have been identified in Europe and elsewhere. This could be attributed to the UK’s 
island status and associated maritime tradition. Shipping to and from areas of continental 
Europe containing resistance foci may have spread the mutations far quicker and further than 
rodenticide-induced selection. What is not clear is whether the UK acted as the source or as a 
sink for resistant rats; potentially it could have done both. The data from this study also shed 
light on previous discoveries of resistance before the molecular methods that would enable 
their identification were available. For instance, resistance was present almost throughout 
Kent by 1970 (Greaves and Rennison, 1973; see Figure 3.3). It is possible that rats in this 
resistance focus have always possessed the Y139F mutation, but this cannot be confirmed. 
Given the now well-known resistance-conferring properties of this mutation (Grandemange et 
al., 2009), had the molecular techniques used herein been available for use in the 1970’s, it is 
possible that sustained use of ineffective rodenticides could have been avoided, along with 
the associated previously-discussed impacts (see Sections 1.4.3 and 4.1.2.3). The same is 
likely true of the south Essex area near Ipswich, where both L120Q and Y139F mutations 
have been found in rats not far from areas of historical resistance (Greaves and Rennison, 
1973). 
 
3.4.3 Methodological constraints 
As described above, obtaining DNA samples for analysis was the greatest hurdle faced in this 
study. Despite a variety of media appearances, adverts in trade publications and appeals from 
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senior industry figures, very few samples were provided when compared with similar studies 
from across Europe. For this reason, faecal samples were used as a source of DNA for 
analysis, but due to the difficulty of retaining their viability in storage and the high likelihood 
of their being contaminated, there was a low success rate in their analysis. In addition, it 
bears stating that this study is useful only for delimiting resistance foci, not for exploring the 
depth of resistance at each site. For this reason, it is acceptable that some of the results may 
have been skewed by the preference of the pest control industry to only get in touch with 
researchers once they had encountered what appeared to be practical resistance. The need to 
avoid false negatives (i.e. samples appearing to show a site as resistance free when in 
actuality it isn’t) is greater than the need to obtain a truly random set of samples. 
 
3.4.4 Future work 
The continuation of this work is vital to the future understanding of resistance in the UK, as 
well as the fight against it. Once these data are published and seen by stakeholders around the 
country, it is likely that interest in the project will increase and more tail samples will be 
made available for analysis. More samples from unexplored areas will only strengthen the 
dataset, and allow much greater analysis of the data therein. This in turn will aid the pest 
control industry and property owners in their attempts to control infestations of Norway rats. 
Experiments are required that will fully elucidate the effects that each of the mutations 
investigated herein have on efficacy of control attempts. Thereby, future editions of maps 
produced for this study will inform PCOs and other stakeholders not just of where resistance 
foci exist, but how best to deal with them.  
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Chapter 4: Determining resistance factors for three 
strains of Norway rat in the laboratory 
4.1 Introduction 
4.1.1 History of laboratory resistance tests 
Very soon after the initial discovery of anticoagulant resistance, rats were captured in the 
wild and brought into the laboratory to be subjected to tests intended to elucidate the impact 
that resistance would have on future attempts at practical control in the field. Breeding 
experiments utilising the offspring of these wild progenitors revealed that resistance is 
controlled by a single, dominant autosomal gene mapped to orthologous linkage groups in 
both Norway rats (Rw; chromosome 1) and house mice (Raw; chromosome 7) (Greaves and 
Ayres, 1969; Wallace and MacSwiney, 1976). Just as laboratory feeding tests were used to 
confirm efficacy of potential anticoagulant rodenticides prior to their marketing and 
subsequent use in the field (Bentley, Hammond and Taylor, 1955; Bentley and Rowe, 1956; 
Bentley and Larthe, 1959; Redfern, Gill and Hadler, 1976) so they were used to confirm 
suspected instances of resistance (Boyle, 1960; Cuthbert, 1963; Lund, 1964) or to confirm 
their efficacy against various resistant strains (Redfern and Gill, 1978; Gill, 1992). As the 
scale of resistance in both Norway rats and house mice became clear (Dodsworth, 1961; 
Bentley, 1968), laboratory tests on these rodents became less reactive and more proactive, 
focusing on level of tolerance that resistance mutations conferred against the various 
anticoagulants. These tests involved offering warfarin baits or warfarin-infused foodstuffs to 
rats at given rates, and monitoring their survivability in what appeared to be largely ad-hoc 
experiments. Individuals that died contributed to the generation of lethal feeding periods 
(LFP01-99) rather than lethal doses (LD01-99), because it was not possible to determine the 
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exact volume of warfarin each individual had consumed. As described in Section 2.2.1, 
although a standard test methodology was established (six days’ feeding on 0.005% warfarin 
bait) that appeared to identify rats resistant to warfarin (Drummond and Bentley, 1965; 
Bentley, 1968; Drummond and Wilson, 1968), a method that was quicker and less 
questionable in its humaneness (because it did not rely on mortality of test animals) was 
quickly posited (Greaves and Ayres, 1967). BCR resistance tests were expanded to include a 
variety of anticoagulant active ingredients, establishing discriminating doses for FGARs and 
SGARs against susceptible rats, and subjecting laboratory-resistant animals of known origin 
and strain to the same test. Using this information, assuming researchers had identified a 
particular strain correctly (i.e. by its nominal geographic designation), these resistance tests 
could be applied to wild rats, and the wild population in question designated as resistant or 
susceptible based on whether or not individuals were “responders” (i.e. to be significantly 
affected by the anticoagulant administered). This designation was based upon the percentage 
coagulation activity (PCA) of test animals. Calibration curves based on dilutions of normal 
plasma in saline are used to convert measured coagulation times in seconds to PCA in order 
to ascertain the level of coagulation capability that blood samples have retained. Examples of 
these tests include chlorophacinone and diphacinone against “Welsh” and “Hampshire” 
resistant strains (Prescott and Buckle, 2000); warfarin against “Welsh” rats (Greaves and 
Ayres, 1967; Martin et al., 1979; MacNicoll and Gill, 1993a), “Scottish” and “Hampshire” 
rats (MacNicoll and Gill, 1993a); and bromadiolone against “Welsh”, “Scottish”, 
“Hampshire” and “Berkshire” rats (Gill et al., 1994). Difenacoum tests were carried out 
against “Welsh”, “Scottish” and “Hampshire” rats (Gill et al., 1993), but because these aimed 
to replicate the results of LFP tests as well as monitor PCA (that is, cause mortality in 
susceptible rats whilst monitoring PCA over several days, rather than classifying rats as 
responders or non-responders in a one-time test) discriminating doses are much higher than 
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expected, and of little use. They also lacked the bonuses of reduced time, cost and 
humaneness issues. There was little consistency between these tests. SGAR tests utilised a 
96-hour period between dosing and blood sampling, whereas a 24-hour period was 
established when testing FGARs. Furthermore, in SGAR tests rats were considered 
responders if their PCA was less than 10%; rats in tests involving FGARs were classified as 
responders if their PCA fell below 17% (see also Baert et al., 2012). The level and standard 
of efficacy necessary to discriminate between susceptible and resistant rats was not consistent 
between studies. Only in the tests involving bromadiolone, diphacinone and chlorophacinone 
was the point of discrimination (ED99 or the upper 95% fiducial limit thereof) established 
prior to testing by Probit analysis (EPPO, 1999b). Furthermore, utilising a different method 
of analysis (e.g. generating a Probit log dose-response rather than a Probit dose-response) 
will create varying estimates of ED99. The methods available to generate dose response data 
are primarily designed to estimate the ED50; as effective dose responses approach 99% (or 
1%) the fiducial limits associated with the predicted effective dose grow wider, compared 
with the size of the predicted effective dose. This effect is compounded when these methods 
are used in tests against vertebrate animals, numbers of which are reduced for humaneness 
reasons wherever possible. So even when standardised, tests to determine ED99s are not 
reliable. In addition to the inherent problems with generating and utilising ED99s, the 
application of these tests was also limited because their main use was simply to ascertain 
whether rats of a given resistant strain could tolerate a dose of a given anticoagulant that 
would kill a given number of susceptible animals. These data cannot be compared without 
making assumptions based on extrapolation and guesswork. The tests were all specific to 
each strain, and other than the nominal geographic naming tendencies in the UK, there was 
no guarantee that results from a particular study could be applied to practical pest control in 
other areas of the UK, or elsewhere. In addition, in the field there are frequently rats 
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heterozygous for the resistance mutations in question, which respond differently to 
anticoagulant and vitamin K-deficient stimuli, than do susceptible or homozygous-resistant 
rats (see Section 1.4.2). 
With the initial identification of the resistance-conferring mutations (Li et al., 2004; 
Rost et al., 2004) and their confirmed locations (e.g. Pelz et al., 2005), data from all future 
resistance tests – and any previous tests wherein viable tissue of the test subjects had been 
retained, or the strain in question was still extant with no further introductions of foreign 
animals – could potentially contribute to the sum of all researchers’ knowledge, regardless of 
the animals’ provenance. Until now, most research has focused on identification and 
delimitation of resistance foci. Given the extent of the L120Q focus in the south-east of 
England (see Section 3.3.1), there is a clear requirement to quantify the level of tolerance 
(resistance factor: RF) to anticoagulants that the various L120Q strains confer. 
 
4.1.2 International normalised ratio (INR) 
The standardised method was established by Prescott et al. (2007) when a range of baseline 
effective doses of the second generation anticoagulant rodenticides were established for 
susceptible laboratory animals. Although there may be a range of differences between 
laboratory and wild rats, using laboratory rats allowed for a homogenous study group of 
known provenance. There are multiple thromboplastin reagents used for the assessment of 
clotting activity, with varying sensitivities, which would result in different Prothrombin Time 
(PT) results when used to assess the same sample. Therefore, a method of standardisation is 
required. In human haematology, the various methods and reagents have been afforded a 
calibration reference system (Denson, 1998) based on a WHO standard. The International 
Sensitivity Index (ISI) measures the sensitivity of each methodology, applying a ratio of 
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sensitivity (the INR) of the method and reagent compared with the reference material. For 
instance, a reagent with an ISI of 2 would obtain a PT for a human blood sample exactly 
twice the time of that obtained by the reference material. The reagent used herein (Diagen 
freeze-dried rabbit brain thromboplastin; RBT) has an ISI of 1.4. Norway rat PCA calibration 
curves produced using the reagent showed that a PCA of 17% corresponded with Diagen 
RBT INR of 5. As suggested by Prescott et al. (2007), and in accordance with instructions 
supplied by Diagen, safe human coagulation has an INR range of 2 – 4.5. Therefore, a PT of 
47.5 seconds (which corresponds to INR 5) was identified as the discriminating point, above 
which rats were classified as “responders” to the applied anticoagulant dose. 
 
4.1.3 Resistant Norway rat strains housed at the University of Reading 
The history of resistant laboratory strains established in the UK is discussed in detail in 
Section 2.2.2.1. There are currently three strains of anticoagulant-resistant rats housed at the 
University of Reading. A previous strain of laboratory resistant rats, derived from animals 
caught in Hampshire, was present until recently; this “Hampshire” strain was lost due to 
excessive inbreeding prior to the start of this work. Some resistance factors were established 
for this strain prior to their loss (Prescott et al., 2007). The central-southern England L120Q 
focus appears to be largely comprised of homozygotes (see Section 3.1), making the 
uniformly homozygous rats housed at the University of Reading a suitable model. 
4.1.3.1 Welsh strain 
Henceforth referred to as Welsh rats, this strain is descended from a group of resistant rats 
from Wales (Bentley, 1968) which were captured and taken to the Pest Infestation Control 
Laboratories, situated at Tolworth. There they were challenged with anticoagulants in order 
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to be selected for homozygosity and back-crossed onto susceptible laboratory rats as 
described in Section 2.2.2.1. The Tolworth laboratories were run under the auspices of the 
Ministry of Agriculture and Fisheries (MAF), and consequently had access to the MAF’s own 
susceptible strain of rats, the Tolworth Albino Susceptible (TAS) rats, and it was onto these 
rats that the wild resistant rats were back-crossed. They are homozygous for the resistance 
mutation Y139S. These rats are grey-black; some individuals attain silver-white hairs on their 
backs. It is thought that their colouration is related to their resistance status (Prescott, pers. 
Comm.; Greaves and Ayres, 1969). The Welsh resistance focus has been repeatedly shown to 
be susceptible to the SGARs, so their inclusion in this study is for the purpose of identifying 
the least toxic compound which can be safely – and effectively – used for their control, and 
also as a comparison with the other strains housed at Reading. 
4.1.3.2 Reading Berkshire strain 
Henceforth referred to as Reading Berkshire rats, this strain is descended from a group of 
resistant rats from north Berkshire where rats were discovered in 1992 to have a mutation that 
conferred technical resistance to Brodifacoum (Gill, Kerins and MacNicoll, 1992) and 
practical resistance to Bromadiolone (Quy et al., 1995). Rats captured at this site were taken 
to the University of Reading where they were back-crossed onto susceptible CD albino 
Norway rats obtained from Charles River Ltd, and the resulting progeny challenged with 
anticoagulants in order to be selected for homozygosity as described in Section 2.2.2.1 
(Hussain, 1998). They are homozygous for the resistance mutation L120Q. These rats are 
white with black hoods and varying sizes and patterns of black patches running down the 
ventral and dorsal surface. 
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4.1.3.3 CSL Berkshire strain 
Henceforth referred to as CSL Berkshire rats, this strain’s wild ancestors originated from the 
same site as those of the Reading Berkshire strain. Rats trapped at this site were taken to the 
Central Science Laboratory (CSL) facility in Yorkshire and back-crossed onto individuals 
from a susceptible strain of rats selected for homozygosity, as described in Section 2.2.2.1. 
Like the Welsh rats, TAS rats were used as the laboratory susceptible rats with which the 
wild resistant rats were crossed. Thereafter they were, for six generations, repeatedly 
subjected to anticoagulant feeding tests devised to achieve partial mortality amongst test 
subjects. Only rats which survived these tests were allowed to breed, resulting in a “Selected 
Line” of highly resistant animals. Rats of this strain are therefore characterised by a much 
greater tolerance to anticoagulants than Reading Berkshire rats, despite possessing the same 
resistance mutation (for which they are homozygous), and appearing largely identical in 
colouration. There may be other unknown differences between the two strains as a result of 
their being descended from different strains of susceptible rats. The strain was later gifted to 
Sorex in its entirety, and was then in turn gifted to the University of Reading. 
 
4.2 Methods 
4.2.1 BCR tests 
BCR tests were conducted using Amelung KC4 micro semi-automatic haemostasis 
equipment (Diagnostica Stago UK Ltd, Theale, United Kingdom). Four cuvettes were used 
for each plasma sample. Diagen freeze dried rabbit brain thromboplastin (Diagnostic 
Reagents Ltd, Thame, United Kingdom) was reconstituted with 5 ml purified water and left 
for 10 minutes, as per manufacturer’s instructions.  
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With each cuvette: 
1. a ball bearing was placed in each cuvette 
2. 50 µl rabbit brain thromboplastin added 
3. 50 µl plasma was added, and the cuvettes were allowed to heat in the Amelung for 
two minutes 
4. 25 µl calcium chloride (Diagnostic Reagents Ltd) solution was added using an 
automated pipette which starts the Amelung timer 
5. On clot formation the ball bearing was prevented from moving and the timer was 
stopped 
6. The clotting time (PT) was recorded 
 
The calcium chloride initiated the clotting cascade by forming complexes with the 
activated clotting factors which could be hosted by phospholipid membranes, which in turn 
activate further clotting factors in the coagulation cascade, resulting in the activation of 
prothrombin to thrombin (See Section 1.3.5.2). For each plasma sample, the replicate values 
were recorded, and if three values were within a 10-second window, the average of these was 
taken as the final PT, and was converted to INR using tables provided with the 
Thromboplastin Reagent. If three values were not within a 10-second window, the process 
was repeated. 
4.2.1.2 Vitamin K 
As described in Section 2.2.2.2, vitamin K was not co-administered to rats used in this study: 
the vitamin K available in the diet supplied was greater than the 0.5 mg/kg bodyweight 
identified as the minimum requirement to prevent vitamin K deficiency (Hussain, 1998). 
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4.2.2 Dosing methodology  
The stock solutions of 10mg/ml and 1 mg/ml, when administered to rats at a standard rate of 
0.5 ml per 100 g of bodyweight, will deliver a dose of 50 mg/kg bodyweight and 5 mg/kg 
bodyweight of active ingredient respectively. Prior to gavage, stock solutions were diluted by 
weight with PEG200 to the required concentrations, as described in Section 2.2.3. Rats to be 
dosed were weighed to within 1 g. After dosing, each rat was given a unique tail mark and 
test code for identification purposes. Blood sampling was conducted 24 hours after dosing. 
The 24-hour interval was chosen over 96 hours in order that the data could be compared with 
the susceptible data generated by Prescott et al., (2007). Rats were sedated under terminal 
anaesthesia with isoflurane (Merial, Harlow, United Kingdom), and 0.9 ml of blood 
withdrawn via cardiac puncture into 0.1 ml of 3.2% tri-sodium citrate (to prevent clotting). 
The latter was made by dissolving 3.2 g of pure tri-sodium citrate crystals (Sanofi UK, 
Guildford, United Kingdom) in 100 ml purified water. The blood samples were centrifuged at 
5300 rpm for six minutes, resulting in plasma being separated from all other blood contents. 
Plasma was removed using a pipette and either processed immediately, or frozen at -21oC for 
future processing. 
 
4.2.3 Second generation anticoagulant rodenticides 
All five SGARs were utilised in this study. It was intended that resistance factors be obtained 
for Welsh, Reading and CSL Berkshire rats against brodifacoum, bromadiolone, difenacoum, 
difethialone and flocoumafen. PEG200 (polyethylene glycol, molecular weight 200) and 
triethanolamine were supplied by Sigma Aldrich, and were used to dissolve and dilute the 
pure SGARs brodifacoum, bromadiolone, difenacoum and flocoumafen to stock solutions of 
either 10 mg/ml (bromadiolone and difenacoum) or 1 mg/ml (brodifacoum and flocoumafen) 
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as described in Section 2.2.3. Difethialone was supplied as a 1 mg/ml dilution in PEG200 by 
Liphatech (Liphatech, Bonnel, 47480 Pont du Casse, France). 
 
4.2.4 Study rats 
Between October 2009 and May 2017, rats were dosed with SGARs and their blood clotting 
activity was determined as detailed in Section 4.2.1. For each resistant strain of Norway rats, 
sexes were dosed separately, and active ingredient was administered over a range of doses in 
order to generate dose response data that can be analysed by Probit analysis (see Section 
4.2.5). Rats were typically dosed when they became available, resulting in highly variable 
group sizes for each round of dosing. SGAR-strain-gender groups ranged in size between 27 
individuals and 67 individuals. Dose rates were based on established ED50 data for 
susceptible rats (Prescott et al., 2007) or on previous data generated within the study from 
active ingredients with a similar level toxicity. As described in Section 2.2.3, a total of 78 rats 
underwent BCR testing without anticoagulant dosing. Results from these tests were analysed 
using Linear Regression Models in R i386 3.2.3 (R Core Team, 2015) in order to discover the 
impact of rodent bodyweight and sex on resting PT. Rats used in the main study typically had 
a minimum bodyweight of 150 g, and a maximum bodyweight of 400 g, for ease of handling. 
However, due to external issues and the late availability of rats retained for breeding this 
maximum bodyweight was occasionally exceeded. Husbandry of the study animals is 
described in Section 2.2.2.2 and Section 2.2.2.3. 
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4.2.5 Data analysis 
As described in Section 2.2.5, data from SGAR-strain-gender groups were analysed using the 
PROBIT procedure in SAS (Statistical Analysis System, Marlow, United Kingdom), in order 
to obtain 95% fiducial limits for effective dose percentiles (ED01-ED99). When fiducial limits 
were obtained, data from both sexes of a SGAR-strain group were compared and analysed by 
the GENMOD procedure in SAS. This established whether the response lines for males and 
females of the same strain were statistically separate, parallel or coincident, and based on 
these results, the data for the two sexes were re-analysed using the PROBIT procedure, to 
provide Probit dose response data with fiducial limits. In situations where fiducial limits were 
large, clotting times from additional animals were determined, and the resulting data set was 
re-analysed. These effective dose percentiles were compared with those of susceptible 
animals (Prescott et al., 2007, in which the same methodology was used thereby affording 
accurate resistance factors) in order to generate resistance factors for each SGAR-strain-
gender group. 
 
4.3 Results 
4.3.1 Effect of weight on PT 
Linear Regression Models were used to compare the resting PT of male and female 
CSLxReading Berkshire rats in R i386 3.2.3 (R Core Team, 2015). No significant regression 
equations were found for bodyweight (F (1, 77) = 0.3814, p = 0.5387; R2 of 0.0049), sex (F 
(1, 77) = 0.0994, p = 0.7534; R2 of 0.0013), sex and bodyweight (F (2, 76) = 0.3065, p = 
0.7369; R2 of 0.008) or an interaction of the two factors (F (3, 75) = 0.3092, p = 0.8186; R2 of 
0.0122). Therefore the PT of non-anticoagulant compromised rats was not affected in any 
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significant way by bodyweight, and it was assumed that rats of any size could be used during 
the BCR tests with SGARs. 
 
4.3.2 Probit response between sexes and between strains 
Male and female CSL Berkshire rats dosed with bromadiolone exhibited separate Probit 
response lines; during the Genmod procedure the Probit response lines deviated significantly 
from a parallel response, and were not analysed further. Male and female CSL Berkshire rats 
dosed with all other SGARs exhibited parallel Probit response lines; during the Genmod 
procedure the Probit response lines did not deviate significantly from a parallel response, but 
when analysed further they deviated significantly from a coincident response. 
Male and female Reading Berkshire rats dosed with brodifacoum exhibited separate 
Probit response lines, as described above. Male and female Reading Berkshire rats dosed 
with difenacoum exhibited parallel Probit response lines, as described above. 
Male and female Welsh rats dosed with bromadiolone and difenacoum exhibited 
separate Probit response lines, as described above. Male and female Welsh rats dosed with 
brodifacoum exhibited parallel Probit response lines, as described above. A summary of these 
results is provided in Table 4.1. 
Male Reading and susceptible rats dosed with brodifacoum and difenacoum exhibited 
separate Probit response lines, as described above. Female Reading and susceptible rats dosed 
with brodifacoum, bromadiolone and difenacoum exhibited separate Probit response lines, as 
described above. Male Welsh and susceptible rats dosed with bromadiolone and difenacoum 
exhibited separate Probit response lines, as described above. Male Welsh and susceptible rats 
dosed with brodifacoum exhibited co-incident response lines; during the Genmod procedure 
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the Probit response lines did not deviate significantly from a parallel response, and when 
analysed further they did not deviate significantly from a coincident response. Female Welsh 
and susceptible rats dosed with brodifacoum and bromadiolone exhibited separate Probit 
response lines, as described above, and female Welsh and susceptible rats dosed with 
difenacoum exhibited co-incident response lines, as described above. A summary of these 
results is provided in Table 4.2. 
 
4.3.3 Probit dose-response percentiles and resistance factors 
By comparing the Summary Probit dose-response data generated in this study with those 
made available by Prescott et al. (2007), resistance factors have been calculated at the ED40, 
ED50, ED60 and ED99 level for all SGARs and resistant Norway rat strains tested herein. 
Summary Probit dose-response data and derived resistance factors are presented for CSL 
Berkshire rats in Table 4.3, for Reading Berkshire rats in Table 4.4 and for Welsh rats in 
Table 4.5. 
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Table 4.1. Comparison of the Probit response between male and female rats for various SGARs against various strains of resistant Norway rats. 
Resistant rat 
strain SGAR 
Deviance 
(Separate) 
Deviance 
(Parallel) 
Deviance 
(Coincident) 
Chi Square 
(Parallel - 
Separate) 
p-value Chi Square (Coincident - Parallel) p-value Result 
CSL Berkshire Bromadiolone 1.0063 7.1859 13.8067 6.1796 < 0.05 - - Separate 
CSL Berkshire Difenacoum 7.4219 7.621 31.8721 0.1901 0.6555 24.2511 < 0.0001 Parallel 
CSL Berkshire Brodifacoum 3.3415 4.4792 27.4704 1.1377 0.2861 22.9912 < 0.0001 Parallel 
CSL Berkshire Flocoumafen 4.4359 4.5443 19.6707 0.1084 0.742 15.1264 < 0.0001 Parallel 
CSL Berkshire Difethialone 0.5726 1.9534 9.8267 1.3808 0.24 7.8733 < 0.05 Parallel 
Reading Berkshire Difenacoum 9.4394 12.6925 35.2156 3.2531 0.0712 22.5231 < 0.0001 Parallel 
Reading Berkshire Brodifacoum 3.2398 8.7854 22.8874 5.5456 < 0.05 - - Separate 
Welsh Bromadiolone 3.6957 14.0363 34.3458 10.3406 < 0.05 - - Separate 
Welsh Difenacoum 9.1407 13.6472 21.5876 4.5065 < 0.05 - - Separate 
Welsh Brodifacoum 3.696 4.9011 24.0659 1.2051 0.2723 19.1648 < 0.0001 Parallel 
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Table 4.2. Comparison of the Probit response between resistant and susceptible rats for various SGARs against males and females. 
Resistant rat 
strain SGAR 
Deviance 
(Separate) 
Deviance 
(Parallel) 
Deviance 
(Coincident) 
Chi Square 
(Parallel - 
Separate) 
p-value Chi Square (Coincident - Parallel) p-value Result 
Reading Berkshire 
female Bromadiolone 16.2938 38.7705 73.0947 22.4767 < 0.0001 - - Separate 
Reading Berkshire 
female Difenacoum 6.6565 17.8135 25.5349 11.157 < 0.05 - - Separate 
Reading Berkshire 
male Difenacoum 2.802 16.5801 20.1458 13.7781 < 0.05 - - Separate 
Reading Berkshire 
female Brodifacoum 5.0272 18.6561 31.2904 13.6289 < 0.05 - - Separate 
Reading Berkshire 
male Brodifacoum 2.448 11.1122 13.8977 8.6642 < 0.05 - - Separate 
Reading Berkshire 
female Flocoumafen 4.2592 11.1408 26.3128 6.8816 < 0.05 - - Separate 
Welsh female Bromadiolone 35.5877 58.6029 59.0535 23.0152 < 0.0001 - - Separate 
Welsh male Bromadiolone 0.8061 15.1577 18.3702 14.3516 < 0.05 - - Separate 
Welsh female Difenacoum 0.0024 0.8313 0.8314 0.8289 0.3626 0.0001 0.992 Coincident 
Welsh male Difenacoum 9.1574 16.8313 29.0137 7.6739 < 0.05 - - Separate 
Welsh female Brodifacoum 6.7137 16.9046 22.959 10.1901 < 0.05 - - Separate 
Welsh male Brodifacoum 1.2177 2.8823 6.024 1.6646 0.197 3.1417 0.0763 Coincident 
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Table 4.3. Effective doses and resistance factors of all SGARs at various percentiles against male and female CSL Berkshire rats. 
 
Effective Dose [mg/kg] (lower – upper fiducial limits) 
Resistance Factor compared with susceptible rats 
Effective 
Dose Sex Brodifacoum Bromadiolone Difenacoum Difethialone Flocoumafen 
40% Male 
0.56 (0.41 – 0.66) 
2.67 
4.61 (3.02 – 4.83) 
10.02 
3.02 (2.48 – 3.68) 
4.72 
0.87 (0.75 – 0.98) 
2.12 
0.71 (0.6 – 0.79) 
2.63 
50% Male 
0.6 (0.47 – 0.71) 
2.73 
4.67 (3.48 – 4.93) 
9.94 
3.28 (2.73 – 4.09) 
5.05 
0.9 (0.79 – 1.02) 
2.09 
0.74 (0.64 – 0.82) 
2.64 
60% Male 
0.64 (0.52 – 0.77) 
2.91 
4.74 (3.95 – 5.09) 
9.88 
3.58 (2.98 – 4.57) 
5.42 
0.93 (0.82 – 1.07) 
2.11 
0.77 (0.67 – 0.86) 
2.66 
99% Male 
1.16 (0.92 – 2.18) 
4.3 
5.32 (5.00 – 14.84) 
9.5 
7.17 (5.35 – 13.31) 
9.08 
1.23 (1.07 – 1.73) 
2.05 
1.08 (0.95 – 1.41) 
3.0 
40% Female 
1.37 (1.06 – 1.57) 
6.23 
6.57 (4.25 – 8.63) 
10.77 
9.17 (7.57 – 11.1) 
11.91 
1.09 (0.97 – 1.21) 
2.54 
0.98 (0.85 – 1.11) 
3.06 
50% Female 
1.47 (1.2 – 1.68) 
6.68 
7.47 (5.13 – 9.79) 
12.05 
9.98 (8.34 – 12.33) 
12.8 
1.13 (1.01 – 1.26) 
2.31 
1.03 (0.9 – 1.16) 
3.12 
60% Female 
1.58 (1.34 – 1.83) 
7.18 
8.49 (6.12 – 11.24) 
13.48 
10.87 (9.12 – 13.8) 
13.59 
1.17 (1.06 – 1.32) 
2.29 
1.07 (0.94 – 1.22) 
3.15 
99% Female 
2.86 (2.29 – 5.35) 
12.43 
24.21 (16.78 – 53.54) 
33.16 
21.8 (16.33 – 40.19) 
22.95 
1.54 (1.35 – 2.18) 
2.23 
1.51 (1.31 – 2.05) 
3.6 
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Table 4.4. Effective doses and resistance factors of brodifacoum, bromadiolone and difenacoum at various percentiles against male and female Reading Berkshire rats. 
 
Effective Dose [mg/kg] (lower – upper fiducial limits) 
Resistance Factor compared with susceptible rats 
Effective 
Dose Sex Brodifacoum Bromadiolone Difenacoum Flocoumafen 
40% Male 
0.13 (0.08 – 0.2) 
0.62 
- 
0.3 (0.16 – 0.5) 
0.47 
- 
50% Male 
0.16 (0.1 – 0.25) 
0.73 
- 
0.39 (0.21 – 0.65) 
0.6 
- 
60% Male 
0.19 (0.13 – 0.32) 
0.86 
- 
0.5 (0.29 – 0.84) 
0.76 
- 
99% Male 
0.77 (0.41 – 4.54) 
2.85 
- 
3.8 (1.96 – 12.01) 
4.81 
- 
40% Female 
0.49 (0.37 – 0.59) 
2.23 
1.51 (1.09 – 1.91) 
2.48 
1.78 (1.09 – 2.69) 
2.31 
0.42 (0.2 – 0.64 
1.27 
50% Female 
0.52 (0.41 – 0.63) 
2.36 
1.77 (1.34 – 2.25) 
2.86 
2.28 (1.45 – 3.5) 
2.89 
0.51 (0.28 – 0.76) 
1.5 
60% Female 
0.55 (0.45 – 0.69) 
2.5 
2.08 (1.63 – 2.7) 
3.3 
2.93 (1.93 – 4.66) 
3.62 
0.57 (0.37 – 0.97) 
1.63 
99% Female 
0.89 (0.71 – 2.01) 
3.87 
7.72 (5.04 – 18.85) 
10.58 
22.4 (11.53 – 76.15) 
23.33 
1.41 (0.88 – 28.73) 
3.28 
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Table 4.5. Effective doses and resistance factors of brodifacoum, bromadiolone and difenacoum at various percentiles against male and female Welsh rats. 
 
Effective Dose [mg/kg] (lower – upper fiducial limits) 
Resistance Factor compared with susceptible rats 
Effective 
Dose Sex Brodifacoum Bromadiolone Difenacoum 
40% Male 
0.19 (0.18 – 0.21) 
0.91 
0.16 (0.06 – 0.34) 
0.35 
0.37 (0.06 – 0.48) 
0.59 
50% Male 
0.2 (0.19 – 0.22) 
0.91 
0.21 (0.09 – 0.48) 
0.45 
0.41 (0.11 – 0.53) 
0.63 
60% Male 
0.21 (0.19 – 0.23) 
0.96 
0.28 (0.13 – 0.7) 
0.58 
0.46 (0.2 – 0.6) 
0.7 
99% Male 
0.27 (0.25 – 0.34) 
1.0 
3.06 (1.08 – 45.22) 
5.46 
1.13 (0.76 – 52.28) 
1.43 
40% Female 
0.25 (0.23 – 0.27) 
1.14 
2.5 (2.0 – 2.87) 
4.17 
0.76 (0.61 – 0.84) 
0.99 
50% Female 
0.25 (0.24 – 0.28) 
1.14 
2.64 (2.21 – 3.09) 
4.33 
0.78 (0.66 – 0.87) 
1.0 
60% Female 
0.26 (0.24 – 0.29) 
1.18 
2.78 (2.4 – 3.38) 
4.48 
0.81 (0.71 – 0.92) 
0.99 
99% Female 
0.34 (0.31 – 0.44) 
1.48 
4.34 (3.51 – 9.54) 
5.95 
1.02 (0.9 – 2.01) 
1.07 
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4.4 Discussion 
4.4.1 Resistance factors and relative anticoagulant efficacy 
In every combination of resistant rat strain and active ingredient, the ED50 was higher for 
females than for males. The same is true for ED40, ED60 and ED99 (with the lone exception 
being that Welsh males have a higher ED99 for difenacoum than Welsh females). This 
echoes the susceptible baseline data for SGARs and FGARs (Prescott et al., 2007), and 
indicates that regardless of resistance status, female Norway rats have a greater tolerance to 
anticoagulants than males. This runs contrary to previous evidence that, in rats susceptible to 
warfarin, females are significantly more sensitive to anticoagulant poisoning than males 
(Back, Steger and Glassman, 1978). In addition, resistance factors for females at each 
effective dose were noticeably greater than those of males (the lone exception again being the 
ED99 for difenacoum against Welsh rats). Because Probit dose-responses of ED99 estimates 
are inherently inaccurate, with the widest fiducial limits – especially in studies where 
numbers of test subjects are kept to a minimum – any discrepancies highlighted by ED99s 
should be ignored. The effective dose percentiles for female resistant rats are expected to be 
greater than those of males due to the females’ greater anticoagulant tolerance, but the 
increased resistance factors indicates that resistance mutations in female rats have a greater 
relative effect on individuals’ PT, suggesting that the character of anticoagulant resistance 
imparted by VKORC1 mutations is different between male and female rats. In addition to the 
most obvious result of this – that female resistant rats are likely to be harder to control in the 
field than males – higher resistance for female rats will also have the effect of enabling 
populations to recover in numbers at a more rapid rate than if male and female had similar 
ED50s. This is because only a single male rat is required to mate with multiple female rats, 
thereby producing multiple litters. 
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The Probit dose-response data for the CSL Berkshire strain of resistant rat show clear 
groupings of the various SGARs in both sexes, with bromadiolone and difenacoum having far 
greater effective doses at all percentiles than brodifacoum, and flocoumafen and difethialone. 
This pattern is repeated in the Probit dose-response data for the Reading Berkshire rats, 
where the effective doses for brodifacoum and flocoumafen against females are lower at all 
percentiles than for bromadiolone and difenacoum, and effective doses of brodifacoum 
against males are lower than those of difenacoum. In the case of male Welsh rats, 
brodifacoum, bromadiolone and difenacoum appear to form a single grouping with uniformly 
low values for all derived effective doses. The Probit dose-response data for female Welsh 
rats show bromadiolone forming a separate group of higher effective doses than difenacoum 
and brodifacoum; brodifacoum effective doses are slightly lower than those of difenacoum.  
While the differences between the ED50 for the SGARs against susceptible rats are 
negligible, these data firmly establish that bromadiolone is less toxic to resistant Norway rats 
than difenacoum. In turn, difenacoum is less toxic to resistant Norway rats than the 
resistance-breaking anticoagulants brodifacoum, difethialone and flocoumafen. The results 
herein show conclusively that less brodifacoum is required than bromadiolone and 
difenacoum to have an anticoagulant effect on Norway rats positive for the L120Q mutation. 
When comparing the Probit dose-response data for the bromadiolone and difenacoum BCR 
tests with CSL Berkshire rats, the ED50s for female rats are high (7.47 and 9.98 mg/kg, 
respectively), as are resistance factors (12.05 and 12.8, respectively). The ED50s are lower for 
male rats (4.67 and 3.28 mg/kg, respectively). The resistance factors for bromadiolone and 
difenacoum against male CSL Berkshire rats vary considerably (9.94 and 5.05, respectively), 
suggesting that difenacoum resistance in males may only be of the technical variety. 
Nonetheless, the severity of the resistance against both bromadiolone and difenacoum 
exhibited by female CSL Berkshire rats indicates that the L120Q mutation can confer 
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practical resistance to these SGARs, and they should not be used for the control of resistant 
rats in south-east England (RRAG, 2012). When comparing the Probit dose-response data for 
difethialone, flocoumafen and brodifacoum against CSL Berkshire rats, the differences 
between ED50s for male rats are small (0.9, 0.74 and 0.6 mg/kg respectively) as are their 
resistance factors (2.03, 2.64 and 2.79 respectively). Meanwhile female rats have slightly 
higher ED50 for brodifacoum (1.47 mg/kg) than for difethialone and flocoumafen (1.13 and 
1.03 mg/kg respectively); in comparison to these relatively similar values, the resistance 
factors of female CSL Berkshire rats for brodifacoum (6.68) are far greater than those for 
difethialone and flocoumafen (2.31 and 3.12, respectively) . The implication is that in the 
case of female rats with the L120Q mutation, brodifacoum is a less efficacious resistance 
breaker than both difethialone and flocoumafen. The raw data from the susceptible baseline 
study (Prescott et al., 2007) elucidate this issue: according to those data, the ED50 for 
brodifacoum against susceptible rats is less than half the ED50 for difethialone, and is less 
than 75% that value for flocoumafen. The whole range of effective dose percentiles for 
brodifacoum against susceptible female rats (ED01 – ED99) is within the range of 0.211 mg/kg 
and 0.233 mg/kg (Prescott et al., unpublished data). This very narrow range of doses 
indicates a very high level of efficacy for brodifacoum against susceptible Norway rats, but 
also cast brodifacoum in an artificially negative light when tested against rats possessing 
anticoagulant resistance. This effect is replicated in the results for Welsh rats and Reading 
Berkshire rats, as all resistance factors are based upon the same susceptible baselines 
(Prescott et al., 2007). Brodifacoum has been shown to consistently cause lethal effects at 
concentrations as low as 0.4 mg/kg in rats thought to be positive for the Y139S mutation and 
as low as 0.6 mg/kg in susceptible laboratory rats (Redfern, Gill and Hadler, 1976). It has 
also been shown to completely control the majority of populations within the Y139S 
resistance focus within 18 days at a concentration of 0.0005% (Rennison and Dubock, 1978). 
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Finally, it has been shown to be efficacious in the south-east of England, in areas where 
bromadiolone and difenacoum had failed to control Norway rat populations (Greaves, 
Shepherd and Quy, 1982; Meyer, 2009). The inflated resistance factors for brodifacoum cast 
doubt on the notion that it could be used to effectively control a wild population of Norway 
rats with a level of resistance comparable to the CSL Berkshire rats tested herein, suggesting 
practical resistance could be encountered in the field. It is more likely, given the low 
brodifacoum doses required to elicit anticoagulant responses in CSL Berkshire rats, that wild 
rats with the L120Q mutation would only possess technical resistance to brodifacoum, along 
with difethialone and flocoumafen. 
The ED50 for brodifacoum against male Reading Berkshire rats is less than half that of 
difenacoum (0.16 and 0.39 mg/kg, respectively), but the associated resistance factors are 
similar due to the effect of the susceptible brodifacoum data described above (0.73 and 0.6, 
respectively). Resistance factors below 1 suggest that male Reading Berkshire rats are more 
susceptible to SGARs than are male wild-type rats. Against female Reading Berkshire rats, 
brodifacoum and flocoumafen elicit very similar ED50s (0.52 and 0.51 mg/kg, respectively), 
much lower than those of bromadiolone and difenacoum (1.77 and 2.28 mg/kg, respectively). 
Again, due to the effect of the susceptible brodifacoum data, the associated brodifacoum 
resistance factor (2.36) is noticeably higher than that of flocoumafen (1.5), but still lower 
than those of bromadiolone and difenacoum (2.86 and 2.89, respectively). ED50s and 
resistance factors for all SGARs against Reading Berkshire rats are low; these rats possess 
only technical resistance.  
When comparing the Probit dose-response data for brodifacoum, bromadiolone and 
difenacoum against Welsh rats, the differences between ED50s for male rats are small and 
notably low (0.2, 0.21 and 0.41 mg/kg respectively), resulting in resistance factors below 1 
(0.91, 0.45 and 0.63 respectively); as with Reading Berkshire rats, male Welsh rats appear 
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more susceptible to SGARs than do wild-type rats. For female Welsh rats, the ED50s show 
greater variety (0.25, 2.64 and 0.78 mg/kg, respectively), whereas the resistance factor for 
bromadiolone is much higher than those for brodifacoum and difenacoum (4.33, 1.14 and 1.0 
respectively). These results show clearly that in Welsh rats, resistance to SGARs at the ED50 
level is either entirely, or almost entirely, undetectable. The exception is resistance to 
bromadiolone in females; with ED50 of 2.64 mg/kg and a resistance factor of 4.33, this is 
likely to be technical resistance with little practical effect in the field. 
Resistance factors were higher at the ED99 than ED50 for all strains and all SGARs 
(the exception being difethialone against CSL Berkshire rats), suggesting that in a resistant 
population, a small proportion of rats will be highly resistant, and that use of ineffective 
rodenticides will select for these rats in the same manner in which a Selected Line is created 
in the laboratory. Typically, the weaker the SGAR, the greater the difference between the 
resistance factors at the various effective doses. The Probit-response lines are steeper for 
resistant rats than for susceptible rats, with the steepest lines generated for the least effective 
SGARs; the less effective the anticoagulant, the more noticeable the effect of the resistance, 
and therefore the greater the likelihood that treatment failure would occur in a practical 
setting. The unreliability of ED99s produced by Probit analysis cast doubt on the accuracy of 
the idea that resistance factors are actually higher for ED99s than ED50s; still, due to the low 
ED99s and associated fiducial limits across resistance breakers, it is recommended that the 
practical impact of resistance-breaking SGARs be further explored in the field. 
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4.4.2 Response between strains 
4.4.2.1 Y139S 
The Probit response lines of Welsh female and wild-type female rats dosed with difenacoum 
were co-incident, as were the Probit response lines of Welsh male and wild-type male rats 
dosed with brodifacoum (wild-type data from Prescott et al., 2007). Because all other Probit 
response lines of Welsh rats compared with wild-type rats dosed with the same 
anticoagulants were statistically separate, it appears that in the majority of cases, rats 
possessing the Y139S mutation in the wild would be significantly harder to control via the 
use of anticoagulants than would susceptible animals. Scrutiny of the resistance factors listed, 
however, shows that in the case of males, Welsh rats appear to be more susceptible to SGARs 
than are susceptible rats: at the ED40, ED50 and ED60 level resistance factors were below 1 (at 
the ED99 level all resistance factors were above or equal to 1). Moreover, resistance factors 
for female Welsh rats against bromadiolone were below 6 at all effective doses, and below 
1.5 against difenacoum and brodifacoum, confirming the findings of Redfern and Gill (1980), 
that bromadiolone is fully effective against Welsh-resistant rats. Indeed, with susceptible rats 
capable of consuming enough 0.005% bromadiolone bait in a single day to achieve complete 
mortality (Marsh, 1977; Redfern and Gill, 1980), a resistance factor below 6 should not be an 
insurmountable obstacle to a well carried-out field trial. Successful trials in the Y139S 
resistance focus have already been carried out using bromadiolone at this strength (Richards, 
1981). The comparatively low resistance factors for difenacoum and brodifacoum reflect 
previous experiments showing little to no impact of the Y139S mutation on the efficacy of 
brodifacoum (Redfern, Gill and Hadler, 1976) and difenacoum (Hadler, Redfern and Rowe, 
1975) in the laboratory, or in the field (Rennison and Dubock, 1978; Rennison and Hadler, 
1975, respectively). 
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4.4.2.2 L120Q 
All Reading Berkshire rats exhibited separate Probit response lines from those of susceptible 
rats of the same sex, dosed with the same SGAR. For all male Reading Berkshire rats, 
resistance factors at the ED40, ED50 and ED60 level were below 1, but at ED99 were above 1. 
These differences in blood clotting response when dosed with SGARs are enough to explain 
the statistical separation between the datasets. Resistance factors were greater than 1 for all 
female Reading Berkshire rats, and were greater than equivalent resistance factors for female 
Welsh rats at all effective doses of all SGARs; male Reading rat resistance factors were lower 
at the ED50 level for brodifacoum and difenacoum than those of male Welsh rats. It has long 
been established that the resistance present in central-southern England (L120Q) has a greater 
negative impact on anticoagulant rodenticide effectiveness than does the resistance centred 
on the Anglo-Welsh border (Y139S): this is confirmation that completely eradicating a 
population of rats with the L120Q mutation will be more difficult than doing the same to a 
population of rats with the Y139S mutation (due to female survival). That is not to say that 
rats with the weaker form of the L120Q resistance (“Reading Berkshire”) cannot be 
controlled: as stated above, this strain of resistant rats possesses only technical resistance to 
SGARs. This lends credence to studies that, upon re-evaluating field trial data from the 1980s 
and 1990s, suggested that Hampshire-Berkshire resistance may not have always been the 
primary cause of reported treatment failure during that period bait (Quy et al., 1992; Quy, 
Shepherd and Inglis, 1992). During initial evaluations of brodifacoum (Redfern, Gill and 
Hadler, 1976) baits comprised of as little as 0.0005% brodifacoum achieved 100% mortality 
after two days’ feeding by non-resistant rats, with lethal doses as low as 0.6 mg.kg-1. Given 
that SGAR baits in the UK will be required to have a strength of less than 0.003% in order to 
be available for registration, as recently suggested by the European Chemicals Agency 
(ECHA), no problems – caused by anticoagulant resistance – eradicating rats with the 
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Reading Berkshire form of the L120Q mutation are foreseen. Despite anecdotal evidence that 
bromadiolone and difenacoum are still efficacious in areas of known L120Q resistance and 
the low resistance factors reported for Reading Berkshire rats, the results of previous 
laboratory tests (Gill et al., 1993; Quy et al., 1995) and the potential for the creation of 
resistant lines such as the CSL Berkshire rats, suggest that usage of these baits in the L120Q 
focus will be harmful to non-target wildlife and select for resistance within Norway rat 
populations.  
In comparison to the Reading Berkshire form of the L120Q mutation, the CSL 
Berkshire form is highly resistant to all comparable SGARs (Tables 4.1 and 4.2). Male and 
female CSL Berkshire rats had higher ED40s, ED50s, ED60s and ED99s than male and female 
Reading Berkshire rats for brodifacoum, bromadiolone and difenacoum, and therefore higher 
resistance factors at all levels. Several years after the two strains were initially separated, the 
CSL Berkshire strain of rats still possesses a much greater tolerance to anticoagulants than 
Reading Berkshire rats. Therefore, it is imperative that the use of difenacoum and 
bromadiolone in the L120Q focus of central-southern England is avoided. It is currently 
impossible to determine if a population has undergone artificial selection due to inappropriate 
use, or misuse, of ineffective SGARs without conducting extensive BCR tests: in order to 
avoid using ineffective SGARs against more highly resistant rats in the field, only use of 
resistance breaking SGARs (brodifacoum; difethialone; flocoumafen) is advocated. Reading 
Berkshire rats appear to be more susceptible to bromadiolone and difenacoum than rats of the 
Hampshire line (Prescott et al., 2007). This adds further weight to the argument that 
bromadiolone and difenacoum cannot be safely used to control rats in the large L120Q focus 
of central-southern England; advice for rodenticide users in Berkshire can be safely applied 
to Hampshire, and indeed the whole of the L120Q focus as well. 
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It is curious to note that with CSL Berkshire rats, bromadiolone is more efficacious 
than difenacoum against females (i.e. bromadiolone elicits “responder” statuses at lower 
doses than does difenacoum), and difenacoum is more efficacious than bromadiolone against 
males; in the BCR tests with Welsh rats, the reverse is true. Regardless, this does not change 
the fact that the use of both bromadiolone and difenacoum against Norway rats should be 
avoided in areas of L120Q resistance, and should not be problematic in areas of Y139S 
resistance. 
 
4.4.3 Liabilities of the methodology 
Despite Linear Regression Models showing that Norway rat resting PT is not affected by 
bodyweight, the true effect of bodyweight on the response of rats dosed with anticoagulant 
rodenticides is not known. The same Linear Regression Models showed conclusively that sex 
can only explain 0.13% of resting PT variation, but as shown above, male and female rats of 
the same resistant strain show parallel or separate responses to the various SGARs, but never 
co-incident responses. It is therefore possible that, when a rat is dosed with or consumes 
anticoagulants, its weight may have a significant effect upon the resulting PT, and therefore 
survival. Exploring this issue would require utilising many more rats in a BCR study using a 
repeated dose of a single anticoagulant in order to elucidate the effect of a factor which will 
be impossible to control for in the field.  
The original intention for this work was to generate Probit dose-response lines for all 
five SGARs against the three resistant rat strains housed at the University of Reading. Doing 
so relies upon a sufficient supply of resistant rats to test. During the course of this 
experiment, the breeding behaviour of the three strains tested has been variable, resulting in 
periods of rat shortage, when the number of BCR tests that could be carried out was limited, 
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therefore prolonging the generation of Probit dose-response lines. Causes of reduced supply 
of rats include refusal of breeding pairs to mate; repeated infanticide; and sex ratios heavily 
biased towards females (as noted by Bishop, Hartley and Partridge, 1977). In order to 
complete all Probit dose-response lines, it is recommended that further work be carried out to 
complete the bromadiolone, difethialone and flocoumafen dosing work with the Welsh and 
Reading Berkshire rats housed at the University of Reading. 
It is important to reiterate that although the Probit analyses herein generated a range 
of effective doses (and associated resistance factors) from the 1% to 99% levels, the most 
accurate and reliable results are those associated with ED50s. It is tempting to read too far into 
the implications of the extreme ends of the fiducial limits of ED99s and ED01s regarding the 
extreme ends of the resistance conferred by VKORC1 mutations and the likely impact in the 
field. This should be avoided however, with the focus of this and any other Probit-related 
discussion remaining on and around the ED50 values. This focus on ED50 values may limit the 
value of these results when attempting to predict the ability of SGARs to gain full control in 
field applications, in areas where resistance has been repeatedly selected for over many years. 
The results herein may be applied successfully to the majority of the population, but some 
individuals may possess resistance factors far exceeding those listed at ED50 level.  
Furthermore, there are several aspects of the methodology which have inherent 
inaccuracies. Rats up to 200 g could be dosed used 1 ml syringes, which are accurate to 
within 0.01 ml, but rats above this weight were dosed with 2.5 ml syringes, which are only 
accurate to within 0.1 ml. In addition, the balances used to weigh out dosing solutions were 
only accurate to within 0.01 g. Finally it is possible that the original stock solutions of the 
SGARs supplied variously by RSSL and Liphatech (see above and Section 2.2.3) could not 
be made up to precisely 10 or 1 mg/ml. Therefore there was potential for inaccuracy at all 
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levels of dosing preparation, further emphasising the need to restrain analysis to the more 
reliable ED50s and associated resistance factors. 
As with all laboratory experiments, these results may not predict with 100% accuracy 
the situations likely to be encountered in attempts to control Norway rats in the wild with the 
anticoagulants tested. Many anticoagulant applications in this experiment elicited 
“responder” status from rats that, based upon known lethal doses of these active ingredients 
(see, for example, Redfern, Gill and Hadler, 1976; Gill, Kerins and MacNicoll, 1992; Quy et 
al., 1995), may not have died if left in observation. It is possible to compare derived 
resistance factors at the ED50 level with previously published resistance factors at the LD50 
level, where the data for both sets of experiments exist. LD50 resistance factors for rats with 
the Y139S resistance mutation are higher than the derived ED50 resistance factors herein for 
bromadiolone (2.7 – 6.9 and 0.45 – 4.33, respectively) and difenacoum (1.1 – 1.3 and 0.63 – 
1.0, respectively), and comparable for brodifacoum (1.0 – 1.1 and 0.91 – 1.14, respectively) 
(Greaves and Cullen-Ayres, 1988). It is noticeable that for these results, the difference 
between LD50 and ED50 resistance factors falls in size as efficacy of the SGAR increases. If 
this pattern continued between strains and was influenced by the level of resistance conferred 
by each mutation, it would further emphasise the need to avoid ineffective anticoagulants. 
Unfortunately, this is not the case; previous results for the Hampshire strain of L120Q 
resistance (Greaves and Cullen-Ayres, 1988; Prescott et al., 2007) show that LD50 resistance 
factors are substantially lower than ED50 resistance factors for bromadiolone (1.5 – 2.9 and 
3.0 – 6.8, respectively), but comparable for difenacoum (3.9 – 4.1 and 2.2 – 5.0, 
respectively). It is therefore uncertain how reliably ED50 resistance factors can predict the 
efficacy of various SGAR doses between strains. For these reasons, the results herein (and 
potential future results from studies involving rats possessing the L128Q, Y139C or Y139F 
mutations) require contextual confirmation in the field. 
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Chapter 5: Assessing the efficacy of three SGARs in the 
L120Q focus of south-east England 
5.1. Introduction 
Resistance to anticoagulant rodenticides in Norway rats has been a growing problem in 
Europe for some time, especially in the UK, where it was first discovered (Boyle, 1960). 
More resistance-conferring mutations are found in the UK than anywhere else in the world 
(RRAG, 2012) and the majority of rats studied in the UK are positive for mutations known to 
confer practical resistance to commonly used SGARs (Section 3.3.1). The L120Q resistance 
focus of central-southern England, in particular, has yet to be entirely delimited and the 
mutation’s effect on control in the field is uncertain. Resistance had been discovered in 
central-southern England by the 1970s (Greaves and Rennison, 1973) and the resistant rat 
populations there were found to be able to tolerate SGARs known to be efficacious against 
established resistance foci in Powys, Wales (Quy, Shepherd and Inglis, 1992). Numerous 
studies in the 1980s and 1990s showed mixed results when testing bromadiolone and 
difenacoum against these strains of resistant rats in laboratory trials and in the field (Redfern 
and Gill, 1978; Richards, 1981; Greaves, Shepherd and Gill, 1982; Quy, Shepherd and Inglis, 
1992; Cowan et al., 1995), with bromadiolone and difenacoum both appearing to be the more 
effective active ingredients. These inconsistent results suggested that there may have been 
multiple resistance phenotypes in central-southern England. This was confirmed in the early 
1990s when over 800 kg of 50 ppm bromadiolone bait was consumed by rats at a farm in 
north Berkshire, without achievement of control (Quy et al, 1995). The two strains of 
resistance are known as Hampshire and Berkshire resistance after the locations where they 
were first found. However, molecular techniques (Rost et al, 2004; Pelz et al, 2005) have 
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confirmed that both strains are positive for the amino acid polymorphism L120Q, one of 
many anticoagulant resistance-conferring mutations of the Norway rat VKOR gene found 
across the UK. A comparison of data on Reading Berkshire rats from Section 4.4.2.2 and the 
limited tests carried out by Prescott et al. (2007) with Hampshire rats suggests that 
Hampshire-resistant rats do in fact possess a greater tolerance to bromadiolone and 
difenacoum than the Reading Berkshire resistant strain. It is now thought that historically, 
control of L120Q-resistant rats in Berkshire may have been achieved using bromadiolone and 
difenacoum when the rats in question did not avoid the bait due to neophobia or presence of 
stored alternative grain, and reinvasion did not occur (Quy et al., 1992; Quy, Shepherd and 
Inglis, 1992).  Despite the nominal difference between the two groups of resistant rats, both 
have now shown demonstrable resistance to bromadiolone and difenacoum, whilst being 
susceptible to the resistance-breaking SGAR brodifacoum. A series of field trials in 
Hampshire showed difenacoum to be of little use against the resistant rats there, with 
bromadiolone performing little better; control was achieved not only at brodifacoum trial 
sites, but also at sites at which difenacoum and bromadiolone had recently failed (Greaves, 
Shepherd and Quy, 1982). Rats from a farm in north Berkshire survived multiple 
bromadiolone treatments, and captured survivors then survived the 5.0 mg/kg body weight 
difenacoum resistance test posited by Gill et al. (1993) before 101 of 116 succumbed to a 
brodifacoum feeding test (Gill and MacNicoll, 1991; Quy et al., 1995). More recently an 
infestation in Hampshire consumed 213 kg of bromadiolone and difenacoum bait over the 
course of two years without control being achieved. In this instance a carefully monitored use 
of brodifacoum bait was applied under an emergency extension of Health and Safety 
Executive (HSE) approval, requiring just 3.4 kg of bait before the infestation was eradicated 
in 18 days (Meyer, 2009). Other studies have shown brodifacoum to be effective in 
controlling rats in both the Y139S (Rennison and Dubock, 1978) and L120Q foci (Greaves, 
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Shepherd and Quy, 1982). Infestations of Norway rats positive for the Y139C resistance 
mutation in the Westphalia region of Germany have been successfully controlled using as 
little as 1.45 kg 0.005% brodifacoum bait (Buckle, Klemann and Prescott, 2012), whereas 
treatments of other Y139C-positive infestations in the region using up to 28.2 kg 0.005% 
difenacoum bait (Buckle et al., 2013) and 43.4 kg 0.005% bromadiolone bait (Endepols et al., 
2012) have failed to achieve control. Despite evidence that brodifacoum is one of the most 
effective anticoagulants currently available, technical resistance has been found in the UK 
(Greaves, Shepherd and Quy, 1982; Gill, Kerins and MacNicoll, 1992). It is important that 
the resistance breaking properties of all the anticoagulants are fully explored; recent 
legislature has banned the use of almost all non-anticoagulant rodenticides in the EU, leaving 
stakeholders with almost no practical recourse for the control of large rat infestations should 
the anticoagulants no longer be efficacious. Until recently, use of anticoagulants for control 
of outdoor rat populations in the UK was limited solely to bromadiolone and difenacoum. 
This resulted in multiple areas where the presence of practical resistance meant that, in the 
absence of acute rodenticides (see Section 1.3.3), no legal control methods could be 
recommended (RRAG, 2012). The recent introduction of the anticoagulant rodenticide 
stewardship scheme (see Section 1.4.4) in the UK, supported by CRRU, has made it possible 
for competent users to utilise resistance-breaking anticoagulant rodenticides in and around 
buildings (Buckle et al., 2017). Given the risk to non-target animals that the use of ineffective 
rodenticides pose (Daniells, Prescott and Buckle, 2011), it is now necessary to determine 
which anticoagulant rodenticides are safe to use in the L120Q focus of central-southern 
England. This will result in effective and targeted applications of anticoagulant rodenticides 
which enable users to control populations of resistant Norway rats, while reducing 
unnecessary risk to non-target species. 
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5.2. Methods 
5.2.1 Trial sites 
A total of 6 field trials were undertaken from 2009 – 2016. These trials were conducted on 
behalf of Syngenta AG, a commercial client and were compliant with guidelines set out by 
the European and Mediterranean Plant Protection Organisation (EPPO, 1999a) and where 
necessary with guidelines set out by the CRRU stewardship scheme (Buckle et al., 2017). In 
the latter case this required two of the workers, employees of the University of Reading, to 
undertake the necessary exams showing professional competence. Workers included the 
primary researcher and three members of the Vertebrate Pests Unit of the University of 
Reading. Two trials were carried out for each of three SGARs: bromadiolone, difenacoum 
and brodifacoum. All rodenticide baits were supplied by Syngenta AG. All 6 sites were 
located within a 520 km2 area, which was entirely within what is now known to be the large 
L120Q focus of southern England (see Section 3.1). All sites were surveyed and maps 
indicating suitable bait locations were drawn prior to each treatment. Before the pre-treatment 
census phases, tracking patches were laid out around the site (see Table 5.1); these remained 
in place throughout the trials, except where stated. Three types of bait point were used during 
the trials: bait trays under natural cover, bait boxes and tyre baiters. These are described in 
detail in Section 2.3.4. Number of bait point types for all trials are described in detail in 
Tables 5.2 and 5.3. Number of bait points used, and apparent level of control based on census 
bait consumption have already been mentioned for Trials A – D elsewhere (Daniells, 2011). 
Some of the field trials considered here are of a commercially sensitive nature and results are 
therefore reported with respect to the volume of active ingredient consumed by rats in the 
environment, rather than volume of bait eaten.  
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5.2.1.1 Trial A 
Trial A was carried out between 13th February and 21st April 2009 at a farm in western 
Hampshire. A proprietary 0.005% bromadiolone pellet bait (ContracTM) was used in this field 
trial. The site was a poultry farm consisting of 13 large sheds for the housing of ~15,000 
chickens, and several augers for the storage and movement of feed. The sheds were arrayed 
in an L shape, with a line of four sheds extending to the south-west, and the remaining nine in 
a line extending to the south-east. During daylight hours, chickens had access to outdoor 
areas associated with each shed. Rats had easy access to spilled chicken feed in these areas 
and under augers, and had found harbourage underneath all of the houses and throughout a 
hedgerow bordering the south-west sheds. To the south, enclosed on two sides by the poultry 
sheds, was an arable field. The site was bordered on all sides by farmland used for pasture or 
crop growth. The site had an area of 2.3 ha. During the pre and post-treatment censuses, 150 
g of whole wheat was placed in each bait point, and replenished when necessary. When 
complete takes of the 150 g were recorded (see Section 2.3.4), the amount of whole wheat 
placed at those bait points was increased to 300 g. When complete takes of 300 g were 
recorded, the amount of whole wheat placed at those bait points was increased to 450 g. Bait 
points and tracking patches were laid out ten days before the start of the pre-treatment census, 
to allow rodents to become accustomed to them. During the treatment phase, bait 
consumption was recorded on Monday and Thursday every week. Bromadiolone bait 
application is described in Daniells (2011). After five weeks both tracking patch activity and 
bait consumption had plateaued, so the treatment phase of the field trial ceased in favour of 
the post-treatment lag phase and census. 
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5.2.1.2 Trial B 
Trial B was carried out between 13th February and 8th May 2009 at a farm in western 
Hampshire. A proprietary 0.005% difenacoum pellet bait (RatakTM) was used in this field 
trial. The site was a dairy farm consisting of four large connected sheds housing ~ 4000 dairy 
cattle, mounted on a concrete apron throughout. Adjacent to the row of sheds on the north-
western side was a smaller calving shed, and to the north-east were silage clamps and a 
compactor, and beyond those were two slurry tanks set into the ground. Rats had easy access 
to an alternative food source in the form of cattle feed which was available at all times on the 
floor of the sheds. Rats were able to find harbourage underneath the concrete apron upon 
which the sheds were mounted, as well as in a swathe of waste ground adjacent to the silage 
clamps, and in burrows bordering the calving shed. The site was bordered on all sides by 
improved grassland for the grazing of cattle. The only buildings in the vicinity were two farm 
sites 100 m to the south and 100 m to the east over open grassland. A small managed 
woodland (2 ha) was located 150 m to the north. Bait points and tracking patches were laid 
out ten days before the start of the pre-treatment census, to allow rodents to become 
accustomed to them. The site had an area of 1.4 ha. During the pre and post-treatment 
censuses, 150 g of whole wheat was placed in each bait point, and replenished when 
necessary. When complete takes of 150 g (see Section 2.3.4) or near-complete takes were 
recorded, the amount of whole wheat placed at those bait points was increased to 300 g. 
When complete takes of 300 g were recorded, the amount of whole wheat placed at those bait 
points was increased to 450 g. When complete takes of 450 g were recorded, the amount of 
whole wheat placed at those bait was points was increased to 600 g. For trial B, the duration 
pre-treatment census was increased to six days due to a lack of consumption by rats on site; 
the extra two days allowed for a maximum daily bait consumption that more accurately 
reflected the perceived size of the infestation. Because of this, the post-treatment census was 
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increased to six days as well. Difenacoum bait application is described in Daniells (2011). 
Despite running concurrently with trial A, the placement of rodenticide bait in trial B lasted 
two weeks longer, and the recording of tracking patches during the treatment phase lasted a 
week longer. This was because these measures of Norway rat activity had not plateaued or 
ceased entirely at the five-week point (see Section 2.3.8). 
5.2.1.3 Trial C 
Trial C was carried out between 26th October 2009 and 24th January 2010 at a farm in West 
Berkshire. As in Trial A, the proprietary 0.005% bromadiolone pellet bait (ContracTM) was 
used. The site was a mixed stock farm with multiple large barns for housing animals and 
storing machinery and feed. There were ~500 cattle, ~300 sheep and ~100 pigs and piglets. 
Low numbers of chickens and geese were left to roam freely throughout the site. Two barns 
contained only machinery and tools, and offered little in the way of food to rats. Another 
housed light aircraft. One barn for the seasonal housing of cattle or sheep was built on hard 
standing and rarely contained animal feed or cover for rats. A smaller barn housed sheep 
when they were not grazing in fields to the north or in a penning area on the east of the site. 
The floor of this barn was covered in straw, affording cover to rats. Cattle were usually 
housed in a shed to the west, separated from the other animal-housing buildings by barns 
containing machinery. Cattle feed was readily available, but there was no cover or housing 
for rats. Two smaller barns were used solely for storage of grain and feed in the open, and 
rats could easily be observed in and around these sources of food. The main part of the 
infestation was centred in and around a pig barn and an adjacent drainage system. In the pig 
barn, feed and harbourage were readily available at ground level at all times. Some waste 
ground interspersed around and between these buildings contained seemingly active burrows. 
All buildings and barns had hollow and easily accessed walls with evidence of rat activity, 
except for the cattle shed and the barn housing light aircraft. Finally, several grain augers 
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were located between the sheep barn and the seasonal cattle and sheep barn. Immediately 
surrounding the farm on all sides was grassland for the grazing of cattle and sheep, while to 
the north-east was a large arable crop field. Further out were more fields for the grazing of 
livestock and arable crops, and a single patch of woodland, 180 metres west of the farm site. 
The site had an area of 1.6 ha. Bait points and tracking patches were laid out ten days before 
the start of the pre-treatment census, to allow rodents to become accustomed to them. During 
the pre and post-treatment censuses, 150 g of whole wheat was placed in each bait point. 
Replenishment of bait points, and increases to the total volume of whole wheat used followed 
the same methods as in Site A. During the treatment phase, bait consumption was recorded 
on Monday and Thursday every week where possible, but due to external factors this was not 
always the case, and on several occasions Site C was visited and bait consumption and 
tracking patch activity recorded on other days. Bromadiolone bait application is described in 
Daniells (2011). After five weeks, weekly bromadiolone consumption was still falling, but 
observable rat activity on the site appeared to be increasing, and the decision was made to 
cease bait application and begin the lag phase and post-treatment census. After a three-day 
lag phase, the post-treatment census started, carried out in identical fashion to the pre-
treatment census. However, due to extremely poor weather, during which roads around the 
site were impassable and tracking patches and bait points largely inaccessible due to 
snowfall, the census was abandoned. The census was restarted after 14 days and carried out 
successfully. 
5.2.1.4 Trial D 
Trial D was carried out between 26th October 2009 and 24th January 2010 at a farm in West 
Berkshire. As in trial B, the bait used was the proprietary 0.005% difenacoum pellet bait 
RatakTM. The site was a small pig farm with a series of pigsties surrounded several barns of 
varying sizes. There were ~80 piglets associated with individual sows, and low numbers of 
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poultry and goats were housed in a courtyard opposite the pigsties. Rarely, the gate to this 
courtyard was open and the stock therein left free to roam. One large barn (approximately 
15m x 30m) housed machinery and offered no harbourage or food for rats. One small barn 
was used for grain storage; grain was openly available here in a large pile. One end of this 
barn contained disused wooden pallets and fencing material, providing harbourage for rats. A 
final barn in the north-east of the site, which was heavily dilapidated and unsafe undoubtedly 
provided cover, harbourage and water to the rats, but for the most part was inaccessible to 
researchers. The centre of the farm was dominated by two rows of concrete pigsties which 
opened onto a central courtyard. Immediately south of the pigsties was a covered hay store, 
with bales stacked several metres in the air. The main part of the infestation was centred in 
this area, with food readily available from the pigsties and adjacent grain storage barn, and 
safe harbourage amongst the hay bales and the nearby small sheds and buildings in various 
states of disuse and dilapidation. Bordering the farm to the south-east was a small field for 
grazing of the farm’s < 10 cattle, beyond which was a separate site with very large storage 
sheds which could have housed rats. To the south and west was the river Lambourn and 
woodland, and to the north were arable crop fields. The site had an area of 0.38 ha. Bait 
points and tracking patches were laid out five days before the start of the pre-treatment 
census, to allow rodents to become accustomed to them. During the pre and post-treatment 
censuses, 150 g of whole wheat was placed in each bait point. Replenishment and increases 
to total whole wheat applied followed the same methodology as at Site A, up to a maximum 
of 600 g, depending on nearby visible rat activity. During the treatment phase, bait 
consumption was recorded on Monday and Thursday every week where possible, but due to 
external factors this was not always the case. Difenacoum bait application is described in 
Daniells (2011). During the first week of the treatment phase one bait point was removed 
because it could not be sheltered effectively during poor weather conditions, and after the 
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fourth week of the treatment phase another was removed for the same reason. In the fifth 
week bait consumption increased, so the decision was made to cease bait application and 
begin the lag phase and post-treatment census. As with trial C, the post-treatment census was 
abandoned due to severe weather conditions, but then restarted and successfully carried out 
fourteen days later. 
5.2.1.5 Trial E 
Trial E was carried out between 22nd April 2016 and 29th July 2016 at a farm near Reading 
in Berkshire. An experimental brodifacoum formulation containing less than 30 ppm of 
active ingredient was used in this field trial. The site was a large dairy farm containing ~550 
cattle, with a large office building in the centre of the site, and a large shed for the intensive 
feeding and milking of cattle to the north-east, and a smaller shed for experimental dairy 
treatments to the south-west. Further farming infrastructure, including slurry tanks, grain 
silos, storage sheds and rearing barns, was spread around the northern half of the site. Due to 
the very large size of the farm, the area selected for the field trial was the surroundings of the 
experimental shed at the south-west of the site, including an adjacent field and woodland 
border and an area of rough scrub housing a disused caravan, old tyres and a disused slurry 
tank. Immediately to the west of the experimental cattle shed was a series of concrete 
hoardings containing various experimental silage formulations. Active rat burrows were 
present throughout the rough scrub, and signs of rat activity were observed in adjacent areas. 
This area of the site was separated from the north-eastern half of the site by the central office 
building and a large swathe of open ground, indicating that the population of rats around the 
experimental shed was separate to the population centred on the intensive rearing barn. 
Surrounding countryside to the west, south and east consisted of cornfields and grassland for 
the grazing of cattle. Further to the south was a largely derelict farm site offering harbourage 
but no food to rats. The countryside to the north was woodland wherein 2000 pheasants were 
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reared annually for shooting. A single field to the north contained 12 sheep and 7 llamas, and 
pheasants were present wherever there was woodland cover. The whole site had an area of 
3.0 ha, but the area used for the field trial had an area of 0.5 ha. Bait points and tracking 
patches were laid out three days before the start of the pre-treatment census, to allow rodents 
to become accustomed to them. During the pre-treatment census, 200 g of whole wheat was 
placed in each bait point, and replenished when necessary. When complete takes (see Section 
2.3.4) or near-complete takes were recorded, the amount of whole wheat placed at those bait 
points was increased to 400 g. During the post-treatment census, 100 g of whole wheat was 
placed in each bait point, and replenished when necessary. During the treatment phase, bait 
consumption was recorded every Monday, Wednesday and Friday. Bait points were 
replenished when there was evidence of rat consumption, or if degradation due to 
environmental conditions was visually identified. During the second week of the treatment 
phase, five bait points were added to the original 50, due to high bait takes. These remained 
in place throughout the remainder of the treatment phase. After four weeks squirrels were 
recorded (via camera traps) entering bait boxes and removing brodifacoum bait. Therefore on 
trial day 45 (site visit 13 of the treatment phase) bait was removed from 5 bait points and 
replaced with cut peanuts. The cut peanuts were ignored by the squirrels, which were 
confirmed to be entering a further 10 bait points in search of rodenticide formulation which 
again was removed and replaced with cut peanuts. When this did not prevent squirrels 
attempting further depredations of rodenticide bait, all bait was removed and the whole 
treatment was temporarily halted. After two weeks of trapping squirrels (using the same 
methodology as described for Norway rats, see Section 2.1.3.1) a total of 6 squirrels were 
removed from the site. Subsequently there was no more evidence of squirrel activity, and the 
treatment was re-started. Ten weeks after the start of the treatment phase, tracking patch 
activity had ceased entirely, and bait consumption had plateaued at a very low level, so the 
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decision was made to cease bait application and begin the post-treatment lag phase and 
census. 
5.2.1.6 Trial F 
Trial F was carried out between 10th October 2016 and 23rd December 2016 at a farm in 
northern Hampshire. An experimental brodifacoum formulation containing less than 30 ppm 
of active ingredient was used in this field trial. The site was a small mixed stock farm 
containing ~100 sheep and ~20 cattle. The farmhouse was at the centre of the site, with a 
large barn used for housing sheep in the winter to the north-east. Attached to this barn was a 
large covered area for storage of hay bales and animal feed, as well as a small pen housing 
cattle, including calves. South-east of the house was a garden with fenced and unfenced 
areas. Approximately 20 geese and chickens lived in the fenced area, with a further 13 
chickens housed in a pen outside of the garden fence. Poultry were usually free to roam 
throughout the day. The rest of the trial site was made up of scrub and waste ground 
containing scrap metal, old wooden pallets and disused fencing. The site was bordered on its 
eastern side by a country road, and to the south-west by a series of crop fields extending for a 
linear distance of between ~250 m and ~600 m. A matrix of semi-natural woodland and 
improved grassland extended >1 km beyond the road. Active rat burrows were visible in 
large portions of the waste ground, and the concrete surface of the indoor barns were thickly 
covered with rat droppings. Old straw (from the previous winter) offered harbourage to rats, 
as did the stacked hay bales in the covered areas. The floor of the barn was scattered with 
wheat husks, and animal feed was openly available to rats in poultry feeders and in open 
storage sacks near the cattle pen. The site had an area of 0.7 ha. Bait points and tracking 
patches were laid out three days before the start of the pre-treatment census, to allow rodents 
to become accustomed to them. Due to external circumstances, the farm’s sheep were 
brought in to the main barn area three weeks earlier than the tenants had previously stated, 
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necessitating the movement or removal of 26 bait points during the treatment phase. A further 
two bait points were moved during the trial phase when a small sheltering structure was 
removed from the farm site. During the pre-treatment census, 200 g of whole wheat was 
placed in each bait point, and replenished when necessary. When complete takes or near-
complete takes were recorded (see Section 2.3.4), the amount of whole wheat placed at those 
bait points was increased by 100 g, up to a maximum of 400 g. During the post-treatment 
census, 100 g of whole wheat was placed in each bait point, and replenished when necessary. 
During the treatment phase, bait consumption was recorded every Monday, Wednesday and 
Friday. Bait points were replenished when bait take was recorded or if degradation due to 
environmental conditions was visually identified. Eight weeks after the start of the treatment 
phase, tracking patch activity and bait consumption had ceased entirely, so the decision was 
made to cease bait application and begin the post-treatment lag phase and census. 
 
5.2.2 Genetic analysis 
Rats from the sites of trials A, B, C and D were trapped both before and after the field trials. 
Live capture traps were set out and left open for 6 days, pre-baited every 2 days to allow rats 
to become accustomed to them. On the 7th day, the traps were baited and set overnight, and 
on the 8th day the traps were brought in, along with any trapped rats. Rats were dispatched 
using a Home Office schedule 1 method and and their tail tips removed and stored 
individually in 70 – 80% industrial methylated spirits at -18ºC until analysis. Fresh droppings 
were taken from the sites of trials E and F, as were tails from fresh carcasses found on site 
during the course of field trials E and F. Droppings were selected and stored as described in 
Section 2.1.3.2; tails were stored in the same manner as those taken from trials A, B, C and 
D. DNA from all samples was extracted as described in Section 2.1.4. Samples from trials A, 
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B, C and D were analysed as described by Rost et al. (2004), and samples from trials E and F 
were analysed as described in Section 2.1.4.  
 
5.2.3 Carcass searching 
During the second and third phases of Trials E and F, searches for carcasses of Norway rats 
and other vertebrates were carried out once a week. These were carried out as described in 
Section 2.3.6. Any carcasses found were stored individually at -18ºC. 
Table 5.1. Numbers of bait points and tracking patches for each field trial 
Trial Census Bait points Trial Bait points Trial / Census Tracking patches 
A 78 77 54 
B 58 57 45 
C 94 97 46 
D 82 90 39 
E 50 55 33 
F 50 90 32 
 
Table 5.2. Number of bait point types during census phases 
Trial Wooden Bait Box 
Plastic Bait 
Box Tyre Baiter 
Bait Tray 
Under Cover 
A 64 0 0 14 
B 27 5 10 16 
C 38 0 10 49 
D 28 0 9 63 
E 35 0 15 5 
F 44 0 6 0 
 
Table 5.3. Number of bait point types during trial phases 
Trial Wooden Bait Box 
Plastic Bait 
Box Tyre Baiter 
Bait Tray 
Under Cover 
A 63 0 0 14 
B 26 5 10 16 
C 35 0 10 49 
D 20 0 9 63 
E 35 0 10 5 
F 55 0 12 23 
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5.2.4 Burrow baiting 
During treatment phases that are achieving apparent success, it is sometimes the case that 
there is clear evidence of rat activity but very little bait take. When this situation arose during 
the field trials described, a thorough search of the trial site was made in order to determine 
the locations of Norway rat burrows. All burrows were baited with up to 20 g of treatment 
bait and entrances blocked with straw, disturbance of which would indicate subsequent rat 
activity. Burrows were subsequently monitored for signs of activity including straw 
disturbance. Bait was, where possible, removed from all burrows before the post-treatment 
lag phase. Because this could not be guaranteed, and the volume of baits applied to burrows 
consumed could not be satisfactorily measured, these values were not included in the total 
bait application figures in Table 5.12. 
 
5.3. Results 
5.3.1 Genetic analysis 
Prior to the commencement of field trials A, B, C and D, tissue samples were obtained and 
successfully analysed from 13 rats from Site A, 18 rats from Site B, 19 rats from Site C and 
27 rats from Site D; as described (Daniells, 2011) all samples were positive for the L120Q 
mutation, with a high incidence of homozygosity (see Table 5.4). Following the end of field 
trials, a further 94 rats were trapped across the sites of these field trials, with 89 producing 
useable results. At Site A, three rats were caught and DNA successfully analysed. At Site B, 
34 rats were caught and their DNA successfully analysed; at Site C, 32 rats were caught and 
their DNA successfully analysed. At Site D, 20 rats were caught and DNA successfully 
analysed. At Site E, 13 fresh droppings were taken prior to the commencement of the field 
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trial and the DNA therein analysed. Only one of these samples was successfully analysed. 
Tails were taken from eight fresh rat carcasses found during the treatment phase, and tissue 
samples analysed; six were analysed successfully. At Site F, tails were taken from ten fresh 
rat carcasses found during the treatment phase, and tissue samples analysed; nine were 
analysed successfully (see Table 5.5).  
Table 5.4. Resistance status of rats before and after trials at sites A-D 
Trial Site 
Genotype Ratios (L120Q Homozygous: L120Q 
Heterozygous: Wild-type) 
Before Trial After Trial 
A 12:1:0 2:1:0 
B 17:1:0 33:1:0 
C 17:2:0 26:5:1 
D 24:3:0 12:5:3 
 
Table 5.5. Resistance status of rats before and during trials at sites E and F 
Trial Site Genotype Ratios (L120Q Homozygous: L120Q Heterozygous: Wild-type) 
E 5:1:1 
F 4:5:0 
 
5.3.2 Bait consumption and tracking patch activity 
5.3.2.1 Trial A 
Bait take at Site A was high during the first week, with consumption of 501.3 mg of 
bromadiolone recorded over week one of the treatment phase (see Table 5.6). The bait 
initially appeared to be very efficacious, with recorded consumption of bromadiolone 
dropping to 165.25 mg during the second week of the treatment phase, and 75.05 mg during 
the third week of treatment. This precipitous drop was followed by a plateau in bromadiolone 
consumption, with a small increase during week four and a small decrease during week five. 
Similarly, recorded tracking scores at Site A peaked with a total score of 49 on the second 
recording day, falling sharply to 8 on the third recording day. Thereafter, tracking scores 
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showed minor peaks and troughs, but never rose above a total value of 21 for the remainder 
of the treatment phase (see Appendix 3). Daily totals of census bait taken and tracking scores 
were recorded during the pre- and post-treatment census periods, so that the maximum daily 
scores of each census period could be compared (see Figure 5.1). Using the values in Table 
5.12 and the formula described in Section 2.3.9, the percentage efficacy of bromadiolone bait 
at Site A was calculated to be 66.4% according to census bait takes, and 37.2% according to 
tracking scores.  
Table 5.6. Trial A: Weekly consumption of bromadiolone active ingredient by Norway rats 
Trial Week (Days) Bromadiolone (mg) 
1 (16-22) 501.30 
2 (23-29) 165.25 
3 (30-36) 75.05 
4 (37-43) 79.15 
5 (44-50) 63.60 
  
 
Figure 5.1. Trial A: Pre- and post-trial census bait takes (hatched vertical bars) and tracking scores (lines) for a 
field trial of 0.005% bromadiolone bait. 
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5.3.2.2 Trial B 
Difenacoum bait take at Site B steadily increased until the third week of the treatment phase, 
when weekly consumption was more than double that of the first week (see Table 5.7). By 
the fifth week of the treatment phase, weekly consumption of difenacoum was still more than 
double that of the first week but had been slowly decreasing since the third week, so the 
decision was made to increase the trial length in order to allow the bait more time to achieve 
control of the rat population. However, weekly bait consumption increased to its peak 
thereafter, so this additional treatment period only lasted 2 weeks. Tracking data were 
constant during the first two weeks (see Appendix 3), afterwards increasing with deep 
fluctuation for the remainder of the treatment phase. Tracking data were not recorded on the 
13th and 14th recorded days (the second week of additional treatment). Daily totals of census 
bait taken and tracking scores were recorded during the post treatment census period, so that 
the maximum daily score of each could be compared with the equivalent values from the pre-
treatment census period (see Figure 5.2). Using the values in Table 5.12 and the formula 
described in Section 2.3.9, the percentage efficacy of difenacoum bait at Site B was 
calculated to be 15.7% according to census bait takes, and -1.8% according to tracking 
scores. This negative score arose because the maximum tracking score of the post-treatment 
census was greater than that of the pre-treatment census, indicating increased Norway rat 
activity over the course of the trial.  
Table 5.7. Trial B: Weekly consumption of difenacoum active ingredient by Norway rats 
Trial Week (days) Difenacoum (mg) 
1 (16-22) 102.75 
2 (23-29) 152.9 
3 (30-36) 242.6 
4 (37-43) 222.35 
5 (44-50) 211.25 
6 (51-57) 242.9 
7 (58-64) 253.6 
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 Figure 5.2. Trial B: Pre- and post-trial census bait takes (hatched vertical bars) and tracking scores (lines) for a 
field trial of 0.005% difenacoum bait. 
 
5.3.2.3 Trial C 
Bromadiolone intake by Norway rats started high at Site C and decreased irregularly during 
each week of the treatment phase, with the biggest reduction in bromadiolone consumption 
being recorded from the fourth to fifth weeks (see Table 5.8). Tracking patch activity fell 
consistently from the second week, but began to rise in the fifth week; for this reason the 
treatment phase was ended. Daily totals of census bait taken and tracking scores were 
recorded during the post treatment census period, so that the maximum daily score of each 
could be compared with the equivalent values from the pre-treatment census period (see 
Figure 5.3). Using the values in Table 5.12 and the formula described in Section 2.3.9, the 
percentage efficacy of bromadiolone bait at Site C was calculated to be -2.4% according to 
both census bait takes and tracking scores; both measures of treatment efficacy suggested that 
the population of Norway rats at Site C was higher after the treatment phase than it was 
before.   
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Table 5.8. Trial C: Weekly consumption of bromadiolone active ingredient by Norway rats 
Trial Week (Days) Bromadiolone (mg) 
1 (19-25) 596.20 
2 (26-33) 493.30 
3 (34-39) 413.35 
4 (40-46) 365.25 
5 (47-53) 232.65 
 
 
Figure 5.3. Trial C: See Figure 5.1 for description. 
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calculated to be 60.6% according to census bait takes, and 57.4% according to tracking 
scores. 
Table 5.9. Trial D: Weekly consumption of difenacoum active ingredient by Norway rats 
Trial Week (Days) Difenacoum (mg) 
1 (18-24) 895.60 
2 (25-31) 539.65 
3 (32-38) 583.70 
4 (39-45) 468.45 
5 (46-52) 495.20 
  
Figure 5.4. Trial D: See Figure 5.2 for description. 
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treatment phase. Due to lack of recorded bait consumption, but the evident continued 
presence of rats on site, 11 rat burrows were baited, as described in Section 5.2.4. One of 
these 11 burrows showed activity thereafter; the entrances of the rest remained blocked with 
straw for the duration. Tracking patch activity was at its peak during the first recorded day, 
after which it fell slowly; during the second week it plummeted, plateauing in the third and 
fourth weeks (see Appendix 3). When the treatment was restarted after squirrels were 
removed, tracking patch activity fell slowly; a total of 0 was recorded for a week before the 
treatment phase ended. Daily totals of census bait taken and tracking scores were recorded 
during the post treatment census period, so that the maximum daily score of each could be 
compared with the equivalent values from the pre-treatment census period (see Figure 5.5). 
Using the values in Table 5.12 and the formula described in Section 2.3.9, the percentage 
efficacy of brodifacoum block bait at Site E was calculated to be 99.6% according to census 
bait takes, and 100% according to tracking scores. 
Table 5.10. Trial E: Weekly consumption of brodifacoum active ingredient by Norway rats 
Trial Week (Days) Brodifacoum (mg) 
1 (16-22) 46.87 
2 (23-29) 41.65 
3 (30-36) 9.52 
4 (37-43) 2.05 
5 (44-50) 0.62 
Trial paused (51-64) - 
8 (65-71) 1.04 
9 (72-78) 1.93 
10 (79-85) 1.86 
11 (86-87) 0.48 
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Figure 5.5. Trial E: Pre- and post-trial census bait takes (hatched vertical bars) and tracking scores (lines) for a 
field trial of < 0.003% brodifacoum bait. 
 
5.3.2.6 Trial F 
Brodifacoum consumption reached its peak in the first week of the treatment phase at Site F, 
and had fallen by two thirds by the second week (see Table 5.11). After the third week of 
treatment, brodifacoum intake by Norway rats fluctuated, before its nadir in the final week of 
the treatment phase. Due to concern at this fluctuation, and the forced movement or removal 
of 28 bait points between the 6th and 12th site visits, 23 rat burrows were baited from the 13th 
site visit, as described in Section 5.2.4. On the 15th site visit 10 fresh burrows were 
discovered and baited. Over the next three site visits a further eight fresh burrows were 
discovered and baited. No burrows showed any activity after baiting. Like Trial E, tracking 
patch activity peaked immediately (see Appendix 3). Thereafter it fell at a steady rate (with 
minor peaks) for the duration. No activity was recorded on the final day of the treatment 
phase. Daily totals of census bait taken and tracking scores were recorded during the post 
treatment census period, so that the maximum daily score of each could be compared with the 
equivalent values from the pre-treatment census period (see Figure 5.6). Using the values in 
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Table 5.12 and the formula described in Section 2.3.9, the percentage efficacy of 
brodifacoum bait at Site F was calculated to be 98.9% according to census bait takes, and 
96.9% according to tracking scores. 
Table 5.11. Trial F: Weekly consumption of brodifacoum active ingredient by Norway rats 
Trial Week (Days) Brodifacoum (mg) 
1 (13-19) 119.26 
2 (20-26) 39.70 
3 (27-33) 14.15 
4 (34-40) 12.97 
5 (41-47) 24.70 
6 (48-54) 11.04 
7 (55-59) 1.15 
 
Figure 5.6. Trial F: See Figure 5.5 for description. 
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Table 5.12. Volume of active ingredient consumption attributed to rats at each trial site and associated population reduction. Population estimates based upon rats consuming 
10% bodyweight per night, and the average rat weighing 200 g (Meehan, 1984; Buckle, Endepols and Prescott, 2007) 
Trial Trial Bait 
Estimated 
Norway 
rat 
starting 
population 
Max daily pre-
treatment 
census bait 
consumption 
(g) 
Max daily post-
treatment 
census bait 
consumption 
(g) 
Population 
reduction based 
on census bait 
consumption (%) 
Max daily pre-
treatment 
tracking patch 
activity (total 
score) 
Max daily 
post-
treatment 
tracking 
patch activity 
(total score) 
Population 
reduction 
based on 
tracking patch 
activity (%) 
Total active 
ingredient 
consumption 
(mg) 
A Bromadiolone 123 2460 916 66.4 43 27 37.2 884.35 
B Difenacoum 110 2200 1855 15.7 57 58 -1.8 1428.35 
C Bromadiolone 272 5440 5570 -2.4 85 87 -2.4 2100.75 
D Difenacoum 535 10708 4221 60.6 115 49 57.4 2982.6 
E Brodifacoum 68 1372 6 99.6 50 0 100 106.03 
F Brodifacoum 159 3180 32 98.9 96 3 96.9 222.96 
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5.4. Discussion 
5.4.1 Efficacy of active ingredients 
The bromadiolone and difenacoum baits utilised in the trials all failed to control the 
populations of Norway rats at sites A, B, C and D, according to EU regulations, which 
require recorded population reductions of > 90% during trials for product authorisation 
(Daniells, 2011). However, the results at Site C (Table 5.8) show a clear reduction in weekly 
bromadiolone consumption, which may not have been clear during the treatment phase (when 
results were recorded twice-weekly; bait consumption had plateaued for the final three site 
visits, and tracking patch activity had increased). Total bromadiolone consumption at Site C 
was 2100.75 mg with an estimated starting population of 272. A model used to predict SGAR 
residues for Trials A – D showed that rats from Trial C would reach whole body residues of 
4.0 mg/kg bromadiolone within a week of initial bait application (Daniells, 2011). Rats 
captured at Sites A and C had average whole-body residues of 3 mg/kg bromadiolone, and 
average liver residues of 15 mg/kg bromadiolone (Daniells, 2011). Data from France show 
lethal effects to foxes with liver bromadiolone residues as low as 0.8 mg/kg and barn owls 
with liver residues as low as 0.2 mg/kg (Berny et al., 1997). Regardless of whether or not 
control might have been achieved, for five weeks predators of rats were exposed to 
potentially lethal volumes of bromadiolone (Daniells, 2011) in rats which, given the 
reduction in consumption, were likely to be slowly dying and therefore easier to catch (Cox 
and Smith, 1992; Brakes and Smith, 2005). If control had been achieved, it is questionable 
whether or not the cost in non-target wildlife and the use of in excess of 42 kg of 
bromadiolone bait would have been acceptable. 
The brodifacoum baits applied at sites E and F both achieved > 90% control. This 
occurred despite the brodifacoum baits used having recorded brodifacoum concentrations of 
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below 0.003%, whereas the difenacoum and bromadiolone baits contained 0.005% active 
ingredient. Recently, the ECHA proposed that nine anticoagulant rodenticides, including all 
SGARs, be classified as toxic to reproduction in baits with concentrations higher than 
0.003%, thereby preventing their authorisation for use by the general public. These proposals 
were adapted to the CLP Regulations (EC no. 1272/2008 on classification, labelling and 
packaging), making them legally binding in the UK (HSE, 2014). It is important, therefore, 
that anticoagulant rodenticides be efficacious at concentrations below 0.003% against both 
susceptible and resistant populations of Norway rats. All DNA samples taken from the six 
trial sites prior to or during the field trials came from rats positive for the L120Q mutation, 
except for one wild-type sample at Site E, and all sites were located within the central-
southern England L120Q focus described earlier (see Section 3.3.1). These results show, 
conclusively, that difenacoum and bromadiolone baits cannot be consistently applied in an 
efficacious and legal manner to sites where Norway rat populations are shown to be positive 
for the L120Q mutation; the mutation confers resistance sufficient to allow animals to survive 
consumption of bromadiolone- and difenacoum-containing baits, but not brodifacoum-
containing baits. As well as failing to achieve control in Trials A, B, C and D, the amount of 
bromadiolone and difenacoum applied in the field trials far exceeded that of brodifacoum 
(see Table 5.6). Despite the known greater toxic effects of brodifacoum (Prescott et al., 2007; 
see Section 4.3.1), the volume of bromadiolone and difenacoum that would have to be used to 
successfully control resistant Norway rats increases the risk not only of primary poisoning to 
non-target wildlife, domesticated animals and humans, but also of secondary poisoning to 
predators eating the surviving rats which have not yet eliminated the active ingredients from 
their liver tissue. Analytical models suggest that use of more potent poisons will reduce the 
risk of non-target poisoning for this reason (Daniells, Prescott and Buckle, 2011). Relative to 
the initial population sizes at all sites, a far lower volume of brodifacoum was consumed by 
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Norway rats than difenacoum and bromadiolone (See table 5.12), whilst achieving a far 
greater level of control. The starting population density at site D was the highest amongst the 
trial sites by a considerable margin (see Table 5.12; these values based upon Norway rats 
consuming 10% of bodyweight per night (Meehan, 1984), with the average adult Norway rat 
weighing 200 g); the vast difference between Site D and all other trial sites suggests that 
population density was not a factor in the effectiveness of the brodifacoum baits. Site D had 
the smallest area of any of the trial sites, and achieved the greatest level of control among the 
non-brodifacoum trials. Given the relatively small size of the brodifacoum trial sites, it might 
be the case that the efficacy of the brodifacoum baits was influenced by the small site areas, 
relative to the areas of Sites A, B and C. 
 
5.4.2 Disparity between measures of population reduction 
The results of Trial A indicate that the bromadiolone bait caused either 37.2% or 66.4% 
reduction in Norway rat numbers on site (measured by changes in tracking patch activity and 
census bait consumption, respectively). The lower figure obtained for tracking patch activity 
indicates that rats were indeed present in high numbers on site, but that many were either 
neophobic or behaviourally resistant to bait points at Site A. Bromadiolone consumption 
during the third week of the treatment phase was only 14.97% of its peak in the first week, 
suggesting that the surviving rats were resistant to the bait, and eating it in low amounts due 
to loss of appetite, or many of them were avoiding it altogether. The raw data (see Appendix 
3 and Table 5.6) show that both measures of rat activity had fallen by the last week compared 
to peaks in the first week. Therefore it is probable that the figure obtained from census bait 
consumption is correct, and the bromadiolone bait caused a 66.4% reduction in rat numbers, 
and the high levels of recording tracking patch activity during the post-treatment census are 
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due to upheaval within rat social systems, as less dominant animals moved in, causing an 
apparent increase in numbers. Alternatively, if the tracking patch figure is correct, it indicates 
that the site suffered reinvasion from rats that were neophobic towards the census bait points. 
It can be inferred from the results of Trial B that, because difenacoum bait consumption 
reached its peak in the last week of the trial, overall numbers of Norway rats at Site B were 
the same (1.8% increase) by the end of the treatment phase as they were at the beginning; the 
site was at carrying capacity, and the minor reduction in census bait take was a result of the 
high neophobia present in the population. The remaining trials show sufficient similarity 
between tracking patch activity and census bait take results that it can be assumed that they 
are an accurate demonstration of the decrease (or increase) in rat populations at those sites. 
 
5.4.3 Factors affecting trial outcomes 
5.4.3.1 Reinvasion 
When viewed as weekly consumption of bromadiolone, the results of site C show a clear 
decline in rat activity during the course of the five-week treatment phase. This suggests that 
the treatment phase may have been inappropriately truncated (see above). It is improbable 
that the enforced three-week post-treatment lag period in Trial C had no influence on the 
results, given the much reduced bromadiolone consumption at the end of the treatment phase. 
Unfortunately, the few data obtained on the one day of the first attempt at a post-treatment 
census cannot be used to infer any conclusions, as it is beyond doubt that the snowfall which 
prevented the researchers accessing bait points and tracking patches also obfuscated the data 
by preventing access by Norway rats. The extended lag period caused by the weather 
conditions at the time provided additional time in which the remaining population at Site C 
could have recovered via high-fecundity breeding and immigration from nearby populations. 
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The final results of the field trial at Site C suggest that the bromadiolone bait achieved 
no control. Two tracking patches (from a total of 46) were removed after the pre-trial census, 
which may have artificially reduced the maximum daily tracking score of the post-treatment 
census. 32 Norway rats were successfully trapped and their L120Q status investigated after 
the treatment phase of field trial II. The reduced L120Q homozygosity of the population after 
treatment compared with before treatment (81.3% and 90.0%, respectively) and the presence 
of at least one wild-type rat suggest that the cause of the apparent population increase in Site 
C is immigration of non-resistant or less resistant rats from nearby populations. Although 
there is some evidence for pleiotropic costs of resistance (Smith, Townsend and Smith, 1991; 
Heiberg, Leirs and Siegismund, 2006; Jacob et al., 2012), it has been shown that the costs 
associated with resistance are not sufficiently deleterious to cause a population wide decline 
in resistance in the absence of anticoagulant selection pressure (Heiberg, Leirs and 
Siegismund, 2003). Methods are available which, using DNA extracted from rat tissue 
samples, can help to elucidate the level of migration to a given geographic area are available, 
and recommended for situations such as this, but it should be acknowledged that they rely on 
the ability to obtain multiple tissue samples from a notoriously neophobic species (Desvars-
Larrive et al., 2017). The final results which suggest a very similar population size to the 
beginning of the trial may indicate that during the pre-treatment census, Site C had reached 
its carrying capacity for Norway rats, and the population had reached this level again during 
the extended post-treatment lag phase.  
Due to the trial site’s location within a large working farm, it is likely that Site E 
suffered from a minor reinvasion of rats during the two week period taken to ensure the 
absence of squirrels. It is possible that these were rats inhabiting some disused pipes in a 
nearby field and had not technically reinvaded the trial site completely; indeed this is likely, 
because in the time that burrow baiting was carried out, only one of eleven burrows was 
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disturbed (and therefore active). Once squirrel bait take was removed from the dataset, it 
became clear that brodifacoum had nearly achieved complete control by the fourth week of 
treatment. Despite issues with squirrels and apparent immigration of rats from nearby satellite 
populations, the brodifacoum bait appeared to achieve 99.6% – 100% control, exceeding 
regulatory requirements. These results are supported by camera traps set up at Site E which 
recorded no Norway rat movements during the post-treatment census. The absence of 
tracking patch activity during the post-treatment census lends further credence to the 
supposition that most rat activity after Site E was declared free of squirrels was due to rats 
which only entered the trial area to forage, and therefore would have been less inclined to use 
the runs around which the tracking patches were located.  
The reduced prevalence of the L120Q mutation at Site D may have been a function of 
mild reinvasion during the enforced lag phase, but it does not refute the plateau in 
difenacoum consumption towards the end of the treatment phase (see Table 5.9), and 
therefore is unlikely to have been a direct cause of treatment failure. 
At Site F, following a period of mild fluctuation in recorded bait take, a sharp drop in 
bait take was recorded on the fourth week of the treatment phase, followed by a sudden 
relatively large increase and steady decline. The fluctuation prior to this is likely to be caused 
by upheaval within the rat population at Site F, where the raw data indicate a large number of 
rats had died very quickly – frequent changes in locations of bait take and activity, and the 
volume thereof, suggest that rats were moving in to more desirable locations after the 
dominant rats there died. The sudden removal of several bait points, due to the 
aforementioned unexpected movement of sheep indoors, may have contributed to fluctuation 
in bait consumption and masked the effects of brodifacoum poisoning on the population. 
Without constant monitoring of the genetic status of the population, it is difficult to determine 
whether sudden changes in rat activity (denoted by bait consumption and tracking patch 
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activity) are due to reinvasion or social upheaval. In order to avoid consistently removing rats 
for tissue samples (which may have further effects on the trial outcome), faecal samples may 
be required to monitor population genetics; faecal samples have been associated with a low 
success rate (see Section 3.4.3). 
Despite sites B, D and E being more vulnerable to reinvasion (due to presence of 
nearby buildings capable of housing rats), Site C was the only site in which the final results 
were clearly affected by reinvasion. It is likely that Site C would have suffered reinvasion 
during the extended lag phase regardless of which rodenticide baits were used. 
5.4.3.2 Refusal to take bait 
The Norway rat population at Site B had, as described above, easy access to ample alternative 
food, and harbourage directly underneath this food source. Because their needs were so easily 
taken care of, the rats at Site B were slow to consume the census and treatment baits. As such 
the census periods were extended to allow a more accurate estimate of population size and 
changes; in both census periods bait consumption rose continuously over the six days, and 
peak difenacoum consumption did not occur until the last (seventh) week of the treatment 
phase. It is possible that the rats at Site B, with their high levels of neophobia and 
susceptibility to disturbance, would have been behaviourally resistant to brodifacoum to a 
limited degree, and increased their rate of brodifacoum consumption much more slowly than 
did the rats at sites E and F. 
At Site F, the large central barn for the seasonal housing of sheep was largely covered 
in whole wheat from prior storage – if whole wheat was more palatable than the treatment 
bait, it was readily available to rats in the barn area. This, in addition to the animal feed left 
open in poultry feeders and storage sacks around the farm may have extended the treatment 
phase beyond the time it may have taken on a site with good housekeeping. 
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Previous research has established that rats homozygous for VKORC1 resistance 
mutations are often smaller than susceptible rats (Smith, Townsend and Smith, 1991; Smith 
et al., 1993), and furthermore that social dominance in rats is linked to size (Smith, Smith and 
Sibly, 1991), and that dominant rats access food first, preventing subdominant animals from 
doing so (Sibly and Nott, 1993). Given the presence of established alternative food sources at 
all sites, it is possible that dominant rats, displaying a level of neophobia towards the 
anticoagulant bait, would have avoided consumption thereof for some time. This would have 
the effect of forcing only resistant rats to consume the treatment bait, assuming that any 
susceptible rats display size-based dominance. Given the L120Q prevalence at all sites (see 
Tables 5.4 and 5.5), the number of susceptible rats that never accessed any treatment bait 
would have been very low. Food competition, therefore, may have contributed to the scale of 
treatment failure at Sites A, B, C and D, but is unlikely to have been the difference between 
success (i.e. 90% population reduction) and failure. 
5.4.3.3 Resistance 
Although the rats are Site B were undoubtedly neophobic, the volume of difenacoum 
consumed over the course of seven weeks strongly indicates that the presence of L120Q in 
the population – with most rats being homozygous for the mutation – conferred a level of 
resistance sufficient enable most rats that did eat the difenacoum bait to survive. Even 
considering high resistance factors against difenacoum for rats derived from wild L120Q-
positive rats (see Section 4.3.3), 1428.35mg is an exceptional volume of difenacoum for 110 
rats to consume without any detectable control. Therefore, assuming that the population 
estimate wasn’t severely inaccurate, the most likely explanation for this level of anticoagulant 
survival is that, spread over 7 weeks, the concentration of difenacoum per rat at any one time 
was low enough to allow the most resistant animals (which formed the majority of the 
population) to recover following elimination of the active ingredient and before absorption of 
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the potentially-lethal bait-meal. The very high volume of alternative bait available on site 
would have provided sufficient food that rats did not need to subsist entirely on the 
difenacoum bait, aiding in their survival over several weeks. A reduction in difenacoum 
consumption occurred after the third week; it is possible that this represents a minor drop in 
the Norway rat population as those individuals heterozygotic for L120Q in the population 
died. Numbers of Norway rats present had already recovered and reached pre-treatment 
levels by the time of the post-treatment census. 
Although the population at Site C suffered a dramatic drop in numbers over the course 
of the treatment phase, the volume of bromadiolone consumed during the course of the trial 
was excessive (see Table 5.12); it is likely that there was a level of tolerance to bromadiolone 
among the resistant population, even supposing constant immigration from surrounding areas. 
Trial D saw the greatest volume of anticoagulant active ingredient (difenacoum) 
consumed during the course of the six field trials (see Table 5.12); the plateau in bait 
consumption after the third week shows that the remaining animals consuming difenacoum 
bait were sufficiently resistant to the bait to allow them to consume it with no repercussions 
beyond possible temporary appetite loss (which are not demonstrated by these data). The 
relatively low rate of L120Q homozygosity at Site D after cessation of the field trial suggests 
that there had been immigration by less- or non-resistant rats during the treatment phase. It is 
possible that the bait consumption plateau towards the end of the treatment phase was not 
affected by this immigration because the newcomers were less likely to enter bait points than 
the resistant rats which were familiar with them. This is a more likely explanation of the 
results of molecular testing at Site D than L120Q-heterozygous and wild-type rats being 
behaviourally resistant to anticoagulant baits. 
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All trial sites had copious alternative food sources for rats, which had a clear impact 
on the acceptance of treatment bait at Site B, and probably had limited effects at the 
remaining sites. The variety of factors negatively influencing bait take in these trials is an 
indication that thorough research into factors beyond anticoagulant resistance is required 
when targeting rat populations, in order to minimise the volume of rodenticides to which non-
target species are directly and indirectly exposed, and to minimise the financial cost of 
purchasing and using unnecessary amounts of rodenticide bait. 
 
5.4.4 Impact of brodifacoum on non-target species 
At Sites E and F, recorded bait take was occasionally attributed to non-target rodents such as 
wood mice (Apodemus sylvaticus), bank voles and field voles due to the repeated presence of 
droppings and kibbles in some bait boxes. These were more frequent in areas away from 
buildings and centres of rat activity. Grey squirrels (Sciurus carolinensis) were also present at 
Site E in limited numbers, and were highly attracted to the trial bait, frequently causing full 
takes either due to direct consumption or removal for caching. Any recorded bait loss that 
could be attributed to non-target animals was not included in the raw data. 
Despite bait take being frequently attributed to non-target rodents, very few non-target 
carcasses were found Site E: an unfledged blue tit Cyanistes caeruleus chick which is thought 
to have fallen from its nest; and two bank voles both of which were found in or near to bait 
points. The bank voles are thought to have died due to rodenticide exposure. No non-target 
animal carcasses were found at Site F. The consistency of bait take by non-target rodents 
suggests that Norway rats were more susceptible to these baits than the non-target mice, voles 
and squirrels which took a limited volume of bait, although this could indicate that squirrels 
may have been caching the brodifacoum bait rather than consuming it. Brodifacoum baits 
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frequently required replacement due to depredations by slugs, which have been shown to 
represent a viable contamination pathway to non-target species (Alomar et al., 2018). 
Because of the lack of non-target carcasses found in Sites E and F, it is not known what 
impact the potentially contaminated slugs had on their predators. The potential impact of 
Trials A-D on non-targets are thoroughly explored by Daniells (2011), wherein the excess 
volumes of both consumed and uneaten difenacoum and bromadiolone to which non-target 
animals were exposed through various routes is acknowledged. 
 
5.4.5 Response to L120Q in south-east England 
All trial sites were within the large central-southern England L120Q focus, and all rats but 
one trapped prior to each trial were positive for the L120Q mutation. Despite the apparent 
differences between the responses of the Hampshire and Berkshire strains of L120Q, it isn’t 
currently possible to ascertain to which strain an individual rat belongs without actively 
administering one of the active ingredients and measuring the response (either in a feeding or 
oral gavage/intraperitoneal injection test). Based upon estimates of the initial populations, 
rats at sites B and C consumed the greatest volume of difenacoum and bromadiolone, 
respectively, but the trials at these sites achieved the lowest levels of control.  This lends 
credence to the suggestion that there are sites in south-east England where repeated use of 
ineffective rodenticides has continually selected for highly resistant animals, in the same way 
in which the CSL-Berkshire strain of L120Q-resistant rats was created. The volumes of 
bromadiolone and difenacoum consumed at those trials (Daniells, 2011), with only limited 
control achieved, suggest that the character of L120Q resistance found there was similar to 
that of the CSL Berkshire rats tested in Chapter 4. This is especially alarming given the 
distances between the four sites; Sites A and B are over 30 miles from Sites C and D. 
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Therefore, the results of all trials considered herein support the proposal that where the 
L120Q mutation is potentially present (ie anywhere in the area covered by the large central-
southern England L120Q focus) the use of difenacoum or bromadiolone is inadvisable 
(RRAG, 2012; Buckle, 2013a). It has been shown that corn silage, which is increasingly used 
in continental Europe, is a suitable food source for Norway rats and in some cases can supply 
the dietary vitamin K required by resistant animals to prevent increased blood clotting times 
(Jacob and Freise, 2011). The silages seen at Sites B and E were not corn based, but if the 
demand for corn silage (e.g. for biofuels) increases in the UK, this may become a factor to 
consider in the prevention of the survival of resistant populations (e.g. Welsh and Hampshire 
resistances). 
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Chapter 6: General Discussion 
6.1 Overview 
Norway rats have acted as pests in the UK for nearly 300 years and, along with house mice, 
are unlikely to be replaced as the foremost vertebrate pests in most areas of the country. 
Anticoagulants obviate the neophobic behaviour of rats, and provide sufficient time to 
provide a viable antidote (Vitamin K) to poisoned non-target humans and domesticated 
animals. However, the time taken to be sure of completely controlling a rat population can 
make their use expensive, and care must be taken to minimise the risk to non-target animals, 
a risk that can never be completely removed. Since the initial discovery of anticoagulant 
resistance in Norway rats (Boyle, 1960), resistance has been discovered in many areas of 
Europe. The south-east of England potentially represents the worst known area in terms of 
number of resistance-conferring mutations, and their impact on the effectiveness of 
anticoagulants (Gill, Kerins and MacNicoll, 1992; Gill et al., 1993, 1994; Pelz et al., 2005; 
Prescott et al., 2010; RRAG, 2012; Haniza et al., 2015). Resistance exacerbates the cost of 
control due to increased baiting periods (and therefore volume of bait applied) or outright 
failure, and also increases the risk of non-target poisoning (Cox and Smith, 1992; Atterby, 
Kerins and MacNicoll, 2005; Shore et al., 2015). Habitat management and good 
housekeeping on farmsteads have been shown to be effective at reducing the impact of 
Norway rats and resistance (Lambert et al., 2008). However, in the case of large-scale 
infestations with the potential to cause a great deal of damage in a short time frame, the only 
viable option for control is the use of anticoagulant rodenticides (see Section 1.3.3). The 
response to anticoagulant resistance in the UK has largely been reactive up until now, with 
the only notable attempt to prevent resistance the aborted containment zone in Wales 
(Drummond, 1966; Pamphilon, 1969). Because of the lack of recent innovation in the 
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production of rodenticides available for use in the UK (Buckle, 2013a), the response to the 
extent and severity of resistance should be to understand the likely impact on control, and 
respond by using anticoagulants in the safest and most effective manner possible. Thus, the 
experiments herein were designed to facilitate this by revealing the extent and impact of the 
VKORC1 resistance-conferring mutations in Norway rats in the south-east of England.  
 
6.2 VKORC1 mutations in the south-east of England 
The results of the study in Chapter 3 are not encouraging for PCOs and landowners who seek 
to control rats in the south-east of England. The vast majority of samples tested for mutations 
were found to be positive for the VKORC1 mutation L120Q, which previous tests have 
shown to confer practical anticoagulant resistance to rats that possess it. In some cases this is 
the strongest known form of resistance (Gill, Kerins and MacNicoll, 1992; Quy et al., 1995; 
RRAG, 2012) with no pleiotropic cost to individual rats or populations (Gill, Kerins and 
MacNicoll, 1992; Smith et al., 1993). Interestingly, the three strongest VKORC1 mutations 
(L120Q, Y139C and Y139F) were all found in the south-east of England, in some cases 
within very close proximity of each other. A previous study investigating gene flow between 
Norway populations discovered 12 individual rats with both the L120Q and Y139C 
mutations, and 53 rats with the Y139C mutation in the area covered by the experiment 
described in Chapter 3 (Haniza et al., 2015). All of the samples from that study were taken 
between 1990 and 2000, so it was unexpected that the results herein do not reflect this. 
Additionally, the only samples from the dataset in Chapter 3 that had multiple mutations were 
from Scotland. Resistance in Germany appears to be limited to the north-west of the country 
in a 27,000 km2 area (Pelz, 2007). This resistance area appears to be growing, but different 
studies disagree on the prevalence of resistance therein (Pelz, 2007; Runge et al., 2013). 
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Studies from the Netherlands (Meerburg et al., 2014), France (Grandemange et al., 2010) and 
Belgium (Baert et al., 2012) show very low prevalence of VKORC1 mutations in Norway rat 
populations (33.04% of samples, 44.57% of sites with the Y139F mutation present, and up to 
20.41% of samples, respectively). This contrasts strongly with the results of this study, 
wherein 73.68% of samples were positive for the L120Q mutation (88.49% were positive for 
any of the five searched-for VKORC1 resistance conferring mutations; admittedly influenced 
by the fact that the majority of samples were received by PCOs who suspected they had 
encountered resistance). There also multiple large resistance foci in the UK, cited in this 
study area, Wales (Drummond, 1966; Pamphilon, 1969) and Scotland (Brodie, 1976); there 
have also been individual resistant animals from the north of England (Haniza et al., 2015; 
Chapter 3). 
The greatest issue faced while conducting the practical work for Chapter 3 was 
obtaining samples, as described in Section 2.1.3.1. This issue has not been described or 
commented on by the authors cited above, which suggests that they received more support 
from organisations dedicated to controlling resistance, whose influence could be brought to 
bear on PCOs and gamekeepers who supplied samples. It is possible though that the difficulty 
in obtaining samples was a function of the aim of this study: to locate and delimit resistance 
foci. Therefore, an even spread of samples were required from all over the study area; every 
site with samples successfully analysed represented a reduction in suitable sites for the future. 
Obtaining samples grew easier as stakeholders became more engaged, and became aware of 
the benefit of contributing to the dataset. Companies whose employees sent samples for 
which results were obtained were increasingly likely to send in more samples, knowing that 
they might receive an explanation for treatment failures. 48 of the samples successfully 
analysed here came from a single source (a local council), with whom an agreement had been 
reached regarding supply of results, if they could be used within this dataset; this could 
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represent a model for future attempts to undertake this kind of study. Once these results are 
made available to all stakeholders, it is likely that any attempt to expand this study to the rest 
of the UK would be made easier. 
 
6.3 BCR Tests  
With the discovery that the L120Q mutation is present almost wherever it is looked for in the 
south-east of England, it was and is necessary to discover the level of resistance conferred to 
Norway rats that possess it. This study was the first of its kind to generate effective dose data 
and resistance factors for resistant strains by following on from previous susceptible data 
(Prescott et al., 2007). The results showed conclusively that resistant female rats are more 
anticoagulant-tolerant than male resistant rats, regardless of resistance mutation and 
susceptible strain with which the wild progenitors were bred. This indicates that resistant 
populations are harder to eliminate than previously thought, because more females will 
survive control attempts than males, allowing a greater surviving effective population. These 
results confirm previous studies that have shown that rats with the Y139S mutation possess 
either no, or limited technical resistance to SGARs (Hadler, Redfern and Rowe, 1975; 
Redfern, Gill and Hadler, 1976; Redfern and Gill, 1980), and therefore the Welsh resistance 
focus is unlikely to present problems with control in the future, unless rats with the L120Q, 
Y139F or Y139C mutations are introduced there. The results for the Reading Berkshire strain 
(L120Q mutation) show that these rats can be controlled by all SGARs, supporting the belief 
of many PCOs in Reading that difenacoum and bromadiolone are still effective there (R Kiff, 
pers. comm.). The missing results for difethialone (and bromadiolone and flocoumafen 
against males) are unlikely to refute this. Previous results for Hampshire-resistant rats (also 
possessing the L120Q mutation) show that they possess a much greater tolerance to 
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bromadiolone and difenacoum (Prescott et al., 2007), which may account for the supposed 
discrepancy between the two strains’ dietary vitamin K requirements (Greaves and Cullen-
Ayres, 1988; Gill, Kerins and MacNicoll, 1992).  
Results for the CSL Berkshire strain, meanwhile, show that rats of this strain are only 
susceptible to the resistance-breaking SGARs, with resistance factors and ED50s against 
difenacoum and bromadiolone that indicate practical resistance. Because of the potential for 
the L120Q mutation to confer resistance of this level (by repeated selection through the use 
of bromadiolone and difenacoum), and the uncertainty of which phenotype of L120Q 
resistance is present in any given site in the large L120Q focus of southern England, it is 
advised that only resistance-breaking SGARs are used for rat control in this area. ED50 and 
resistance factor data are not currently published for rats with the L128Q, Y139C and Y139F 
mutations, so there is not yet any evidence to dispute that CSL Berkshire rats possess the 
greatest resistance factors against any SGAR. Given the results for the Welsh rats in this 
study, any results for L128Q are unlikely to be of use. Y139C and Y139F strains are 
currently being investigated by collaborators in Germany; these results will be of interest due 
not only to their known impact in the laboratory and field trials (Grandemange et al., 2009; 
Endepols et al., 2012; Buckle et al., 2013), but also because these mutations are present in 
south-east England. 
Some inaccuracies are likely to have resulted from the methodology employed in 
Chapter 4 due to the difficulty of ensuring that rats received the exact dose prescribed, but 
this cannot be controlled for. Fiducial limits are wider for rats that are more tolerant to given 
SGARs, resulting in some exceptionally wide fiducial limits at the ED99 level (see Tables 4.3, 
4.4 and 4.5). Results at the ED50 level are therefore the most useful and trusted, but cannot be 
used to replace LD99 data. The greatest difficulty faced in carrying out the practical work for 
Chapter 4 was attempting to source enough rats to carry the experiments out on. All three 
 150 
strains faced breeding difficulties at some point during the study (i.e. refusal to breed despite 
changing and creating new breeding pairs; repeated infanticide; sex ratios of offspring 
skewed towards females). This resulted in the study being prolonged by months, if not years, 
with some Probit lines unfinished. 
The uncertainty of the application of these results to the L120Q focus of southern 
England and the likely discrepancies between effective and lethal doses meant that 
confirmation of these results in the field was required. 
 
6.4 Field trials 
The results of the field trials conducted for this study are clear: regardless of whether they 
took place in Berkshire or Hampshire, the trials utilising bromadiolone and difenacoum baits 
failed to achieve control. The only equivocacy is in the steady reduction of bromadiolone 
consumption during the treatment period in Trial C, which may indicate that control was 
being achieved before the trial was ended. The resistance status of the rats trapped prior to 
this Trial (100% L120Q; 90% homozygous), in combination with the steady reduction of 
bromadiolone consumption, indicates that this form of L120Q might have been controlled by 
sufficient volumes of bromadiolone. A total of 2100.75 mg of bromadiolone was consumed 
during the five weeks of the treatment phase at Site C, equivalent to 42.02 kg of 0.005% bait, 
yet did not achieve complete control of a population of ~272 rats within five weeks. This 
represents a large volume of bait and/or contaminated rats to which non-target animals were 
exposed.  
Both brodifacoum trials achieved success in attaining >90% control of rats at Sites E 
and F, but treatment phases took 11 and seven weeks, respectively. This may represent too 
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great a cost in time and money for some stakeholders, but use of resistance breakers 
represented the difference between control success and failure, and under the UK rodenticide 
stewardship scheme, saturation baiting (as took place in Trials A – D; Daniells, 2011) is 
unlikely to be supported. 
The results of these trials reflect the results and conclusions of similar studies in 
Germany against rats with the Y139C mutation, in which brodifacoum was found to be 
efficacious (Buckle, Klemann and Prescott, 2012), but bromadiolone (Endepols et al., 2012) 
and difenacoum (Buckle et al., 2013) were not. Given the results of Chapter 4 regarding rats 
with the Y139S mutation, and previous studies against rats with the L128Q mutation (Hadler, 
Redfern and Rowe, 1975; Greaves and Ayres, 1982; Greaves and Cullen-Ayres, 1988), field 
trials against Welsh and Scottish rats are unlikely to be of importance. Results of initial 
studies investigating the strength of resistance to SGARs conferred by the Y139F mutation 
suggest that similar field trials involving this strain would be useful (Grandemange et al., 
2009). Since recent legislative changes in the UK, Trials E and F are the first of their kind to 
offer evidence that resistance breakers used at a concentration of below 0.003% can be fully 
efficacious against L120Q-resistant rats in both Hampshire and Berkshire (although see 
Greaves, Shepherd and Quy, 1982). Because all SGARs are classified as toxic to 
reproduction, and the risk that exposure to these chemicals presents to human pregnancies is 
only accepted at conentrations below 0.003%, the failure to achieve control using difenacoum 
and bromadiolone at 0.005% during Trials A – D is confirmation that these SGARs should 
not be used in the south-east of England, due to their ineffectiveness against the L120Q 
mutation, which appears to be present throughout this area.  
These trials had voles and mice repeatedly entering bait points. Because these rodents 
are smaller than Norway rats, they can access any bait point that a rat can – this cannot be 
prevented except by refraining from using SGARs outdoors. This being the case, if SGAR 
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baiting is to continue, it must be ensured that permanent baiting does not occur, and only 
proven, effective baits should be used in order to minimise the duration of bait use. All 
anticoagulant application should also be conducted and monitored by trained, competent 
users.  
 
6.5 The future of anticoagulant rodenticides as rat control in the United 
Kingdom 
Given the recommendations made above, the advent of the UK rodenticide stewardship 
scheme is fortuitous and timely. Under the stewardship of CRRU, competent users 
(designated as such by attending a training course – see CRRU UK, 2016) are afforded the 
use of resistance breaking SGARs. The results herein indicate that with the use of 
brodifacoum (or other resistance breakers) Norway rat resistance as it stands in south-east 
England should not be problematic. Therefore, the success of the scheme relies upon users 
utilising SGARs in responsible fashion, and continued monitoring of non-target species 
(Buckle et al., 2017). 
Regardless of the stewardship scheme, the expansion to the rest of the UK of the 
study described in Chapter 3 is advised. It is possible that there are areas of the UK where the 
use of bromadiolone or difenacoum might still be feasible, if doing so would present less of a 
risk to non-target animals. Expanding this form of monitoring will give stakeholders the 
knowledge to prevent selecting for resistance and consequently creating strains with similar 
resistance statuses to CSL Berkshire rats. Furthermore, identifying and delimiting all 
resistance foci will enable researchers to monitor how resistance changes temporally; the 
results herein represent only a snapshot in time, rather than an investigation of how resistance 
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came to become so prevalent in south-east England. Such information may help with the 
prevention of the establishment of resistance elsewhere. The completion of the Probit lines 
left unfinished in Chapter 4 is also required. We do not currently know which form of L120Q 
resistance is present in any given site within the large focus of central-southern England, and 
therefore we should attempt to generate these data for all of them. 
The L120Q, Y139C and Y139F mutations are all found in south-east England, and are 
also all found in North-Western Europe. It is possible that these mutations originally come 
from continental Europe, and rats from this area infested ships bound for England, or vice 
versa. An investigation of rat populations in the UK suggest they are not yet at equilibrium, 
having only relatively colonised the country (Haniza et al., 2015). Further investigations of 
this sort in both the UK and Europe may elucidate the provenance of the various resistance 
mutations, and aid in future attempts to prevent their spread. It would be hasty to assume that 
resistance will no longer be a problem in the UK, because effective rodenticides are now 
available to users. As noted elsewhere, SGARs are currently the only large scale option for 
the control of Norway rats in this country. It may appear unlikely now, but if their efficacy or 
availability is ever reduced for any reason, the situation could become untenable. The results 
of Chapter 3 show conclusively that resistance in south-east England is widespread and 
prevalent; it is the first attempt to fully delimit and identify every resistance mutation in a 
geographic space. Chapters 4 and 5 represent the first quantification of resistance factors for 
resistant strains, and the first confirmation that the L120Q focus identified in Chapter 3 can 
be successfully controlled in light of changes to the registration and use of SGARs in the UK, 
despite their apparent similarity to Selected Lines of rats with increased tolerance to 
anticoagulants. It is important therefore that the above recommendations are taken into 
account, so that our knowledge can be expanded, and the fight against resistance become 
proactive for the first time.  
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